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A crucial step in the development of improved drugs for asthma therapy is a thorough 
understanding of the mechanisms, which are important for effective treatment, and the 
identification of target cells in asthma pathogenesis. In this work these two key questions 
were tackled using a murine model of asthma.  
 
The analysis of the GC action mode revealed that the suppression of inflammation was 
strongly depended on DNA-binding and dimerisation of the GR. In absence of this molecular 
mechanism GC should no longer exert their anti-inflammatory functions in asthmatic mice 
despite the presence of the DNA-binding independent mode of GR action and non-genomic 
effects.  
 
Analysis of the efficiency of GC therapy in different cell type-specific GR-deficient mice 
surprisingly demonstrated that treatability of AAI was independent on GR expression in 
immune cells. This notion was corroborated by experiments with bone marrow chimeras of 
GR
dim
 mice that revealed that the efficiency of GC therapy was mostly dependent on effects 
on non-immune cells of the lungs. Additionally, an inducible GR knockout in AT2 epithelial 
cells led to a strongly diminished effectiveness of GCs in the suppression of the inflammatory 
reaction. This observation correlates with the importance of these cells in the regulation of 
innate and adaptive immune responses and the initiation of asthmatic reactions. 
 




 bone marrow chimeras and GR
SPCcreERT2
 
mice showed that the treatment with GCs exerts its anti-inflammatory functions via 
downregulation of mRNA expression in lung cells of the following genes: IL-4 and IL-13, 
IL-1β and IL-33, IL-25 and RANTES, TSLP and TNF-α, Eotaxins (1&2) and iNOS. The 
expression of IL-9 and β-Tryptase could also be important for asthma treatment because of 
the activation of mast cells, but based on the efficient treatability of mast cell deficient mice, 
these genes do not seem to be crucial for GC therapy. The treatment reduced mRNA 
expression of genes critical for the DC activation and could improve the barrier function via 
upregulation of ZO-1 mRNA expression. These effects of GC on gene expression of several 
inflammatory mediators demonstrate how important the regulation of epithelial cell activation 




Graphical abstract: Mechanisms of asthma therapy with GCs. Airway epithelial cells express a 
variety of mediators involved in inflammation and host defense. Microbial or virus infection and 
epithelial damage in the respiratory airways can lead to the development of an asthmatic reaction. 
During the treatment of asthma GCs can suppress the larger part of pro-inflammatory mediators but 
only a suppression of a few of these cytokines/chemokines seems to be crucial for treatment 
efficiency. The schema visualizes the hypotheses of key mediator regulation by GCs. (Red arrows 
indicate the reduction of mRNA expression and mediator release. Green ones indicate the upregulation 
of TLR and ZO-1 expression by GC therapy. Blue arrows indicate the interaction between epithelial 
and immune cells).  
 
Taken together the results of this work demonstrate that the suppression of AT2 cells and 
other structural cells of the lungs could be critical targets for asthma therapy by GCs and that 
the effects of GCs are mediated by the DNA-binding dependent mode of GR action. This 
information could become interesting for the development of new anti-asthmatic drugs that 
selectively inhibit crucial aspects of epithelial-immune or the epithelial-mesenchymal 
interactions. 
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1.1.1. Characteristics of allergic Asthma  
Asthma is a common chronic disorder of the airways that is characterized by airflow 
obstruction in association with hyperresponsiveness (AHR) and inflammation of the airways. 
These structural changes which are triggered by an immune response directed against inhaled 
antigens lead to various symptoms that are typically associated with asthma such as wheezing, 
breathlessness, chest tightness, and coughing (Holgate, 2013).  
 
Figure 1: Anatomy of asthma attack. Asthma is characterized by a complex interaction of airflow 
obstruction, airway hyperresponsiveness and inflammation. The symptoms, which occur during an 
asthma attack, are spasmodic contraction of the airway smooth muscles, increased mucus secretion 
and infiltration by immune cells. These structural and cellular changes impede breathing to a greater or 
lesser extent. (Encyclopædia Britannica, Inc., 2001) 
 
The pathophysiology of asthma and the corresponding dysfunction of the airways is based on 
the release of potent inflammatory mediators that recruit inflammatory cells on the one hand 
and cause airway wall remodelling on the other hand.  
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1.1.1.1. Cellular changes 
Airway inflammation in asthma is a multicellular process involving different cell types like 
T cells, mast cells, basophils, dendritic cells, B cells, macrophages and neutrophiles. 
However, the reaction is largely based on the development of a strong eosinophilia in the 
lungs. The distribution of infiltrating eosinophils differs between the peripheral and central 
airways and the lung parenchymal regions which may have important functional 
consequences. Interestingly, in patients with severe and steroid-dependent forms of asthma 
another type of the granulocyte population begins to infiltrate the inflamed lungs as well. In 
these patients a pronounced neutrophilia can occur instead of eosinophilia. This effect and its 
underlying mechanism is only poorly understood but can possibly be used as a marker for the 
severity of diesease progression or to evaluate the effects of long-term glucocorticoid-
treatment during therapy.  
 
1.1.1.2. Structural changes 
The structural changes in the lungs of asthmatic patients can be characterized by an increase 
of airway wall smooth muscle mass, mucus gland hypertrophy and vascular congestion 
(Saetta and Turato, 2001). These features together can strongly contribute to the airflow 
limitations due to thickened airway walls with markedly reduced airway caliber and 
increasing airway resistance. Additionally, the difficulties with air uptake can be worsened by 
increased amounts of secreted mucus and infiltrating cells which blockade the free space in 
the conducting airways and cause an increased surface tension leading to airway closure. 
Mucus hypersecretion and the increase in smooth muscle mass, which are based on 
hypertrophy of mucous glands and goblet cells hyperplasia (Aikawa T. et al., 1992; Shimura 
S. et al., 1996) and strong proliferation of smooth muscle cells, respectively, are induced by 
inflammatory mediators (Noveral et al., 1992), cytokines (De et al., 1995) and growth factors 
(Noverale et al., 1992; Stewart et al., 1994) from the inflamed lung tissue and cellular 
infiltrates. Other prominent structural changes have been reported as well. These include 
vascular congestion with increased vessel area in the airway wall and subepithelial fibrosis 
with increased thickness of the reticular basement membrane and deposition of collagen types 
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1.1.2. Pathogenesis of an asthmatic reaction  
Although millions of people in the world are suffering from asthmatic symptoms, the precise 
cellular and biochemical processes underlying chronic inflammation and airway remodeling 
are poorly understood. Asthma usually develops in childhood and is associated with contact 
and sensitization to common aeroallergens derived from house dust mites, animal dander, 
fungi and pollen. The question why these harmless substances can induce strong 
inflammatory response in one part of population while they are tolerated by others has yet to 
be resolved.  
 
One approach which was used to reveal risk factors for asthma development was a genome-
wide linkage screen of asthmatic and healthy persons in different populations to detect 
chromosomal regions that are linked to the disease. Several studies investigated this topic and 
a number of chromosomal regions have been reported to have a biological relevance for 
asthma and allergic diseases. These include the cytokine cluster on chromosome 5q which 
harbors the genes encoding Interleukin (IL)-3, IL-5 and GM-CSF but also FCER1B on 11q, 
IFN-γ and STAT6 on 12q and IL-4R (the IL-4Rα chain which is also a part of the IL-13R) on 
16p (March et al., 2011).  
 
Figure 2: Protective and risk factors for asthma development identified with the help of genome 
wide association, linkage and candidate gene studies (modified and adopted from Michael E. 
March, 2011) 
1.   INTRODUCTION 
 
4 
Although there are many different studies investigating this topic (Ober and Hoffjan, 2006; 
Vercelli, 2008; Zhang et al., 2008), the identified ―risk factor‖ genes can be categorized into 
the following groups: epithelial barrier function and innate immunity, tissue response, genes 
involved in TH2 cell polarization and genes critical for the cellular responses that characterize 
atopic disease and genes important for the environmental sensing and immune detection of 
microbial products (Figure 2). Mutations in these groups of genes are associated with an 
increased risk of asthma development (Michael E. March et al., 2011) 
 
Unfortunately, very little is known about ―protective factors‖ for asthma because this topic is 
less well explored. In the current literature, protective factors like healthy family members, 
exposure to pets and/or livestock and contact to farm animals have been proposed. The 
duration of breastfeeding or the exposure to endotoxins may also play an important role. The 
protective role of endotoxins such as LPS is presumably based on its binding to the CD14 
molecule or interaction with TLR-4. Another factor that can suppress the development of 
asthma is an immune modulation inducing a TH1-biased response. Furthermore, the proteins 
TBX21 and IL-12B were reported to promote the development of TH1 cells which suppress 
atopic phenotypes (see Figure 2). 
 
The current studies of risk and protective factors in asthma and allergy development underline 
the importance of the epithelial barrier function, of molecules involved in sensing of and 
effector function of innate immunity as well as the critical role of the TH1/TH2 balance. 
 
1.1.2.1. Cellular mechanisms of asthma development 
The initial step which leads to an asthmatic reaction remains poorly understood. However, it 
is known that this process requires the presentation of allergenic peptides on MHC class II 
molecules together with co-stimulatory ligands to naïve T cells. This is performed by a special 
subset of cells, the so-called professional antigen-presenting cells (APCs) which also polarize 
the immune reaction in favour of a TH2 phenotype (Riffo-Vasquez and Spina, 2002; Pearlman 
et al., 1999).  
 
APCs include B cells, macrophages and dendritic cells (DCs) with the latter being the most 
potent inducers of T cell responses. They are present in large amounts in the lung and are 
required to initiate and maintain an adaptive TH2 response to allergen.  
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Like all other body surfaces, the lung is lined with an elaborate network of DCs which are 
dispersed throughout the conducting airways, lung interstitum, pleura, lung vasculature and 
bronchial lymph nodes (Geurts van Kessel and Lambrecht, 2008). The lungs DCs perform a 
sentinel function in the pulmonary immune response and act as a bridge between innate and 
adoptive immunity. They can also recognize inhaled antigens through expression of pattern-
recognition receptors such as Toll-like receptors (TLR), nucleotide-binding oligomerization 
domain (NOD)-like receptors, and C-type lectin receptors (Barrett et al., 2009). On the other 
hand, DCs react to mediators that are released upon damage of the tissue caused by 
pathogens, trauma, vascular damage or necrosis. Using these features, DCs can sense various 
danger-signals in the airways migrate to regional draining lymph nodes and process the 
relevant antigens (Vermaelen et al., 2001). In contrast to alveolar macrophages, DCs in the 
lung are reported to be very effective in generating T cell responses (Belz et al., 2004) and 
play a crucial role in initiating and perpetuating T cell hyperresponsiveness associated with 
asthmatic reactions (van Rijt et al., 2005; Hammad et al., 2010).  
 
Several studies reported that the presence of DCs is essential for the development of a TH2 
response in murine models of asthma (Kool et al., 2008a, 2008b) and that these cells are 
necessary for primary immune response to inhaled allergens. On the other hand, DCs also 
play a very important role in protective immunity and respiratory tolerance (Tournoy et al., 
2006) where they lead to inhibition of T-cell activation and induction of regulatory T cells 
(Lambrecht et al., 2006).  
 
Although DCs seem to be necessary for the induction of TH2 responses to many different 
antigens, other cell types do also act as APCs in the lung. These include alveolar 
macrophages, B cells (Holt 2000), epithelial cells or basophils (Sokol et al., 2009). 
This heterogeneity of potential APCs correlates with the complexity of immune-challenging 
pathogens that enter the lungs but may also constitute a possible reason for the failure of 
respiratory tolerance in some cases.  
 
Based on genetic studies, patient biopsies and new research data obtained from animal models 
it could be shown that many different factors contribute to asthmatic symptoms which include 
various cell types, cytokines, chemokines and other mediators. The list of main players which 
acting during the development of inflammatory response after antigen presentation consists of 
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immune cells such as B cells, mast cells, eosinophils and TH2 cells but also non-immune cells 
like epithelial cells, fibroblast and smooth muscle cells of the lung.  
 
Figure 3: Cells and mediators involved in the induction of allergic asthma. The allergic response 
starts with antigen (Ag) sensitization, in which an antigen-presenting cell (APC) digests Ag and 
presents it to a naïve T cell on MHCII directing the differentiation in favour of a TH2 cell phenotype. 
TH2 cells produce various cytokines: IL-4, which promotes IgE synthesis via a B cell; IL-5, which 
promotes eosinophil maturation and activation; IL-9 and IL-13, which promote goblet cell hyperplasia 
and mucous secretion. Triggered by Ag–IgE cross-linking, the mast cell releases histamine and 
proteases (leukotrienes and thromboxanes) that cause smooth muscle contraction and airway edema. 
Eosinophil-derived granule proteins lead to airway injury promoting activation of epithelial cells that 
is accompanied by chemokine and cytokine release (modified from Renauld et al., 2001; Jarjour et al., 
2002 and Holgate et al., 2013).  
 
The development of asthma generally starts largely with a selective expansion of TH2 
lymphocytes that secrete a range of cytokines including interleukins IL-3, IL-4, IL-5, IL-9, 
IL-13 and granulocyte macrophage colony-stimulating factor (GM-CSF), which are tightly 
regulated (Holgate, 2012; Renauld et al., 2001). These TH2-specific cytokines orchestrate the 
allergic inflammatory cascade since they enhance survival of TH2 cells (IL-4), promote 
production of Immunoglobulin (Ig) E by B cells (IL-4 and IL-13) and lead to mast cell 
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differentiation, maturation and activation (IL-3, IL-9, IL-13). In addition, they promote 
eosinophil maturation and survival (IL-3, IL-5 and GM-CSF) and cause hypersecretion of 
mucus through epithelial cells in the lung (Vignola et al., 2000; Vignola et al., 2003; Hammad 
et al., 2008; Holgate, 2013). The functions and the role of TH2 cells are closely connected 
with the functions of the produced cytokines (Figure 3).  
 
Activated TH2 cells stimulate the production of IgE antibodies from B cells not only by 
secreting IL-4 but also through the cytokines IL-13 and IL-9, although the latter are less 
potent. IgE leads to mast cell activation via binding to the high affinity IgE receptors (FcεRI) 
on the surface of mast cells and basophils. Cross-linking of IgE triggers the release of 
preformed vasoactive mediators such as histamine but also promotes the synthesis of 
prostaglandins and leukotrienes and the transcription of several cytokines. Following antigen 
contact, mast cells release the contents of their granula which leads to immediate 
hypersensitivity reactions like the rapid induction of mucosal oedema, mucus hypersecretion 
and smooth muscle constriction of the lungs. The activated mast cells also release chemotactic 
factors that contribute to the recruitment of inflammatory cells, particularly eosinophils, and 
produce a wide range of cytokines. These include IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, 
IL-13, IL-16, tumor necrosis factor beta (TNF-β) and transforming growth factor beta (TGF-
β). In addition, several chemokines including IL-8, lymphotactin, CCL1 (TCA-3), CCL5 
(RANTES), CCL2 (monocyte chemoattractant proteins, MCP-1) and CCL3 (MIP-1a) are 
secreted as well (Barret et al., 2009). It could be shown that these mast cell-derived mediators 
do not only play a role in cell recruitment but also induce activation of DCs and T cells 
(Robinson et al., 2004).  
 
Even if the role of eosinophils in asthmatic reactions remains enigmatic, this cell population 
plays a prominent role in the initiation- and late phase of asthma pathogenesis. Eosinophilia 
has been described to be a major cause of tissue damage that occurs in the airways. Unlike 
mast cells, eosinophils do not express FcεRI on their surface constitutivly but, once activated, 
start to express high levels of this receptor. Activation of the eosinophils causes the release of 
several mediators including major basic protein, eosinophil cationic protein and free radicals. 
These potent cytotoxic proteins and molecules not only lead to significant tissue damage 
because of their cytotoxic effects via osmotic lysis, but can also initiate the activation of mast 
cells and basophils upon degranulation. The accumulation of activated eosinophils in the 
lungs initiates the activation of other inflammatory cells which leads to the remodeling of the 
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airways through hyperplasia and hypertrophy of the smooth muscle layer and mucous 
secreting glands. The combination of all these effects leads to reduced airways calibers 
(Renauld et al., 2001). Synthesis of prostaglandins, leukotriens and different cytokines 
including IL-5 acts as a positive feedback loop by activating additional eosinophils and 
enhancing infiltration. Interestingly, eosinophils play an important role in tissue damage 
during asthma pathogenesis, but are reported to be not required for allergen-induced airway 
hyperresponsiveness (Renauld et al., 2001) 
 
In addition to cell types like eosinophiles which strongly enforce the pathogenic effects of 
inflammatory responses, there are also cell populations which do not only have pro-
inflammatory but also anti-inflammatory functions. The alveolar macrophages play either an 
immunogenic or tolerogenic role depending on the signals received. Each of these 
characteristic may belong to a different macrophage phenotype with different functions in 
inflammatory responses (Stout et al., 2004; Mosser et al., 2008). Kreider and Martinez for 
example reported that the exposure of macrophages to IL-4 or IL-13 resulted in a population 
of anti-inflammatory macrophages which are involved in tissue repair responses (Kreider et 
al., 2007; Martinez et al., 2009). Additionally, these macrophages could produce IL-10, one of 
the most potent anti-inflammatory cytokines that can prevent inflammation (Mosser et al., 
2008). Classically activated macrophages are also present in the lungs and besides their 
cytotoxic functions can also prevent the onset of allergic airway inflammation upon IFNγ-
stimulation by TH1 cells (Korf et al., 2006; Tang et al., 2001). 
 
It is not really clear how the different macrophage phenotypes (pro-inflammatory and anti-
inflammatory) impact the severity of asthma or the effectiveness of therapies but new 
investigations suggest that the development of GC-resistance in severe asthma may contribute 
to the activation of pulmonary macrophages (Balhara and Gounni, 2012; Yang et al., 2012).  
 
Another cell type which are involved in asthmatic reaction are regulatory T cells (T reg). Like 
anti-inflammatory macrophages, T reg cells play a key role in negative immune regulation by 
inducing immune tolerance to inhaled allergens (Wu et al., 2008). T reg cells act during the 
initiation stage of an immune response and regulate the establishment of stable contacts 
between APCs and naive T cells. This cell population can inhibit APC activity, or prevent 
effector T cell development via different strategies. Human studies reported that asthmatic 
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individuals have fewer functional T reg cells which underline their important anti-
inflammatory role in this context. 
 
1.1.2.2. Effects of TH2 mediators during airway inflammation 
The pathogenesis of asthmatic reactions is complex and multifactorial. During the 
development of airway inflammation, a variety of cell types interact with each other by 
releasing different mediators which exert anti-inflammatory and pro-inflammatory effects. 
From the first steps of inflammation on, TH2 cytokines play the key role in orchestrating the 
disease course and symptoms appearance. 
 
One of the key TH2 cytokines in allergic reactions is IL-4. This mediator plays a crucial role 
not only during the priming of naïve T cells in favour of a TH2 phenotype (Herrick and 
Bottomly, 2003) but also regulates the isotype switching in B cells to IgE. Furthermore, it 
induces expression of MHCII and CD23 on APCs, of adhesion molecules on endothelial cells 
and stimulates chemokine production and activation of eosinophils and mast cells (Wills-Karp 
et al., 2000). Interestingly, the primary function of IL-4 is of central importance only at the 
beginning of an asthmatic reaction. After the initial priming steps, a strong IL-4 presence is 
important for the development of inflammation but it cannot induce airway hyperreactivity on 
its own (Renauld et al., 2001). Hence, it has been reported that IL-4 inhibition does not 
prevent the development of asthma in experimental models (Hogan et al., 1997; Renauld et 
al., 2001) 
 
In contrast to IL-4, inhibition of another important TH2 cytokine, namely IL-13, completely 
blocks airway hyperreactivity in mouse asthma models although the signal transduction 
pathways of both cytokines overlap since IL-13 also binds to the α chain of the IL-4 receptor. 
Although IL-13 shares many functions with IL-4, based on recent publications, this cytokine 
plays a role not in the initial priming phase but also in the following steps. IL-13 
overexpression induces strong inflammation with mucus hypersecretion, subepithelial fibrosis 
and eotaxin production which leads to eosinophil infiltration into the lungs. Because IL-4 and 
IL-13 are strongly related to each other concerning their functions, increased secretion of 
IL-5, eosinophilic infiltration and IgE production are only prevented in the absence of both 
mediators (Renauld et al., 2001).  
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Another cytokine which is functionally related to IL-13 and IL-4 is IL-9. This cytokine is 
produced by TH2 cells and does not only stimulate cell-proliferation and prevent apoptosis, 
but is also involved in lung eosinophilia, mucus hypersecretion, Ig production, and pulmonary 
mastocytosis (Dong et al., 1999; Longphre et al., 2001; Louahed et al., 1995; Petit-Frere et al., 
1993). It was reported that mucus hypersecretion by goblet cells could be directly stimulated 
with IL-9 independently of IL-13 in murine models of asthma (Townsend et al., 2000). On the 
other hand, IL-9 alone could not compensate for the function of other TH2 cytokines in the 
development of an asthmatic reaction.  
 
IL-5 which was originally defined as a T-cell-derived cytokine that triggers antibody 
production in activated B cells is currently believed to play the crucial role in the development 
of eosinophilia in the lungs. As described in several publications, this cytokine is a key 
mediator of eosinophil differentiation, maturation, recruitment and activation at the sites of 
allergic inflammation (Humbert et al., 1997; Greenfeder et al., 2001). Furthermore, the high 
abundance of IL-5 mRNA in the sputum of asthmatic patients reflects eosinophil infiltration 
in the lungs (Truyen et al., 2006).  
 
The thymic stromal lymphopoietin (TSLP) belongs to the key mediators of asthmatic 
reactions. This epithelial-derived cytokine does not only promote the development and 
migration of basophiles but is also associated with increased IL-4 and IL-13 production. 
Overexpression of TSLP in the lungs leads to spontaneous inflammation (Yoo et al., 2005). 
This strong influence on the immune response is probably based on DC stimulation. TSLP is 
able to upregulate expression of co-stimulatory molecules and TH2-attracting chemokine 
ligands in DCs. Interestingly, TSLP is also reported to directly act on naïve CD4
+
 T cells to 
promote proliferation in response to antigen (Leonard 2002) 
 
IL-25 (also known as IL-17E) is a member of the IL-17 superfamily. This cytokine is 
produced by TH2 cells, mast cells and epithelial cells. IL-25 has the ability to induce the 
expression of key mediators of asthmatic reactions such as IL-4, IL-5, and IL-13. Its 
overexpression leads to inflammation mediated by eosinophils and increased IgE production 
in a murine model of asthma (Fort et al., 2001). This function of IL-25 was also observable in 
human samples of TH2 cells (Wang et al., 2007). Because allergic airway inflammation can be 
effectively inhibited in murine models by antagonizing the function of IL-25, this cytokine 
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belongs to a group of potential asthma therapy targets, and a blocking antibody is already in 
clinical development (Ballantyne et al., 2007). 
 
IL-33 belongs to the earliest released signaling molecules during airway inflammation. The 
damage or activation of epithelial cells of the lungs leads to the upregulation of IL-33 
expression. It was reported that IL-33 can be produced by epithelia and myeloid cells as an 
alarmin for the rapid induction of IL-13-driven immunity (Prefontaine et al., 2010). This 
cytokine has comparable effects to TH2 cytokines such as IL-5 and IL-13. IL-33 stimulates the 
inflammatory mediator release of T cells, eosinophils, mast cells, dendritic cells and basophils 
(Borish and Steinke, 2011) 
 
In contrast to the other cytokines discussed above, IL-10 has inhibitory effects on the 
inflammatory response. This cytokine can suppress effector mechanisms and production of 
pro-inflammatory cytokines and chemokines by macrophages, eosinophiles and neutrophils. It 
could be shown that asthmatic patients express reduced levels of IL-10 (Takanashi et al., 
1999), thus illustrating the important role of this cytokine in the regulation of inflammatory 
processes.  
 
Chemokines also play important roles in asthmatic reactions because these mediators can 
direct the infiltration of leukocytes into the airways. In particular, Eotaxin 1&2 (CCL11, 
CCL24), RANTES (CCL5) and MIP-1α (CCL3), CXCL12 (SDF-1) as well as chemokine 
receptors and ligands like MCP-1, CXCR3 and CXCR4 have been identified as being 
important for the exacerbation of experimentally induced asthma. 
 
Although overexpression of IL-13 alone is sufficient to induce an inflammatory response, it 
could be shown that airway and lung tissue eosinophilia is dependent on eotaxin expression. 
Eotaxin 1 and eotaxin 2 are strongly overexpressed in asthmatic lungs (Corrigan et al., 1999). 
These mediators have the ability to chemoattract and activate inflammatory leukocytes, 
particularly lymphocytes, monocytes, eosinophils and basophils, as well as some stromal cells 
such as endothelial and smooth muscle cells (Alam et al., 1997). Because only Eotaxin 1 and 
2 bind specifically to the eosinophil receptor CCR3, only these chemokines can specifically 
regulate eosinophilia during asthmatic reactions (Ugoccioni et al., 1997; Heath et al., 1997).  
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Another important chemokine that can bind to CCR3 and that is among the major CC 
chemokines induced during atopic (Alam et al., 1996) and nonatopic (Humbert et al., 1997) 
asthmatic responses in clinical asthma is RANTES (Tonnel et al., 2001). It was reported that 
RANTES has not only chemoattractant effects on mast cells, eosinophils, baseophils and T-
cells but also enhances the production of IgE and IgG4 by activated B cells. The fact that the 
severity of asthma and atopy is associated with a polymorphism in the RANTES promoter 
(Fryer et al., 2001) demonstrated the importance of its regulation for asthmatic reactions 
(Schuh et al., 2003).  
 
The regulation of chemokines does not only affect the cell migration into the lungs but also 
influences the inflammatory response type. MCP-1 can polarize the naïve T cells towards the 
IL-4-producing TH2 phenotype while MIP-1α was reported to promote the TH1 response with 
increased secretion of IFNɣ and diminished production of IL-4. These effects on TH1/TH2 
balance have a strong influence on asthma progression. 
 
CXCR3 is a chemokine receptor that is preferentially expressed on TH1 cells, epithelial cells 
and some endothelial cells. In previous studies it could be shown that this chemokine receptor 
is able to regulate leukocyte trafficking and promotes TH1 cell maturation that leads to the 
suppression of a TH2 response. In contrast to CXCR3, the CXCR4 chemokine receptor 
(specific for CXCL12) is strongly expressed in inflammatory tissues and on TH2 cells and 
nearly absent in healthy organs. Its ligand CXCL12 (or SDF-1) is one of the inflammatory 
cytokines that is strongly chemotactic for inflammatory cells such as macrophages. A small 
molecule inhibitor of CXCR4 (AMD3100) was reported to be able to reduce inflammation 
and AHR in mice with AAI. The inhibitory effects are probably associated with a reduction in 
TH2 cytokines (Lukacs et al., 2006). The possibility that CCL12 may also be involved in the 
mobilization of eosinophil progenitor cells from the bone marrow - since eosinophils express 
CXCR4 (Dorman et al,. 2005) - make this receptor-ligand pair interesting for the development 
of new anti-asthmatic therapeutics. 
 
1.1.2.3. Non-immune cells of the lungs in the context of an inflammatory response 
The role of structural elements of the lungs during asthmatic reactions was largely ignored for 
decades. However, new investigations in this field clearly demonstrated that, although asthma 
is a TH2-driven inflammatory response, innate immunity and particularly non-immune cells of 
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the lungs like epithelial cells, smooth muscle cells or fibroblasts play key roles in disease 
initiation and progression. 
 
Figure 4: The interaction between the immune system and structural cells of the lungs during an 
inflammatory response (Holgate and Riccardo Polosa, 2008) 
 
Besides the primary function of the lung tissue which is to perform gas exchange, the lung 
cells are responsible for several important non-respiratory functions. Similar to other surface 
regions of the body, the lungs are in constant contact with the environment. Because of this, a 
variety of mechanisms developed in the lungs to avoid infection and to differentiate between 
pathogenic and harmless substances. This is achieved by downregulating or activating the 
non-specific and immune-mediated responses. The complexity of this sensitive coordination 
creates an immunocompetent and equally tolerant milieu to combat infections and to prevent 
collateral damage, respectively. The airway epithelium forms the first site of interaction 
between the internal milieu and the external environment. Because of this, the epithelial cells 
of the lungs continuously make contact with a variety of inhaled substances, in particular with 
airborne viruses, allergens, and environmental pollutants (Folkerts et al., 1998). The lung 
epithelium consists of many different cell types that allow gas-exchange, barrier-, regulatory- 
and defensive functions.  
 




Figure 5: The mechanisms of host defense in airways and alveolus of the lungs. Because the lung is 
constantly challenged by inhaled pathogenic and harmless substances several mechanisms developed 
to perform defensive and regulatory functions (Wright et al., 2005) 
 
About eight morphologically distinct epithelial cell types are present in the human respiratory 
epithelium. These cell types can be grouped into three different categories: basal-, ciliated and 
secretory epithelial cells (Spina et al., 1998). While ciliated cells transport the mucus from the 
lung to the pharynx (Harkema et al., 1991), mucus secreting goblet cells are responsible for 
efficient mucociliary clearance. In asthmatic reactions, epithelial cells upregulate the 
production of mucus in responses to TH2 cytokines such as IL-4, IL-13, and IL-9 which leads 
to goblet cell hyperplasia. The cells of the third group, the basal cells, belong to the primary 
stem cell type which can develop to mucus secretory or ciliated epithelial cell types. Besides 
the stem cell features, basal cells can secrete a number of bioactive mediators (Knight and 
Holgate, 2003). Particularly, Clara cells which are a subgroup of basal cells produce 
bronchiolar surfactant and specific proteases (De Water et al., 1985).  
 
From an immunological point of view, the cells of the alveolar epithelium are in the focus of 
interest. The alveolar epithelium consists of two highly specialised cell types: alveolar type 1 
and 2 cells (AT1 and AT2). While AT1 cells perform gas exchange functions, the AT2 cell 
population regulates a variety of processes including ion transport, surfactant metabolism, 
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alveolar repair and immune modulation. Recent investigations demonstrate that AT2 can 
produce a number of pro-inflammatory cytokines upon activation. These consist of pro-
inflammatory as well as regulatory mediators including arachidonic acid products, nitric 
oxide, endothelin-1, TGF-ß, TNF-α, and cytokines such as IL-1, IL-6 and IL-8 (Knight and 
Holgate, 2003). Surprisingly, the AT2 cells express MHCII molecules and can act as 
professional APC in the lungs directly influencing T cell priming and inflammatory responses 
(Holgate 2010). 
 
The inflammatory reaction in the airways leads to a strong induction of growth factor release 
from epithelial cells such as TGF-β. This occurs in response to damage that directly 
influences the synthesis of matrix proteins by fibroblasts / myofibroblasts (de Boer et al., 
1998; Vignola et al., 1997) but also their activation and proliferation. This fibroblast 
stimulation leads to airway remodelling and pulmonary fibrosis, the characteristically 
pathologic components of asthma development (Araya et al. 2010). The TGF-β release from 
epithelial cells and fibroblast / myofibroblast influences not only airway remodelling and 
immune cell homeostasis (Takizawa et al., 2001, Redington et al., 1997) but also plays a 
crucial role in the induction of immunosuppressive T reg and pro-inflammatory TH17 cells (Li 
et al., 2008). This dual role of TGF-β provides the opportunity to either promote inflammation 
with airway epithelial cell stimulation or to suppress inflammation with the help of T cells 
(Luo et al., 2010; Nakao et al., 2000). These features of fibroblast in communicating 
inflammatory signals correlate with their localization in the tissue which is between the 
epithelial cells and accumulating submucosal layer inflammatory cells such mast cells, 
eosinophils, DCs and T cells. 
 
Another cell type that plays an important role in asthma pathogenesis are smooth muscle cells. 
In biopsies of asthmatic patients, the smooth muscle layer is strongly increased. These 
changes are based on smooth muscle cell hyperplasia, hypertrophy or increased extracellular 
matrix. On the other hand, airway smooth muscle (ASM) cells are biologically active and can 
produce a variety of mediators. ASM cells are able to promote migration of DCs and interact 
with mast cells (Saalbach et al., 2010, Schirmer et al., 2010). When exposed to IL-1β, TNF-α, 
IFN-γ, IL-4 or IL-13 in vitro, ASM cells are able to release inflammatory mediators such as 
IL-8, eotaxin, MCP-1, -2, and -3, GM-CSF, IL-5, RANTES, IL-6 and IL-11 (Ghaffar et al., 
1999; Laberge et al., 1999). The investigation of bronchial biopsies of ASM cells from 
asthmatic patients also demonstrates the increased expression of RANTES and eotaxin which 
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is indicative that these cells exhibit these mediator release also in vivo (Chung et al., 1999). 
Because these cytokines influence the migration and survival of eosinophils, mast cells, 
monocytes and other immune cells, the ASM cell population of the lungs may play a crucial 
role in inflammatory responses (Lazaar et al., 2001). 
 
Taken together, the data about non-immune cells of the lung demonstrate new aspects of 














1.2.1. Glucocorticoids and the glucocorticoid receptor  
Glucocorticoids (GCs) are one of the most effective anti-inflammatory drugs available for the 
treatment of many autoimmune and inflammatory diseases including asthma. Although long-
term therapy or high dose applications of these drugs are often associated with dramatic side 
effects, GCs have been used for many decades and remain the treatment of choice until today.  
GCs, such as the endogenous hormone cortisol or synthetic compounds like Dexamethasone, 
belong to the class of steroid hormones that exert their function through binding to the 
glucocorticoid receptor (GR).  
 
The endogenous ligands of the GR are synthesized under the control of the hypothalamic-
pituitary-adrenal axis in the zona fasciculate and zona reticularis of the adrenal cortex and 
released diurnal in a pulsatile manner (Scheff et al., 2012). GCs are directly released into the 
circulation where they preferentially bind to their transporter protein transcortin (Richard et 
al., 2010).  
 
The synthesis and concentration of GCs are tightly regulated by the hypothalamic-pituitary-
adrenal (HPA) axis (Herman et al., 2003). Upon either inflammatory, physical or psychosocial 
stimulation, the cells of the paraventricular nucleus in the hypothalamus secrete 
corticotrophin-releasing hormone (CRH). This, in turn, stimulates the anterior pituitary gland 
to release adrenocorticotropin hormone (ACTH) into the bloodstream. In the adrenal cortex, 
ACTH finally induces the synthesis and release of GCs (Figure 6). This way, the 
hypothalamus can influence the immune system through activation of the HPA axis, but the 
immune system can also influence the hypothalamus vice versa through cytokine release 
(Mulla and Buckingham 1999; Webster et al. 2002; Webster and Sternberg., 2004). 
 
In addition to their effects on the immune system, endogenous GCs play an important role in 
the body’s metabolism. Their functions include regulation of body growth and development, 
blood pressure, salt and water balance and energy metabolism (Andrews and Walker., 1999). 
As a result of GC effects on glucose metabolism, GC induce a state of insulin resistance, 
leading to diminished suppression of glucose production and reduced peripheral glucose 
uptake (Rizza et al., 1982, Macfarlane et al., 2008). In the immune system, GCs play a role in 
the regulation of lymphocyte apoptosis, T cell development and inflammatory responses.  





Figure 6: Effects of GCs on the HPA axis (A) and structure of the GR (B).  
(A) This scheme shows the sites of synthesis and action of the main HPA hormones and the targets of 
GC action. Stress factors cause excitation of the hypothalamus, which responds by releasing CRH. 
This in turn acts on the anterior pituitary to induce synthesis and release ACTH which stimulates the 
adrenal cortex to release GC such as cortisol. (B) Linear representation of the 777 amino acid long 
sequence of the GR shows the principal domains. DBD = DNA binding domain; LBD = ligand 
binding domain; τ1 and τ2= the two activation domains; NT = amino terminal; CT= carboxy terminal 
(adopted from Newton et al., 2000) 
 
The GR, which is similar in structure to other nuclear receptors, is composed of several 
domains and subdomains. The six different domains can be classified in tree major functional 
units: the aminoterminal trans-activation domain AF1, the DNA-binding domain (DBD) and 
the carboxyterminal ligand-binding domain (Beato et al., 1995; Beato and Klug, 2000). The 
AF1 is a ligand-dependent activation domain that performs specific interactions with other 
transcriptions factors and components of the transcriptional machinery. The DBD consists of 
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two zinc finger motifs and can recognize and bind to specific palindromic DNA-sequence 
motifs which are called GC response elements (GRE) (Luisi et al 1991; Umesono and Evans, 
1989; Green et al., 1988). The sequence of the DBD contains five amino acids which are 
important for the formation of GR homodimers and their binding to the GRE (Beato et al., 
1989; Luisi et al., 1991). The carboxyterminal ligand-binding domain consists of a ligand-
binding site for specific and selective steroid hormone binding and a trans-activation domain 
with sequences important for dimerisation, nuclear localization as well as interactions with 
chaperons or other transcription factors (Beato and Klug, 2000). 
 
The GR is present in almost every vertebrate cell. In the absence of hormone, the GR is 
localized in the cytoplasm where it is part of a large heteromeric complex (Morishima et al., 
2003; Pratt and Toft, 2003). The role of this complex is to prevent the entering of the nucleus 
(Czar et al., 1995) and to support an optimal conformation for ligand binding. A number of 
chaperones act as subunits (hsp90, hsp70, hsp40) and cofactors (the co-chaperone p23; the 
immunophilins FKBP52 and Cyp40) (Gehring et al., 1993; Pratt et al., 1996). Because of the 
lipophilic character of GCs, these molecules can freely diffuse across the cell membrane and 
bind to different GC transporters and the GR. The binding of GCs to the GR induces a 
conformational change of the receptor resulting in disruption of the complex with chaperons 
and cofactors (Freedman et al., 2004). After the dissociation, the GR molecules become 
unmasked and translocate into the nucleus with the help of importin proteins (Freedman and 
Yamamoto. 2004; Tuckermann and Kleiman, 2007).  
 
The GR influences inflammatory and metabolic processes by several mechanisms:  
 non-genomic inhibition of signaling pathways 
 DNA-binding dependent GR-mediated trans-activation of genes  
 DNA-binding independent GR-mediated trans-repression of genes 
 
Non-genomic mechanisms influence signaling pathways via direct interactions of the GR with 
signaling transduction components including the MAPK protein JNK and PI3K (Caelles et al., 
1997; Kino et al., 2003; Limbourg and Liao, 2003). The effects of non-genomic GC action 
occur within minutes and are dependent on the production of second messenger molecules 
(Buttgereit and Scheffold, 2002) and activation of signal transduction pathways either by the 
cytosolic GR or by the membrane-bound GR (Stellato et al., 2004).  
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Genomic mechanisms of GR action can be subdivided into two modes based on the binding 
partner for the GR and the effects on the gene expression. They are referred to as trans-
activation and trans-repression. 
 
Figure 7: Mechanisms of GC action. GCs act through several modes of action: 1) non-genomic 
pathways through direct interactions of the GR signaling pathways. 2) DNA-binding dependent GR-
mediated transactivation of through binding of GR homodimers to GREs in the promoter region of 
target genes. 3) DNA-binding independent transrepression of genes through binding of the GR as 
monomers to DNA-bound transcription factors. GR: glucocorticoid receptor; GRE: glucocorticoid 
responsive element; TFREs: transcription factor responsive elements; HSPs: heat shock proteins; TF: 
transcription factor (adopted from Schweingruber et al., 2012) 
 
The DNA-binding dependent mode of action occurs in a short period of time via binding of 
the GR as a homodimer to GREs (McNally et al., 2000; Metivier et al., 2003). The 
dimerization of the GR is realized with the help of distinct hydrophobic motifs in the ligand 
binding domain of each GR molecule (Bledsoe et al., 2002) and motifs present in the second 
zink-finger of the DBD. Furthermore, the DBDs N-terminal zinc finger motifs also directly 
contact the GRE of the DNA (Luisi et al., 1991; Cheung and Smith, 2000). After binding to 
the response element, the GR interacts with the basal transcription machinery and various 
1.   INTRODUCTION 
 
21 
cofactors to enhance the expression of the regulated gene. This process is part of the GR mode 
of action and called trans-activation. Through this mechanism, GCs can increase the 
production of different genes including the NFκB chaperone protein IκB, dual specificity 
mitogen associated protein kinase phosphatase-1 (MAPK-1) (Kassel et al., 2001), 
glucocorticoid inducible leucine zipper (GILZ), lipocortin (annexin-1), IL-10, and surfactant 
protein D (Ito et al., 2006). It can also downregulate genes via negative gene regulation 
elements (nGREs) via this mechanism (Chambon et al., 2011).  
 
The second genomic mechanism of GR action is DNA-binding independent. The so-called 
trans-repression is based on GR-mediated inhibition of other transcription factors. In this 
mode of action, the GR monomer suppresses gene expression without dimerization (Reichardt 
et al., 1998) via direct interaction with inflammatory transcription factors such as NF-κB 
(Reichardt et al., 2001), AP1 (Tuckermann et al., 1999) and Stat proteins (Tronche et al., 
2004). The GR binds to the DNA-bound transcription factors and influences their 
transcription via direct inhibition, stimulation of chaperone production, co-factors inhibition 
or epigenetic mechanisms (Barnes et al., 2003; Stahn et al., 2007; Adcock et al., 2008; Ito et 
al., 2006; Löwenberg et al., 2008). Additionally, GCs also have post-transcriptional effects 
and are able to decrease the stability of some pro-inflammatory mRNA species (Barnes 
2011).  
 
1.2.2. Therapeutical and side effects of asthma therapy with GCs 
After the establishment of GCs as a potent anti-inflammatory substance in the late 1940s, 
systemic treatment with GCs was introduced in the therapy of asthma. Today, millions of 
asthmatic patients are treated daily with different inhaled corticosteroids that have been in use 
for over 35 years. The therapy of asthma with GCs is very efficient and can strongly reduce 
asthmatic symptoms. GCs reduce airway inflammation, airway hyperresponsiveness, allergen-
induced peribronchial fibrosis (Miller et al., 2006) but also the frequency of exacerbations, the 
production of TH2 cytokines and can even prevent irreversible airway changes (Barnes et al., 
1998; O'Byrne et al., 2006; Barnes 2011).  
 
At the cellular level during asthmatic reactions, GCs were reported to strongly reduce the 
number of inflammatory cells in the airways including eosinophils, T cells, mast cells and 
DCs (Barnes et al., 1998). These effects of GCs can be achieved through the suppression of 
cytokine and chemokine secretion as well as adhesion molecule expression and by inhibiting 
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the survival of inflammatory cells in the airways (Figure 8). This inhibition of inflammatory 
cell recruitment and induction of apoptosis successfully leads to a reduced level of 
inflammation. 
 
Although great efforts have been made to structurally modify GCs in order to develop more 
efficient and safe anti-asthmatic drugs, long-term therapy with GCs unfortunately is still 
accompanied by dramatic side effects. These include problems with glucose (Pidala et al., 
2011) and amino acids metabolism, diabetes, osteoporosis (Canalis et al., 2007), cataract, 
hypertension and immunodeficiency (Barnes et al, 2010). Recent studies identified a 
correlation between positive and negative GC-effects and the mode of GC action. Based on 
these findings, transactivation is believed to be largely responsible for the reported side 
effects while the trans-repression activity of GCs is mostly associated with their beneficial 
therapeutic effects.  
 
Figure 8: Effects of trans-activation and trans-repression on the expression of anti-inflammatory 
and pro-inflammatory mediators. There are indications that the beneficial effects of GC therapy are 
mainly mediated through transrepression, whereas side-effects correlate with transactivation (adopted 
from Barnes, 2011) 
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1.2.3. Effects of GC-therapy in murine models of inflammatory diseases 
The correlation between trans-repression and suppression of inflammation and immune 
activity opens the possibility to improve treatment efficacy and reduce side-effects using GCs 
without trans-activation activity, so-called dissociated GCs. In order to investigate this 
possibility and to study the molecular mechanism and function of GR action in detail, mouse 
mutants with different types of GR mutations were developed (Cole et al., 1995; Reichardt et 
al., 1998; Tronche et al., 1999; Baschant et al., 2011).  
 
Mice completely lacking a functional GR are not able to survive and die shortly after birth 
(Cole et al., 1995; Tronche et al., 1998) which makes this model unsuitable to analyse GR 
function in vivo. To investigate the molecular mechanism of GC action in vivo and to dissect 
the effects of trans-activation and trans-repression, the GR
dim
 mouse was developed 
(Reichardt et al., 1998). This
 
mouse express a genetically modified form of the GR (Reichardt 
et al., 1998) that can only act via the DNA-binding independent mode of GR action because 
of a point mutation in the dimerization domain of the GR that effectively prevents GR 





 mouse opens up the possibility to test the concept concerning the mechanisms 
underlying the therapeutical and side effects which occur during GC-therapy. Analysis of 
therapeutical efficiency of GCs in GR
dim
 and wild type mice in a murine model of irritative 
skin inflammation demonstrated that suppression by GCs was intact in GR
dim
 mice (Reichardt 
et al., 2001). On the other hand, GR
dim
 mice with a contact hypersensity reaction (CHS, 
Tuckermann et al., 2007), septic shock (Bhattacharyya et al., 2007; Kleiman et al., 2011) or 
antigen-induced arthritis (Baschant et al., 2011) demonstrated strongly reduced GC efficacy. 
These data show the dependency of GC-therapy efficiency on the inflammatory reaction and 
disease type (Baschant et al., 2011). 




Figure 9: Therapeutic effects and side effects of GC-treatment in wild type and GR
dim
 mice. To 
dissect the trans-activation dependent from trans-repression dependent effects of GR action, the GR
dim
 
mouse was analyzed in different disease models (adopted from Tuckermann and Kleiman., 2007).  
 
Because the therapeutic efficiency in different disorders was found to be cell type specific 
(Baschant et al., 2011), the mechanism of GC-therapy is not the same for the treatment of all 
inflammatory disorders. While GC-therapy in murine models of contact hypersensitivity and 
septic shock is dependent on the suppression of myeloid cells, GC treatment of experimental 
autoimmune encephalomyelitis (EAE) exclusively required repression of T cell function 
(Wüst et al., 2009; Schweingruber et al., 2012). These new findings concerning the target 
cells of GC-therapy were obtained using different cell-type specific GR knockout mice. Those 
included mice lacking GR expression in myeloid cells (GR
lysM
, Tuckermann et al., 2007), in T 
cells (GR
lck





Caton, Smith-Raska and Reizis 2007) or B cells (GR
CD19
, Rickert, Roes and Rajewsky 1997).  
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1.3. Aim of the study 
GCs are the measure of choice for the treatment of inflammatory conditions such as asthma. 
To improve therapy new insights into the mode of action and target cells of GCs are needed. 
For this aim a mouse model of AAI should be analysed in this work. 
 
It is well documented that most GC effects are mediated by the GR via transactivation or 
transrepression. The first mode of action requires dimerization of GR, its binding to 
regulatory DNA elements and subsequent activation of target genes. Alternatively, GR may 
control transcription in a DNA binding-independent manner, which is mediated by tethering 
interactions with other transcription factors such as AP-1 and NF-κB. While the first 
mechanism is thought to account for many side effects of GC, the second one presumably 
underlies the majority of its anti-inflammatory actions. To determine the requirement of both 
GR functions for GC intervention of asthma, GR
dim
 mice which express a modified form of 
the GR that is no longer able to dimerize and therefore lack DNA-binding dependent gene 
regulation by GR should be analyzed. To this end the treatability should be compared with 
wild type mice using various experimental approaches. 
 
Since the GR is present in almost every vertebrate cell including immune cells and structural 
cells of the lungs, it is difficult unclear which cells are important for the anti-inflammatory 
effects of GCs during asthma therapy. Another aim of this work was therefore to identify the 
essential target cells of GCs. To answer this question, mast cell deficient mice (cKit) and 
several cell-type specific GR-deficient mice which lack GR in T cells (GR
lck





) or B cells (GR
CD19
) should be used to investigate the role of different 
immune cells and non-immune cells for the suppression of asthma by GCs. 
To further investigate the role of GC effects on non-immune cell populations of the lungs 
GR
dim
 bone marrow chimeras and GR
SPCcreERT2
 mice with an inducible GR knockout in AT2 
cells were analyzed.  
 
Treatment of the different mutant mice with GCs was thought to reveal differences in the 
immunosuppressive effects compare to wild type mice and to provide more information about 
the mechanisms of GC-treatment of asthma. The animals should be analyzed by a series of 
methods including histology, ELISA, FACS and gene expression profiling to investigate GC 
effects in specific cell types. The resulting findings should help to identify the molecular and 
cellular mechanisms of GC action in the therapy of asthmatic reaction.  
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2. Material and Methods 
2.1. Material 
2.1.1. Mice 
All mice which were used during this work were kept under specific pathogen-free conditions 
in individually ventilated cages with unlimited access to the food and water, under a 12 hour 
day-night cycle. Wild type BALB/c and C57Bl/6 mice were obtained from Charles River 
Laboratories (Wilmington, USA). 
 
To determine the mechanism of GC-treatment and the dependency of GC-therapy on 
transactivation vs. transrepression, GR
dim
 mice were used (Reichardt et al., 1998), which 
express a modified form of the glucocorticoid receptor that is no longer able to dimerise and 
therefore lack DNA-binding dependent gene regulation by the GR. These mice were 
backcrossed to the BALB/c background for more than 10 generations and bred in our own 
animal facility in Göttingen. 
 
Because the GR is present in almost every vertebrate cell, it is difficult to determine the 
crucial target cells, which are important for anti-inflammatory effects of GCs during asthma 
therapy. To identify essential target cells of GCs we therefore used cell-type specific GR-
deficient mice which lack the GR in T cells (GR
flox/flox
; lckCre (designated GR
lck
) Baumann S, 
et al. (2005)), myeloid cells (GR
flox/flox
; lysMCre (designated GR
lysM
) Tuckermann JP, et al. 
(2007), in T cells and myeloid cells ((GR
flox/flox





; CD11cCre (designated GR
CD11C
, Caton ML, Smith-Raska MR, Reizis B (2007)) 
or B cells ((GR
flox/flox
; CD19Cre (designated GR
CD19
, Rickert RC, Roes J, Rajewsky K (1997). 
These mice were generated by crossing GR
flox/flox 
mice with lckCre, lysMCre, CD11CCre or 
CD19Cre transgenic/knockin mice, respectively, and back-crossed for at least four 




 mice on a BALB/c background were generated at the Leibniz Institute for Age 
Research by crossing them for at least four generations to the BALB/c background. These 
mice were used to analyze GR expression on eosinophils and to analyze the lack of the GR on 
myeloid cells. These mutants were kindly provided by our co-operation partner Jan 
Tuckermann from the Leibniz Institute for Age Research in Jena. 





(in the following text named as cKit) mice have been described previously 
(Grimbaldeston et al., 2005) were kindly provided by Professor Mauerer (Charite Berlin). 
These mice have a constitutive abolishment of mast cells in all tissues. Because of this 
feature, these animals can be used in experiments to analyze the dependence of GC effect on 
mast cells during asthma-like reaction. 
 
The inducible knockout GR
SPCcreERT2





 mice (obtained from Brigid Hogan, Duke University Medical Center Durham). 
This mouse express a tamoxifen-inducible Cre recombinase (Cre-ERT2) (Feil et al., 
1997;Rock et al., 2011; Xu et al., 2012), which is under the control of the surfactant protein C 
promoter (SPC). Because the SPC promoter is specific for alveolar type II epithelial cells, the 
GR
SPCcreERT2
 mice are lacking the GR expression only in these lung epithelial cells. The 
GR
SPCcreERT2
 mice were backcrossed to C57Bl/6 and used to analyze the role of alveolar 
epithelial cells as the possible key player in the treatment of asthma-like reaction with GCs. 
 
 
2.1.2. Technical equipment 
 
Centrifuge Manufacturer 
Centrifuge Sigma 2-5 for 96-well plates 
Sigma Laborzentrifugen GmbH, 
Osterode am Harz, Germany 
Centrifuge 5417R for reaction tubes Eppendorf, Hamburg, Germany 
Centrifuge  5804R for FACS tubes Eppendorf, Hamburg, Germany 




Microscope Primo Star Zeiss, Jena, Germany 








Incubator, HERAcell 240 Heraeus, Hanau, Germany 
Incubator HERAcell150 Hereaus, Hanau, Germany 





Laminar airflow cabinet, HERASafe Heraeus, Hanau, Germany 
Laminar airflow cabinet Steril Gard Hood 
The Baker company, Sanford, Maine, 
USA 
Interactive SafeChange station (animal facility) 





Water bath Manufacturer 
Water bath W12 
Labortechnik Medigen, Dresden, 
Germany 





Thermocycler Heraeus, Hanau, Germany 
7500 Real-Time PCR System 
AB Applied System Applera GmbH, 
Darmstadt, Germany  









Nanodrop ND-1000 Spectrophotometer ThermoScientific, Wilmington, USA 
Photometer Eppendorf, Hamburg, Germany 





Freezer Liebherr Comfort -20°C 
Liebherr International Deutschland 
GmbH, Biberach an der Riss, Germany 
Freezer Hera -80°C Heraeus, Hanau, Germany 
Freezer VIP plus -150°C 





FACS device Manufacturer 
BD FacsCanto II 
Becton Dickinson Biosciences, 
Heidelberg, Germany 
BD FACS Sorter (BD FACSAria special order 
research product) 
BD Bioscience, Heidelberg, Germany 
Other used devices Manufacturer 
Vortex Genie-2 Bender&Hobein AG, Zürich, Swiss 
RS 225 X-Ray Research System 
Gulmay Medical Systems, Camberley, 
Surrey, UK 
Vapor2000 
Dräger Medical Gmbh, Lübeck, 
Germany 
Perspex chamber Uni Göttingen, Germany 
T18 basic Ultra-Turrax®high performance 
dispenser 
IKA, Staufen, Germany 






Consumables  Manufacturer 
Cannula BD Microlance 3 20G ½  
(0.9 x 40 mm)  
BD Biosciences, Heidelberg, Germany 
Cannula B. Braun Sterican 26G ½  
(0.45 x 12 mm)  
B. Braun, Melsungen. Germany 
Venous catheter BD Venflon Pro 22GA  
(0.9 x 25 mm)  
BD Biosciences, Heidelberg, Germany 
Syringe BD Discardit II (10 and 20 ml)  BD Biosciences, Heidelberg, Germany 
Syringe BD Plastipak 1 ml  BD Biosciences, Heidelberg, Germany 
Neubauer improved haemacytometer 
Henneberg-Sander GmbH, Gießen, 
Germany 
UV System camera and gel imager Intas GmbH, Göttingen, Germany 
ChemoStar gel imager,  Intas GmbH, Göttingen, Germany 
Accu-jet® pro pipette controller Brand GmbH, Wertheim, Germany 
Scale 1003 Sartorius, Göttingen, Germany 
Heating plate HI1220 Leica Microsystems, Nussloch, Germany 
Microtom Leica SM2000R Leica Microsystems, Nussloch, Germany 
Dehydrationssystem TP1020 Leica Microsystems, Nussloch, Germany 
Tissue embedding system EG1160  Leica Microsystems, Nussloch, Germany 
Microplatte Counter 2450 Microbeta
2
 
Perkin Elmer precisely,  Downers Grove, 
USA 
Filtermate Harvester Perkin Elmer, Downers Grove, USA 
Arium®611 laboratory water purification system Sartorius AG, Göttingen, Germany 
Millipore Purification System Millipore GmbH Schwalbach, Germany 
2.   MATERIALS AND METHODS 
 
31 
Diabetic syringe Omnifix 1 ml (25G x 5/8‖)  B. Braun, Melsungen AG, Germany 
FACS tubes  
Greiner Bio-One, Frickenhausen, 
Germany  
ELISA Plates NUNC, Roskilde, Denmark 
Centrifuge tubes (15 and 50 ml)  
Greiner Bio-One, Frickenhausen, 
Germany 
Round bottom culture tube (14 ml)  
Greiner Bio-One, Frickenhausen, 
Germany 
PCR tubes  Sarstedt, Nümbrecht, Germany 
Disposable pipettes (5 ml, 10 ml and 25 ml)  
Greiner Bio-One, Frickenhausen, 
Germany 
Glas pipettes (5 ml and 10 ml)  
Brand Gmbh+CO KG, Hamburg, 
Germany  
Pipette tips for volume 100 µl-1000 μl Sarstedt, Nümbrecht, Germany 
Pipette tips for volume 10 µl– 200 μl 
Greiner Bio-One, Frickenhausen, 
Germany 
Pipette tips for volume 0.1 μl – 10 μl Sarstedt, Nümbrecht, Germany 
24-/ 48-well suspension culture plates  
Greiner Bio-One, Frickenhausen, 
Germany 
96-well optical reaction plate MicroAmp  
AB Applied BioSystems, Foster City, 
USA  
Optical adhesive covers  







FCS Gibco, Invitrogen, Karlsruhe, Germany 
BSA Roth, Karlsruhe, Germany 
DEPC Sigma-Aldrich, Taufkirchen, Germany 
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DNase I Roche, Basel, Swiss 
Ethanol Roth, Karlsruhe, Germany 
Glucose Ferak, Berlin, Germany 
Isopropanol Roth, Karlsruhe, Germany 
H2O2 30%  Carl Roth, Karlsruhe, Germany  
H2SO4  Merck, Darmstadt, Germany  
HCl  Carl Roth, Karlsruhe, Germany  
HEPES  Merck, Darmstadt, Germany  
ß-Mercaptoethanol Roth, Karlsruhe, Germany 
KCl  Merck, Darmstadt, Germany  
KH2PO4  Merck, Darmstadt, Germany  
KHCO3  Merck, Darmstadt, Germany 
Na2CO3  Merck, Darmstadt, Germany  
Na2HPO4 x 12 H2O  Merck, Darmstadt, Germany 
Na3C6H5O7  Carl Roth, Karlsruhe, Germany 
NaCl  Carl Roth, Karlsruhe, Germany 
NaH2PO4 x H2O  Merck, Darmstadt, Germany 
NaHCO3 x 3 H2O  Merck, Darmstadt, Germany 
NaN3  Carl Roth, Karlsruhe, Germany  
NaOH  SIGMA-Aldrich, Taufkirchen, Germany  
Neomycin trisulfate salt hydrate  SIGMA-Aldrich, Taufkirchen, Germany 
NH4Cl  Merck, Darmstadt, Germany  
Proteinase K AppliChem, Darmstadt, Germany 
Taq-Polymerase (5U/µl) Genaxxon Bioscience GmbH, Germany 
Tris AppliChem, Darmstadt, Germany 
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Trizol Invitrogen, Karlsruhe, Germany 
Penicillin/Streptomycin Gibco, Invitrogen, Karlsruhe, Germany 
Tween 20 Carl Roth Gmbh, Karlsruhe, Germany 
3,3’,5,5’-Tetramethylbenzidine SIGMA-Aldrich, Taufkirchen, Germany 
Agarose UltraPure Invitrogen, Paisley, UK 
Dexa-ratiopharm® 100 mg Injektionslösung  Ratiopharm GmbH, Ulm, Germany  
DMSO  Carl Roth Gmbh, Karlsruhe, Germany  
Ethidium bromide  Carl Roth Gmbh, Karlsruhe, Germany 
EDTA Serva, Heridelberg, Germany 
CaCl2x2 H2O  Merck, Darmstadt, Germany 
Citric acid  Merck, Darmstadt, Germany 
Sevorane Sevoflurane Abbott, Illinois, USA 
Paraformaldehyde (PFA) SIGMA-Aldrich, Taufkirchen, Germany 
Protease inhibitor cocktail SIGMA-Aldrich, Taufkirchen, Germany 
PfuS DNA polymerase Own production 
Alhydrogel 2% (Alum) InvivoGen, Toulouse, France 
Albumin from chicken egg white (Ovalbumine/ 
OVA) 
SIGMA-Aldrich, Taufkirchen, Germany 
Concanavalin A  Sigma-Aldrich, Taufkirchen, Germany 








5´-AGG CAG CTA AGA TGC TGA AGC GG-3´ 
5´-CTC CCA CGA TGC CCA CTC GC-3´ 




5`-CGG GAG AGC CTA CAG AGC CCA G-3` 
5`-GGG ATG GAG CCT GGG TGA GCC-3` 
CCL24 (Eotaxin-2) 
5`-TCC CAA GGC AGG GGT CAT CTT CA-3` 
5`-TCG GTG CTA TTG CCA CGG CG-3` 
CXCR3 
5`-ACT GCT CTG CGT GTA CTG CA-3` 
5`-CCA CTA CCA CTA GCC TCA TAG-3` 
CXCR4 
5´-GGC GTC TGG ATC CCA GCC CT-3´ 
5´-GGC AGG ACG AGA CCC ACC A-3´ 
CXCL12 (SDF-1) 
5´-CCC TTC AGA TTG TTG CAC GG-3´ 
5´-TCC TTT GGG CTG TTG TGC TT-3´ 
GILZ 
5´-TTC CGG GGT TTC CGG GGT TTC-3´ 
5´-GTG AGA GAG GAG GTG GAG-3´ 
HPRT 
5´-GTC CTG TGG CCA TCT GCC TA-3` 
5´-GGG ACG CAG CAA CTG ACA TT-3` 
iNOS 
5´-CCG CAC CCG AGA TGG TCA GG-3´ 
5´-GCA AGG CTG GGA GGG GTC CT-3´ 
IL-4 
5´-CCC CCA GCT AGT TGT CAT CCT GC-3` 
5´-ATC TCC CTG CAT GGC GTC CCT-3` 
IL-5 
5`-TGC TGA AGG CCAGCG CTG AAG-3` 
5`-GGG ACA GGA AGC CTC ATC GTC TCA T-3` 
IL-9 
5´-GGC CAG AGA TGC AGC ACC A-3´ 
5´-AGC AGC TGG TCA CGT TGC CG-3´ 
IL-10 
5´-AGG CAG AGA AGC ATG GCC CAG A-3´ 
5´-CGG GAG AAA TCG ATG ACA GCG CC-3´ 
IL-13 
5`-CCC CTG TGC AAC GGC AGC AT-3` 
5`-CGG GGA GGC TGG AGA CCG TA-3` 
IL-17 
5`-AAA GCT CAG CGT GTC CAA AC-3` 
5`-CTT CAT TGC GGT GGA GAG TC-3` 
IL-25 
5´-TGT CCG GCA TGT ACC AGG CTG T-3´ 
5´-GCC ACT CCT CCG GGG GTT CT-3´ 
IL-33 
5´-TCA ATC AGG CGA CGG TGT GGA-3´ 
5´-AAG GCC TGT TCC GGA GGC GA-3´ 
MIP-1a (CCL3) 
5´-CAG CCA GGT GTC ATT TTC CT -3´ 
5´-CTC AAG CCC CTG CTC TAC AC-3´ 
MCP-1 (CCL2) 
5´-AGC ACC AGC CAA CTC TCA CT-3´ 
5´-CGT TAA CTG CAT CTG GCT GA-3´ 
ZO-1 
5´-CCA GCC TCT CAA CAG GTG TA-3´ 
5´-TCA AGG TCT CTG CTG GCT TG-3´ 




All oligonucleotides were designed using the Primer-BLAST software and purchased from 
Metabion (Martinsried, Germany). 
 
 
2.1.6. Media and Buffers 
Occludin 
5´-CCT CCA CCC CCA TCT GAC TA -3´ 
5´-CTT CAG GCA CCA GAG GTG TT -3´ 
RANTES (CCL5) 
5´-GTG CCC ACG TCA AGG AGT AT-3´ 
5´-GGA AGC GTA TAC AGG GTC A-3´ 
TNF-α 
5`-CGT CAG CCG ATT TGC TAT CT-3` 
5`-CGG ACT CCG CAA AGT CTA AG-3` 
TSLP 
5´-AGG ACT GTG AGA GCA AGC CAG C-3´ 
5´-AGG GTA GCC TGG GCA GTG GT-3´ 
TGF-ß 
5´-TGA CGT CAC TGG AGT TGT ACG G-3´ 
5´-GGT TCA TGT CAT GGA TGG TGC-3´ 
GRquant 
5´-CAG CAA CGG GAC CAC CTC CC-3´ 
5´-GTG CTG TCC TTC CAC TGC TCT-3´ 
GT3´GT5´ 
5´-CCA TTA CCT TCC AGG TTC ATT C-3´ 
5´-GTG TCT TGA TGA TAG TCT GCT C-3´ 
Media and Buffers Components or Manufacturer 
PBS 
13 mM NaCl  
2.6 mM KCl  
6.5 mM Na2HPO4 * 2 H2O 
3.6 mM CaCl2 * 4 H2O  
0.5 mM MgCl2 * 6 H2O  
PBS/BSA 0.1 % BSA in PBS 
FACS Buffer 
0.1 % BSA in PBS, pH 7.2 
0.01 % NaN3 
RPMI 1640 Gibco, Invitrogen, Karlsruhe, Germany 
RPMI-10 
RPMI 1640 
10 % heatinactivated FCS (30 minutes at 56 °C) 
1 % Penicillin/Streptomycin 
TAC Buffer 20.0 mM Tris/HCl pH 7.2 





155 mM Ammonium chloride 
DMEM Gibco, Invitrogen, Karlsruhe, Germany 
ELISA Assay diluents 10 % FCS in PBS 
ELISA Coating Buffer 0.1 M Sodium carbonate, pH 9.5 
ELISA Wash Buffer 0.05% Tween-20 in PBS 
ELISA Substrate Buffer 
0.1M Citric Acid 
0.2M Na2HPO4x2H2O 
dH2O 
ELISA developing  solution 
1 % TMB in DMSO (0.01 g/ ml (w/v)) 
0.2 % H2O2 (3.5 % solution) 
Substrate buffer 
ELISA Stop Solution 2N H2SO4 
Alsevers 
27 mM NaCl  
125 mM D-Glucose  
3 mM Citric acid  
30 mM Na3C6H5O7 
10 x DNaseI-Buffer 
500 mM Tris-HCl, pH 7.5 
50 mM CaCl2 
10 mM DTT 
50x TAE Buffer 
4.8 g Tris 
1.1 g glacial C2H4O2 
0.29 g EDTA 
1 L dH2O 
Tail-extraction Buffer 
5 mM Tris/HCl (pH 8.0) 
100 mM NaCl 
100 mm EDTA (pH 8.0) 
1 % SDS 





Antigen Fluorochrome Isotype Clone 
CD4 APC Rat IgG2a, κ RM4-5 
CD3 PerCP Rat IgG2b, κ 17A2 
F4/80 FITC Rat IgG2b, κ CI:13-1 
CD11b PE-Cy7 Rat IgG2b, κ M1/70 
Gr-1 (Ly-6G/C) APC-Cy7 Rat IgG2b, κ RB6-8C5 
Siglec-F PE Rat IgG2a, κ E50-2440 
CD16/CD32 purified Ms IgG1, κ 2.4G2 
Podoplanin PE Syrian Hamster IgG 8.11 
CD45.2 APC Ms (SJL) IgG2a, κ 104 
CD34 PeCy5 Rat IgG2a κ MEC 14.7 
The Antibodies for flow cytometry were purchased from BD Biosciences (Heidelberg, 
Germany) or Biolegend (San Diego, USA).  
 
 
2.1.8. Commercial assays 
 
Kits Manufacturer 
Qiagen RNeasy® Plus Universal Kit Qiagen, Hilden, Germany 
iScript cDNA Synthesis Kit Bio-Rad, Hercules, CA, USA 
Power SYBR® green 
Applied Biosystems, Foster City, California, 
USA  
dNTPs (dATP Na4 x 3 H2O, dCTP Na4 x 3 
H2O, dGTP Na4 x 3 H2O, dTTP Na4 x 3 H2O) 
Genaxxon bioscience, Ulm, Germany 
5x Phusion® Reaction Buffer HF with 
7.5 mM MgCl2 
Thermo Scientific, Waltham, Massachusetts, 
USA  
IgE-HRP (goat anti-mouse) 
IgG2a-HRP (goat anti-mouse) 
Southern Biotech, Birmingham, USA 
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IgG1-HRP (goat anti-mouse) 
Mouse IL-2 ELISA MAX
TM
 Standard Set 
Mouse IL-4 ELISA MAX
TM
 Standard Set 
Mouse IL-5 ELISA MAX
TM
 Standard Set 
Mouse IFNγ ELISA MAX
TM
 Standard Set 
Biolegend, San Diego, USA 
BD OptEIA
TM
 Set Mouse IL-2 
BD OptEIA
TM
 Set Mouse IL-4 
BD OptEIA
TM
 Set Mouse IFNγ 
BD Bioscience, Heidelberg, Germany 
Mini RNA Isolation Kit Zymo Research, Freiburg Germany 






BioTek® Gen5™ version 1.09 BioTek, Bad Friedrichshall, Germany 
7500 System SDS Software v. 1.4.0.25 Applied Biosystems, Foster City, California, 
USA  
BD FACS Diva software version 6.1.2 BD Biosciences, Heidelberg, Germany 
FlowJo software version 7.6 Tree Star, Inc., Ashland, Oregon, USA 
Prism version 6.0 GraphPad Software, La Jolla, CA, USA 
Primer-BLAST http://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 









2.2.1. Animal work 
2.2.1.1. Induction of experimental asthma 
In order to investigate mechanisms of GCs in the treatment of asthma in a murine model, it 
is a prerequisite to induce robust allergic airway inflammation (AAI). This can be achieved 
by immunizing and challenging mice with specific antigens (Zosky et al., 2007; Campbell et 
al., 1999; Clarke et al., 1999; Tounoy et al., 2000) in combination with a potent adjuvant 
such as aluminium hydroxide (Alum). 
 
Figure 10: AAI induction schema. For the induction of experimental asthma, mice were immunized 
by intraperitoneal injection once a week for 4 consecutive weeks with Ovalbumin (Ova) emulsified 
in aluminium hydroxide (Alum) or with Alum in PBS alone (control group). Four weeks after 
immunization, the mice were challenged with intranasal applications of Ova. One group of Ova-
immunized and challenged mice remained untreated whereas another group was treated with 
Dexamethasone (Dex) intraperitoneally. About 40 hours after the last challenge samples were 
collected. 
 
Immunization with chicken-egg Ovalbumin (Ova) as the allergen induces a robust, allergic 
pulmonary inflammation in laboratory rodents (Kumar et al., 2008) and is a widely used 
model to induce airway eosinophilia, pulmonary inflammation and elevated IgE levels found 
during asthma in patients. To induce AAI in the lungs, 8-12 week-old mice were immunized 
on day 0, 7, 14 and day 21 by intraperitoneal injections of 10 µg of Ova diluted in sterile 
PBS and emulsified in 2 mg Alum. The Ova was allowed to conjugate to the Alum for 1 hr 
at the room temperature on the shaker before immunization. Control mice received 
intraperitoneal injections of Alum alone. On day 28 and 29, the mice intranasally received 
250 µg Ova solubilised in sterile PBS with or without GC-treatment via intraperitoneal 
injection of Dexamethasone (10 mg per 1 kg body weight) 1 hour after each Ova-challenge. 
On day 31, about 40 hours after the last challenge, the bronchoalveolar lavage (BAL) fluid 
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was collected from the lungs. In addition, the spleen, blood and the lung tissue was collected 
to study inflammation using FACS, ELISA, RT-qPCR and histological analyses.  
 
2.2.1.2. Establishing of bone marrow chimeras 
To investigate how important GR-expression on non-immune cells is for the therapeutic 





 mice as recipients and GR
wt
 mice or GR
dim
 mice as donors of bone marrow cells 
were generated.  
 
Figure 11: Reconstitution schema of bone marrow chimeras. The reconstitution of the 
hematopoietic system was achieved via transfer of bone marrow into irradiated recipient mice. About 
6-8 weeks after the transplantation and successfully reconstitution of the hematopoietic system the 
AAI was induced in the chimeric animals. 
 
To reconstitute the host´s hematopoietic system by donor cells, recipient mice at the age of 
8-10 weeks were lethally irradiated with 8.5 Gy at a rate of 1 Gy per minute using a RS 225 
X-Ray Research System (Gulmay Medical Systems) operated at 200 kV, 15 mA and with 
0.5 mm Cu filtration to delete their own hematopoietic cells.  
 
To prevent infection of the irradiated mice 25 µg/ml Neomycin were added to the drinking 
water starting one day before irradiation. The water with Neomycin was changed every third 
day during the following six weeks. 
 
On the next day animals received bone marrow cells from donor mice. To isolate bone 
marrow cells from the donor mice, they were euthanized with CO2. After removing the skin 
from the legs, the muscle was cut safety from the femur and tibia. The bones were isolated 
and placed in PBS on ice. After that, the tibia was separated from the femur at the knee 
level. The ends of the bones were cut off under sterile conditions. Through the small hole in 
the end of the bone the bone marrow was flushed out using a 26-gauge needle placed on the 
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5 ml syringe filled with ice cold PBS containing 0.1 % BSA. The isolated bone marrow was 
resuspended using a 30-gauge needle. The resulting cell suspension was passed through a 
40 µM cell strainer to remove large fragments and washed in PBS by centrifugation for 
5 minutes at 350 g and 4 °C. Afterwards the cell number was determinate and the bone 
marrow cell suspension was diluted with PBS to achieve a final concentration of 4 x 10
7
 
cells per 100 µl. The resulting cell suspension was stored on ice until intravenous injection 
into recipient mice.  
 
2.2.1.3. Induction of epithelial cell-specific knockout 
To analyse the role of alveolar epithelial cells as possible key players in the treatment of 
asthma-like reactions with GCs an inducible GR
SPCcreERT2
 mice were used. 
To study the function of lung epithelial cells a SPC
creERT2 
mouse was generated by Brigid 
Hogan from Duke University Medical Center Durham. This mouse expresses a tamoxifen-
inducible Cre recombinase (Cre-ER
T2
), which is under the control of the surfactant protein C 
(SPC) promoter. To this end, the Cre coding sequence was fused to a mutated ligand-
binding domain of the estrogen receptor (ER
T2
). This mutated ligand-binding domain retains 
the fusion protein in the cytoplasm and can translocate into the nucleus (with following 
excision of the loxP-flanked DNA sequence) only upon binding of tamoxifen as a ligand 
(Kellendonk et al., 1996; Feil et al., 1997). Because the surfactant protein C is exclusively 
expressed in the type II alveolar epithelial cells, this knockout occurs only in lung epithelia.  
In this study the SPC
creERT2
 mice, kindly provided by Brigid Hogan were crossed with GR
flox
 
mice to obtain alveolar epithelia specific knockout of the GR in GR
SPCcreERT2
 mice. 
Expression of the GR in alveolar epithelial cells was evaluated using RT-qPCR analysis of 
isolated epithelial cells. 
 
Tamoxifen treatment of mice 
An aliquot of tamoxifen was dissolved in sun flower oil. This 20 mg/ml tamoxifen solution 
was dissolved by incubation at 56 °C for about 20 hrs in a water bath with repeated mixing 
on a vortexer. For oral administration the solution was administered to the mice three times 
(3 mg of tamoxifen dissolved in 150 µl) by a feeding needle every other day. Then, 2 days 
after the last tamoxifen administration the mice were used for induction of allergic asthma-
like reaction in the lungs. 
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2.2.1.4. Histological and imaging analysis of the lung 
2.2.1.4.1. NIRF Imaging 
In vivo imaging by Fluorescence Molecular Tomography (FMT) and Near-Infrared 
Fluorescent (NIRF) Imaging is relatively new method to investigate biological processes in 
mouse models of diseases. In the last few years the new Optical Imaging devices (like the 
FMT 2500 device applied in this work) were developed and now are available for animal 
applications. The feature of this technique is to provide an insight into the cellular processes 
in the body (during for example an inflammatory disease) via a non-invasive mode of action 
in the real time. Disease progression and therapeutic responses, cells of interest or biological 
markers can be monitored and quantified through labelling with light emitting reporters (like 
ProSense680 or anti-SiglecF-AlexaFluor750) (Lyons SK, 2005; Pomper et al, 2005; 
Hickson J et al, 2009; Leblond F et al , 2010). 
 
An imaging agent applied in this work for the examination of asthma-like reactions in the 
lungs of Ovalbumin-sensitised mice was ProSense680, a near-infrared (NIR) protease-
sensing imaging agent. Because this dye is only protease-activatable, it is optically silent in 
its unactivated state in the absence of proteases such Cathepsin B, L, S and Plasmin. These 
Cathepsins are expressed at basal levels in all living cells (Turk et al, 2001), they play an 
important role in several physiological processes such as lysosomal protein degradation, 
antigen presentation and apoptosis. The application of ProSense680 for the monitoring of 
inflammatory diseases is depended on the specific characteristic of the cathepsins, namely 
these proteases are associated with pathological conditions and diseases such as cancer, 
osteoporosis and bronchial asthma (Turk et al 2001; Zavasnik-Bergant & Turk, 2006; 
Vasiljeva et al, 2007). In addition, cathepsins are active in intracellular lysosomes of 
inflammatory eosinophils, which leads to the accumulation of the imaging agent in the lungs 
in vivo. 
 
As another marker for inflammation in the lungs an AlexaFluor750 labeled anti-SiglecF 
antibody was used. In mouse, Siglec-F is an inhibitory receptor specifically expressed on 
eosinophils. Because one of the typical characteristic of asthmatic reaction is a strong 
eosinophilia in the lungs, the anti-SiglecF-AlexaFluor750 provides the opportunity to 
analyse the eosinophil influx into the lungs, the severity of asthmatic reactions and effects of 
GC-therapy on eosinophil migration. 
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2.2.1.4.1.1. In vivo imaging procedure and analysis 
After the second Ovalbumin-challenge the mice were narcotized using a 4 %-
Isofluran/Oxygen mix produced in a Dräger Vapor 2000 device and transferred into a 
customized Perspex chamber. Afterwards, the mice were depilated to minimize fur 
interference with the fluorescent signal. Depilating crème was applied thickly onto the skin 
over the upper torso (front and both sides) of each mouse, after a few minutes the crème was 
rinsed off with warm water; this procedure was repeated until all fur was removed from the 
regions of interest. 4 hrs later, the control mice and the Ovalbumin-sensitized mice were 
imaged using the FMT 2500 fluorescence tomography in vivo imaging system (VisEn 
Medical, Inc.) to determine the basal fluorescence from the lungs and from other body 
regions before injection of the fluorescence imaging agent. After this prescan the mice were 
injected with 4 nmol of the commercially available Prosense680 dye in 100µl of PBS via 
intravenous administration or 12 µg anti-SiglecF-AlexaFluor750 diluted in 100 µl PBS.  
 
After 24 hours the mice were narcotized and carefully positioned in the imaging chamber in 
the FMT device. With the help of a NIR laser diode the light was passed through the mouse 
body and then collected on the opposite side by signal detection via a thermoelectrically 
cooled charge-coupled device camera. The image acquisition took approximately 4 to 5 min 
per mouse. Scans were performed with 1.5 mm (whole body scans) or 1.0 mm (regions of 
interest) raster, photon collection time (so called integration time) of 0.5–0.7 s per scan point 
and varying laser power. Prosense680 fluorescence was measured using excitation at 670 
nm in combination with a 700 nm long-pass emission filter. The fluorescence of anti-
SiglecF-AlexaFluor750 was analysed using excitation at 730 nm. The collected fluorescence 
data were analysed with the OPTIX-OptiView-2 02-00 (ART) software. The obtained 
fluorescence signal was normalized to the basal fluorescence of each animal (prescan) and 
the laser power which was used during acquisition. The relative fluorescence unit intensity 
and the distribution in lung tissues were automatically calculated by the software.  
 
2.2.1.4.1.2. Ex vivo Tissue Imaging 
To confirm that the observed fluorescence in Ova-sensitized and challenged mice after 
induction of AAI originates in the lungs and is not a fluorescence signal from another 
compartment (like the liver), NIR fluorescent images of excised lungs were record and 
analyzed as well. 
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2.2.1.4.2. Histology and immunohistochemistry 
 
2.2.1.4.2.1. Preparation of lung sections 
To assess airway inflammation and mucus cell content in the airway wall, lungs were 
excised from the thorax and fixed in 4 % paraformaldehyde overnight at room temperature. 
On the next day the samples were washed and incubated for 2 hours in PBS at room 
temperature. After this incubation time the lungs were dehydrated in dehydrationssystem 
device through an ascending ethanol gradient: in 70 %, 80 %, 95 % and 99 % ethanol.  
 
The dehydrated organs were incubated in xylene followed by incubation in liquid paraffin. 
Subsequently, the lungs were immersed and embedded in pure paraffin in small plastic 
molds. After the samples were cooled down to solidify the paraffin the lungs could be cut 
into 5-μm sections using a microtome (Leica). The sections were placed with the rough side 
on cold deionized water in a glass cuvette and after short incubation were smoothened on a 
42 °C warm water bath. When the sections had lost their folds they were transferred onto 
Superfrost Plus glass slides (Roth) and fixed overnight at 56 °C in an incubator. 
 
To prepare cryo-sections of lung tissue the fresh biopsies was plunged into a suitable cryo-
agent and quickly frozen. After that the samples were placed on a cryostat chuck and could 
be embedded in a suitable embedding medium OCT. Then, cryo-sections were cut into 
10 µm sections with the help of a cryotom device.  
 
2.2.1.4.2.2. Hematoxylin-eosin staining  
Hematoxylin and eosin are one of the most important standard staining methods used in 
histology. It gives a structural overview of the tissue, allowing differentiation of the 
structures being classified as normal, inflamed or pathological. First, the nuclei are stained 
with a hematoxylin solution, appearing blue or dark violet. During the second step the tissue 
is counterstained with a xanthene dye, e.g. eosin Y, eosin B. In this process cytoplasm, 
collagen, keratin and erythrocytes are stained red (Llewellin et al., 2009).  
 
To perform hematoxylin-eosin staining 5 µM paraffin sections from the lungs were 
deparaffinized for 2x15 minutes in xylene and rehydrated through a descending ethanol 
gradient (2x5 minutes 99 % ethanol, 2x5 minutes 96 % ethanol, 2x5 minutes 70 % ethanol 
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following by incubation for 5 minutes in distillated water). After 10 minutes incubation in a 
hematoxylin solution the sections were washed in distillated water. To develop the color 
reaction the samples were incubated for 10 minutes under running tap water. Afterwards the 
sections were washed in distillated water and incubated for 5 minutes in a 0.1 % eosin 
staining solution. After a quick washing step in distillated water the sections were 
dehydrated through an ascending ethanol gradient (2x5 minutes 70 % ethanol, 2x5 minutes 
96 % ethanol, 2x5 minutes 99 % ethanol) and incubated for 2x15 minutes in xylene before 
they finally were mounted with Entellan under a cover glass.  
 
2.2.1.4.2.3. Anti-SiglecF immunohistochemistry  
The cryo-sections were washed for 10 minutes in Tris (pH 7.6), then for 10 minutes in 
Methanol containing 0.3 % H2O2, followed by two washing steps for 5 minutes in Tris. 
After that, the sections were incubated in Avidin solution for 10 minutes. The samples were 
washed in Tris for 5 minutes and incubated for 10 minutes in Biotin solution. After rinsing 
in Tris, unspecific binding was blocked by incubation with blocking Buffer-Fish for 
15 minutes. Then the solution was taped from the sections, the sections were incubated with 
the rat anti-SiglecF antibody (1:50; BD, Heidelberg, Germany) overnight at 4 °C in the 
humid chamber. On the next day the sections were rinsed two times with Tris for 5 minutes, 
followed by incubation for 1 hour with the appropriate biotinylated secondary goat anti-rat 
antibody (1:2000; Dako, Hamburg, Germany). After that, the samples were washed with 
Tris two times for 5 minutes and were incubated for 1 hour at room temperature with 
Avidin-Peroxidase complex (1:400; Thermo Scientific, MA, USA). After rinsing the 
samples with Tris the sections were incubated with AEC (pH 5.2) at room temperature for 
30 minutes and stained with HE as a counterstain to the SiglecF-staining. Finally, the 
sections were dehydrated in an ascending ethanol gradient (2 minutes in distillated water, 
2x2 minutes in 70 % ethanol, 2x2 minutes 96 % ethanol, 2x2 minutes 99 % ethanol) 




The stained paraffin-embedded sections or cryosections of the lung were inspected using a 
microscope fitted with a 10x, 20× or 40x objective lens. 
  




2.2.1.6.1. Cytokine ELISA 
To analyse the cytokine production of splenocytes their titers were determined by ELISA. 
The experiments were performed according to the manufacturer’s instructions. Firstly, 
microtiter plates were coated with the respective capture antibody (Ab) and incubated 
overnight at 4°C. On the next day the plates were washed with ELISA wash buffer and 
blocked with assay diluents for 1 h at the room temperature. The standards were prepared 
using assay diluent. Also the cell supernatans were diluted with assay diluent and added 
along with the standards to the plate after three washing steps. Standards and samples were 
incubated at the room temperature for 2 h with continuous shaking. After that the plates 
were washed and incubated with the biotin-labeled detection Ab for 1 h at room 
temperature. This was followed by three washing steps and incubation with the avidin-horse 
radish peroxidase mix for 30 min at room temperature. Finally, five washing steps were 
carried out followed by addition of the substrate buffer with TMB and H2O2. After 30 min of 
incubation the reaction was stopped using 1 M H2SO4 and the samples were measured using 
a photometer. Measurements were carried out at 450 nm and 570 nm. 
 
2.2.1.6.2. Ovalbumin-specific Ig ELISA 
To analyse antigen-specific Ig production Ova-specific ELISAs were performed. Microtiter 
plates were incubated overnight at 4°C with 50 µg/ml Ova diluted in ELISA coating buffer. 
On the next day, the plates were washed three times with ELISA wash buffer and blocked 
for 1 h at room temperature with assay diluents to prevent unspecific binding to the plate. 
Serum samples were diluted with assay diluent. The dilution grade was dependent on the Ig 
isotype and on the genotype of the mice. To avoid IgG-contamination in IgE detection, the 
diluted samples were incubated with Protein G Sepharose to bind IgG in the serum samples. 
After three wash steps prepared the samples were added to the plate and incubated overnight 
at 4°C. The next day unbound Igs were washed away by three wash steps and the detection 
Ab were added. After 1 h incubation at room temperature the plates were washed three times 
and the substrate buffer mix with 3,3’,5,5’-Tetramethylbenzidine (TMB) and H2O2 could be 
added to develop the colour reaction based on the oxidation of TMB to tetramethylbenzidine 
diimin. The resulting diimine causes the solution to adopt a blue colour. The reaction was 
stopped using 1M H2SO4 and the plates were measured using an ELISA Reader at 450 nm 
(product) and 570 nm (background).  
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2.2.2. Cell biological methods 
All cell biological experiments were carrying out under sterile conditions to avoid possible 
contamination. 
2.2.2.1. Determination of cell numbers 
The absolute cell number in cell suspensions was determinate using a Neubauer Counting 
chamber. First of all, the volume of the sample was measured and 10 µl of cell suspension 
were taken out and mixed with PBS. This diluted cell suspension was vortexed briefly and 
10 µl of it were placed under the cover glass of the counting chamber. 4 x 16 fields were 
counted and the absolute cell number was calculated using the following formula: 
(Counted cell number/4) x dilution factor x V (ml) x 10
4
 (chamber factor) = absolute cell 
number of sample 
 
For the determination of the cell number of a single cell population in the BAL, the 
following calculation was used:  
(Absolute cell number of the BAL) x (relative percentage [%] of subpopulation of interest) x 
0.01= absolute cell number of subpopulation 
 
2.2.2.2. Ovalbumin-specific restimulation of splenocytes ex vivo 
To examine the antigen-specific proliferation of T and B cells, 300.000 splenocytes were 
cultured for 72 hrs in round-bottom 96-well plates at 37 °C and 5 % CO2. The cells were 
incubated in 200 µl complete RPMI medium supplemented with 10 % heat-inactivated FCS 
and 1% penicillin/streptomycin with or without the addition of Ovalbumin (10 µg/ml). As a 
positive control proliferation after addition of Concanavalin A (ConA) at a concentration of 
2.5 µg/ml was used.  
 
After the culture, 50 µl of supernatant were removed from the plate and frozen at -20 °C for 
ELISA analysis of produced cytokines, whereas the cells were cultured for another 16 hrs 
with 
3
H-Thymidin (1 µCi per well) at 37 °C and 5 % CO2. On the next day the cells were 
soaked into a filter (Printed Filtermat A) using Filtermate Harvester, and a MeltiLex A 
scintillator sheet was molten onto the filter in the microwave at 800W for 2 minutes. The 
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2.2.2.3. Collection of samples 
The mice were euthanized via CO2 inhalation and nebulised with 70 % ethanol, followed by 
exposure of the peritoneum cavity. Afterwards the BAL, spleen, blood, lung tissue and tail 
biopsy were collected. 
 
Schema of sample collection. To investigate the modulation of the inflammatory response by GC-
therapy the following methods were applied: FACS, RT-qPCR, ELISA, 
3
H-thymidine assay, 
microvascular permeability test, histology and NIRF Imaging in vivo and ex vivo. 
 
2.2.2.3.1. Isolation of splenocytes 
 
To isolate lymphocytes from the spleen for proliferation assay, the freshly isolated organs 
were passed through a 40 µm cell strainer and resuspended in PBS. The cell suspension was 
centrifuged for 7 minutes at 300 g and 4 °C. After removing the supernatant the cell pellet 
was resuspended in 1 ml PBS and incubated with 6 ml TAC buffer for 12 minutes. To stop 
this reaction 25 ml PBS was added to the tube and the sample was centrifuged for 7 minutes 
at 300 g and 4 °C. The resulting cell pellet was resuspended in 1 ml PBS containing 0.01 % 
BSA. 
 
2.2.2.3.2. Isolation of the bronchoalveolar lavage (BAL) 
BAL isolation was performed about 40 hrs after the last intranasal Ovalbumin challenge. The 
mice were euthanized via CO2 inhalation and nebulised with 70 % ethanol, followed by 
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exposure of the peritoneal cavity and the diaphragm. After removing the skin and thyroid 
gland an indwelling cannula was inserted into the trachea. Afterwards the BAL was collected 
by gentle flushing the lungs three times with 1 ml aliquots of cold sterile PBS/BSA solution. 
The recovered cell suspension was centrifuged for 6 minutes at 350 g at 4°C. After removing 
the supernatant the BAL cells were resuspended in 1 ml PBS and incubated with TAC buffer 
for 12 minutes at room temperature to lyse erythrocytes in the sample. Then cells were then 
washed with PBS/BSA for 6 minutes at 350 g and 4°C. Afterwards the supernatant was 
removed and the cells were resuspended in the reflux. The total volume of the BAL samples 
and the absolute cell numbers were determined. One part of cell suspension was used for the 
analysis of the cell composition via FACS. Another part was used for RNA isolation, 
followed by reverse transcription and gene expression analysis via RT-qPCR. 
 
2.2.2.3.3. Isolation of serum 
 
After the exposure of the peritoneal cavity and the diaphragm, blood sample was isolated 
from the heart using cannula injection in the left and right heart ventricle. The isolated blood 
was collected into a centrifugation tube. After incubation at room temperature samples were 
centrifuged for 30 minutes at full speed and room temperature. Afterwards the liquid 
transparent supernatant was carefully transferred into a new centrifugation tube and stored at 
-20 °C until analysis. 
 
2.2.2.3.4. Isolation of the lungs 
After isolation of the BAL the upper torso region was opened and the lung was taken out. 
Then thymus, heart, lymph nodes and intestinal tract were separated from the lungs. The lungs 
were used for histology and gene expression analysis. For histology half of the freshly 
isolated lungs was incubated with 4 % paraformaldehyde overnight at room temperature. The 
other half of the lungs was transferred into a new tube right after isolation and quickly frozen 
in solid carbon dioxide snow. Then the samples were stored at -80 °C until RNA isolation. 
 
2.2.2.3.5. Epithelial cell isolation from the lung 
To isolate epithelial cells mice were sacrificed by CO2 inhalation. After the peritoneal cavity 
and diaphragm were exposed blood was flushed from the lungs by perfusion with 20 ml ice-
cold PBS with 5 mM EDTA. To achieve this, a small cut was done into the apex cordis and a 
thin cannula was placed into the right ventricle of the heart. Then blood was rinsed out with 
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constant pressure until the lungs changed colour to white and were visually free of blood. In 
the next step the BAL was isolated from the lungs to avoid contamination of the epithelial 
cells by infiltrating cells. After that the trachea was intubated by an indwelling cannula and 
the lungs were filled with 1 ml of pre-warmed (37°C) Dispase (50 U/ml). Then pre-warmed 
low melt agarose (1 %, 0.5 ml, stored in a 45°C water bath) was infused slowly via the 
catheter to seal the airways and thereby to prevent leaking out of the Dispase. The lungs were 
immediately covered with crushed ice and incubated for 2 min. Afterwards, the lungs were 
moved into 2 ml of pre-warmed Dispase in a 15 ml tube and incubated for 20 minutes at room 
temperature. Then the lungs were transferred to a 60-mm Petri dish and cut with the scissors 
in small pieces (approximately 1 mm
2
) and placed in incubator for another 20 minutes at 
37°C. Afterwards 10 ml of DMEM with 100 µl DNase (2000 U) solution was added to the 
tissue. The digested tissue was placed on a shaker for 10 minutes at room temperature. The 
resulting suspension was filtered through 100 µM and then 40 µM cell strainers into 50 ml 
tube and washed intensively with DMEM to avoid a loss of cells. The filtered suspension was 
centrifuged at 130 g for 10 minutes at 4°C. After centrifugation the supernatant was removed 
and the cell pellet was resuspended in the reflux. To avoid contamination with remaining 
erythrocytes the lung cell suspension was incubated with TAC-buffer (as described above) 
followed by a washing step in FACS Buffer (130 g for 10 minutes and 4°C). After this 
centrifugation step, the cell pellet was resuspended in the reflux and the cell number was 
determined. To further purify the resulting epithelial cell fraction an immunoisolation 
techniques via FACS-Sorting was used. 
 
2.2.2.4. Analytical FACS analysis 
All FACS measurements were performed using a FACSCanto device. Data analysis was 
performed with the program FlowJo. To analyze differential cell compositions of murine 
bronchoalveolar lavage fluid by FACS the isolated cells were stained with a combination of 
commercially available fluorochrome-labelled antibodies: CD3-PerCP, CD4-APC, SiglecF-
PE, F4/80-FITC, CD11b-PE-Cy7 and GR1-APC-Cy7. This combination of antibodies allows 
identifying T lymphocytes, macrophages and monocytes, eosinophils and neutrophils in BAL.  
 
Before the BAL samples were analysed via FACS, a compensation setup was made and the 
FACS antibody-combination was tested to avoid spectral overlap of the fluorochromes.  





 cells were transferred into FACS tubes and washed with 4 ml of FACS Buffer 
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for 5 minutes at 350 g and 4°C. After removing of the supernatant, the cell pellet was 
incubated with 20 µl Fc-Block antibody (anti-CD16/CD32) at 4°C for 15 minutes to avoid 
nonspecific staining of the cells. Then the antibody cocktail was added to the cell suspension 
and after briefly vortexing the cells were stained for another 20 minutes at 4°C. Subsequently 
the cells were washed with 4 ml FACS Buffer and centrifuged for 5 minutes at 350 g and 4°C. 
After removing of the supernatant the cell pellet was resuspended in the reflux and analysed 
using the FACS device (BD FACS Canto II). 
 
2.2.2.4.1. Cell sorting via FACS 
To isolate eosinophils from the BAL, the cells were stained with the antibodies cocktail 
against T lymphocytes, macrophages and monocytes, eosinophils and neutrophils (as 
described above) after pre-incubation with Fc-block. The sorting of eosinophils was 
performed by positive selection of the cell population, which was marked with the eosinophils 
cell surface marker SiglecF. 
 
To isolate epithelial cells from the lung of wild type and knockout mice the cell suspension 
was pre-incubated for 15 minutes with Fc-block and stained for another 20 minutes at 4°C 
with the following combination of fluorochrome-labelled antibodies: Podoplanin-PE, CD34-
PeCy5, CD45.2-APC and F4/80-FITC. This combination of antibodies identifies endothelial 
cells, stromal cells (fibroblasts), macrophages and all other hematopoietic cells. The isolation 
of epithelial cells was performed by negative selection because these cells should be not 
marked with antibodies against hematopoietic cells or stroma cells which are the possible 
contamination of the isolated epithelial cell suspension from the lungs. After gating the cell 
populations of interest, epithelial cells and eosinophils could be collected into the FACS tubes 
and placed on the ice until RNA isolation.  
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2.2.3. Molecular biological techniques 
2.2.3.1. Isolation of RNA from lung tissue 
Pieces or whole deep-frozen lung tissues was homogenized in 900 µl Qiasol Lysis Reagent 
with a tissue homogenisator. The lysates were transferred into Eppendorf tubes and 
incubated for 5 minutes at room temperature to initiate the dissociation of the nucleo-
protein-complexes. To reduce possible contamination with genomic DNA, 100 µl of gDNA 
Eliminator Solution was added to each sample and mixed for 15 second on a vortexer. 
Afterwards, 180 µl chloroform was added to the samples. The resulting homogenates were 
vortexed for 15 seconds and incubated for 3 minutes at room temperature. The tubes were 
centrifuged for 15 min at 4°C at full speed; thereby the sample separated into three phases: 
an upper, colourless, aqueous phase containing RNA; a white interphase; and a lower, red, 
organic phase. The 600 µl of the aqueous upper phase including the RNA was transferred 
into a new tube and mixed with 600 µl 70 % ethanol by pipetting up and down. After that, 
samples were transferred to an RNeasy Mini spin column placed in a 2 ml collection tube 
and centrifuged for 20 seconds at full speed at room temperature. Then 700 µl Buffer RWT 
were added to the column and centrifuged for another 20 second at 8000 g to wash the 
membrane. After this centrifugation step 500 µl Buffer RPE were added to the column and 
centrifuged for 3 minutes and 8000 g to wash the membrane and dry the spin column 
membrane, ensuring that no ethanol was carried over during RNA elution. After that, the 
RNeasy spin column was placed in a new collection tube and 35 µl of RNase-free water 
were added directly to the spin column membrane. To elute the RNA, the samples were 
centrifuged for 1 minute at 8000 g. To obtain more RNA another 35 µl of RNase-free water 
were added into the RNease spin column and centrifuged once more for 1 minute. The 
obtained RNA was used immediately or stored at -20°C for future use.  
 
2.2.3.2. Isolation of RNA from cells 
To isolate RNA from BAL cells or epithelial cells the Mini RNA Isolation Kit was used. 
This kit is designed for rapid isolation of total RNA from small amounts of cells. The cell 
samples were collect by gentle centrifugation at 350 g for 5 minutes and the supernatant was 
removed. 600 µl of RNA ZR Extraction Buffer were added to the samples and mixed briefly 
by 15 seconds of vortexing. Afterwards the mixture was transferred to a Zymo-Spin Column 
and centrifuged at full speed for 1 minute into a 2 ml Collection Tube. The flow-through 
from the collection tube was emptied whenever necessary to prevent contamination of the 
2.   MATERIALS AND METHODS 
 
53 
column by the flow-through. In the next step 400 µl of Pre-Wash buffer were added to the 
Zymo-Spin Column and centrifuged at full speed for 1 minute to wash. Another 700 µl of 
Wash buffer was added to the Zymo-Spin Column and the centrifugation step was repeated 
twice as above. Afterwards the column was transferred to a new RNase-free 1.5 ml tube. 
After adding 40 µl DNase and RNase free water directly to the column membrane, the 
samples were incubated for 1 minute at room temperature and spun briefly to elute the RNA. 
The obtained RNA was used immediately or stored at -20°C for future use.  
 
2.2.3.3. Purification of RNA 
For RNA purification the RNeasy Mini Kit II (Quiagen, Hilden, Germany) was used. Firstly, 
the prepared RNA was incubated with a DNaseI containing mixture (10 µl 10 x DNase I- 
buffer containing 1 µl DNase I) for 30 minutes at 37°C. Afterwards 350 µl RLT buffer 
(containing 10 µl of β-Mercaptoethanol per 1 ml RLT solution) were added into the 
centrifuge tube containing the RNA sample. After briefly vortexing 250 µl of absolute 
Ethanol (96 %) were mixed with the sample by gentle pipetting up and down. In the next 
step the resulting solution was added on the RNeasy Column and centrifuged at full speed 
for 30 seconds into a 2 ml Collection Tube. The flow-through from the collection tube was 
emptied. The sample was washed twice with 500 µl of RPE buffer for 30 seconds at full 
speed and 4°C followed by an eluation step with DEPC-water. For that 30 µl of DEPC-water 
were added directly to the column membrane and centrifugated for 1 minute at full speed 
and 4°C after 1 minute of incubation at room temperature. The obtained RNA was measured 
with a Nano Drop device to analyze the nucleotide concentration and quality. As another 
RNA quality control test the samples were mixed with OrangeG and run on a 1.5 % agarose 
gel. The obtained RNA was used immediately or stored at -20°C for future use.  
 
2.2.3.4. Reverse transcription of RNA 
To generate complementary DNA (cDNA) from RNA templates, reverse transcription was 
done with help of the iScript™ cDNA Synthesis Kit. This kit provides all required reagents 
to create first-strand cDNA. Because all kit components are optimized to facilitate efficient 
cDNA synthesis using 1 pg to 1 µg of total RNA samples were diluted with DNase/RNase-
free-water to obtain this concentration.  
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The iScript reverse transcriptase mixture contains a recombinant RNase H+ MMLV reverse 
transcriptase and a recombinant RNase inhibitor. This unique blend of buffers, stabilizers, 
and dNTPs streamlines reaction setup and ensures robust synthesis of first-strand cDNA 
(adopted from iScript™ cDNA Synthesis Kit manufacture instructions). 
A master mix with all components, except the RNA was prepared and then dispensed into 
each tube with RNA on ice.  
 
Components Volume 
Nuclease-free water variable 
5x iScript select reaction mix 4 µl 
iScript reverse transcriptase 0.35 µl 
RNA sample (1 pg to 1 µg total RNA) variable 
Total volume 20 µl 
 
All components were gently mixed and incubated in a Thermocycler as follows: 
 
Duration and temperature (°C) Function 
5 minutes at 25°C Binding of Oligonucleotides 
30 minutes at 42°C cDNA synthesis by reverse transcription 
5 minutes at 85°C Heat-inactivation of reverse transcriptase 
 
The resulting cDNA product was used directly for PCR amplification or stored at -20°C (for 




In this work PCR was applied in genotyping of animals and examination of reconstitution 
efficiency after bone marrow transplantation, but also to test the DNA and cDNA quality 
before gene expression analyses via RT-qPCR. In the last case, the DNA/cDNA quality was 
tested via PCR analysis of the housekeeping gene β-Actin or HPRT. To do this, the DNA 
was mixed with sequence-specifically oligonucleotides, Taq polymerase, nucleotides, water 
and MgCl2-containing PCR buffer.  




cDNA/ DNA (genomic) 
(undiluted BAL cDNA; lung cDNA in 1:10-dilution) 
1 µl  
Oligonucleotids 0.5 µl (from 10 µM mix) 
dNTP 1 µl (5 mM) 
Taq-Polymerase 0.2 µl (5 U/µl) 
10xPCR-Puffer (with 1.5 mM MgCl2) 2.5 µl 
H2O 19.8 µl 
Total volume 25 µl 
 
The PCR analysis involves the following heating and cooling steps: 
 
Duration and temperature (°C) Function 
5 minutes at 94 °C initial denaturation step 
 
1 minutes at 94 °C denaturation of the template 
1 minutes at 58 °C    ......   35 cycles 
annealing of oligonucleotides to the 
template 
1 minutes at 72 °C binding of DNA-polymerase to the 
template, elongation of PCR product 
10 minutes at 72 °C final elongation of amplicons 
 
Termination of the PCR was achieved by chilling the sample mixture to 4 °C in the 
thermocycler. The resulting amplicons were analysed by agarose gel electrophoresis. All 
PCR analyses were performed using a thermocycler device.  
 
2.2.3.5.1. Quantitative reverse transcription PCR (RT-qPCR)  
In the present work the ΔΔCt method was used for relative quantification of gene 
expression. As an endogenous housekeeping gene Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) was chosen because this gene is constitutively expressed 
at low levels which is useful for RT-qPCR analysis.  
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All RT-qPCR analyses were performed using an ABI 7500 instrument (Applied Biosystems, 
Darmstadt, Germany). The analyses were run according the following program:  
 
 




cDNA 1 µl 
Oligonucleotides  0.5 µl (from 10 pM mix) 
SYBR Green reaction mix 12.5 µl 
H2O 11 µl  
Total volume 25 µl 
 
  
Duration and temperature (°C) Function 
2 minutes at 50 °C 
10 minutes at 95 °C 
Initial denaturation step  
and enzyme activation 
 
15 seconds  at  95 °C          
 
Denaturation of the template 
                   .....            40 cycles  
1 minute at 60 °C 
 
Annealing, Amplification 
15 seconds at 95 °C Denaturation of DNA 
1 minute at 60 °C Hybridisation 
15 seconds at 95 °C Test of melting curve 
15 seconds at 60 °C final elongation of amplicon 
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2.2.3.6. Genotyping of bone marrow chimeras 
2.2.3.6.1. DNA extraction from the blood and tail biopsy 
For genotyping DNA was extracted from blood cells or tail biopsy. To isolate blood cells 
from mice, a small piece of the tail was cut off (and used for tail analysis) and 3 blood drops 
were collected in 1.5 ml Alservers into centrifugation tubes. Afterwards the samples were 
centrifuged for 5 minutes at 350 g and 4 °Cand the supernatant was removed. Cell pellets of 
blood samples or tail biopsies of the mice were digested in 750 µl tail buffer containing 
20 µl Proteinase K at 56 °C overnight. On the next day the samples were mixed with 280 µl 
saturated NaCl solution for 5 minutes and centrifuged for 10 minutes at room temperature 
and full speed. In the next step 850 µl of the upper phase was mixed with 600 µl 
Isopropanol. After 3 minutes of incubation the sample was centrifuged for 10 minutes at 
room temperature and full speed. After removing the supernatant the RNA pellet was 
washed with 500 µl of 70 % ethanol and centrifuged again for 10 minutes. The supernatant 
was carefully removed and the pellet dried at room temperature. In the last step the pellet 
was dissolved in 100 µl TE-Puffer and analyzed by PCR or stored at 4 °C. 
 
2.2.3.6.2. Reconstitution efficacy analysis 
Reconstitution efficacy of bone marrow chimeras was analyzed by monitoring the peripheral 
blood chimerism six weeks after transplantation. To test the reconstitution efficiency of 
GR
dim
 bone marrow chimeric mice blood samples and tail biopsy were genotyped by PCR 
with primers located in exons 3 and 5 of the GR gene (like described before by Reichardt et 
al., 1998). PCR reactions were performed as described above. To distinguish between both 
alleles, an aliquot of the resulting PCR product was digested by incubation with the enzyme 
BsrGI for 2 hrs at 37 °C. Afterwards, the digested sample was separated on a 1.5 % agarose 
gel, and visualization of the bands was achieved using the ChemoStar gel imager (Intas 
GmbH). The wild-type allele shows a band at 0.24 kb whereas the GR
dim
 allele shows two 
bands near the size of 0.12 kb. The appearance of two instead of one band is due to a new 
restriction site for BsrGI introduced by the point mutation in the GR
dim
 mice. Based on this 
analysis the efficacy of reconstitution could be successfully verified. 
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2.2.3.7. Agarose gel electrophoresis  
DNA or RNA samples were separated by (1 % or 2 %) agarose gel electrophoresis. The gels 
were prepared by dissolving the agarose in the 1xTAE buffer. To visualize the DNA, 50 µl 
of (10 mg/ml) ethidium bromide were added to 450 ml (1 % or 2 %) agarose solution. DNA 
or RNA samples were mixed with 6×OrangeG Loading Buffer before loading on the gel. 
Electrophoresis was performed at 120 V for 35 Minutes. Visualization of the bands was 
performed using a UV light with UV System camera and a gel imager device.  
To determine the fragment sizes of the analyzed samples, a DNA molecular weight marker 
(standard 1 kb DNA ladder) was used. 
 
2.2.3.8. Statistical analysis  
Statistical evaluation was performed using the GraphPad Prism 5 and 6 Software (GraphPad 
Software). The 2way ANOVA test and Bonferroni test were chosen to compare two groups, 
if not otherwise stated.  
 
Results are presented as mean ± SEM (standard error of the mean). Based on the calculated 
p-value the significance of the data could be analyzed: p-values < 0.05 were considered to 








3.1. Establishment of AAI as a mouse model of human Asthma bronchiale 
Asthma is defined as a chronic inflammatory disease of the airways induced by a of TH2 
immune response (Gina et al., 2006; Bousquet et al., 2000). The selection of the TH2 
inflammatory pathway is initiated by the uptake of allergens by professional APCs that 
present selected peptides on MHCII molecules to naïve T cells. The antigen presentation by 
APCs directs the specification of naive T cells in favour of a TH2-cell phenotype 
accompanied by the production of several TH2 cytokines, chemokines and other mediators 
that leads to lung infiltration by inflammatory cells (e.g. eosinophilia), production of 
immunoglobulins (IgE, IgG1), cytokine production and hypersecretion of mucus by 
epithelial cells of the airways (Vignola et al., 2000, 2003; Hammad et al., 2008). 
 
To induce allergic airway inflammation (AAI) in the lungs of mice chicken-egg Ovalbumin 
(Ova) was used as an allergen because of its feature to induce a robust, allergic response in 
laboratory rodents (Kumar et al., 2008). For the induction of AAI, mice were immunized by 
intraperitoneal injection once a week for 4 consecutive times with Ova emulsified in 
aluminium hydroxide (Alum) as a TH2 driving adjuvant or with Alum alone (control group). 
Four weeks after immunization, the mice were challenged by an intranasal application of 
Ova. One group of Ova-immunized and challenged mice remained untreated whereas 
another group was treated with Dexamethasone intraperitoneally. About 40 hours after the 
last challenge the mice were sacrificed. The BAL was isolated from the lungs and prepared 
for analysis of the cell composition by FACS and for RNA isolation. The spleen was 
isolated to test for proliferation and priming ex vivo; blood was collected for the 
determination of immunoglobulin and IL-5 production; the lung tissue was isolated for 
histological and gene expression analyses. 
 
3.1.1. Histological analysis of lung inflammation in wild type mice 
In order to investigate inflammation in the lungs after induction of the allergic response, the 
lung tissue was analysed for characteristic cellular and structural changes. Based on the 
analysed lung sections from healthy and asthmatic mice the mouse model of asthma that was 
used in this work leads to a strong infiltration of the lungs by lymphocytes and to 
hyperplasia of epithelial cells with increased mucus secretion.  
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This observation is based on the histological analysis of lung tissue from healthy and AAI 
mice by HE-staining (Figure 12) and PAS-staining (data not shown). 
 
Figure 12: Histological analysis of the lung structure by HE-staining of paraffin sections from 
healthy (left) and AAI (right) mice. The lungs were collected 40 hrs after the last challenge with 
Ova. After fixation in PFA the lungs were cut in 4 µm sections and stained with HE. The left 
pictures represent the lung parenchyma (at 10x magnification) and conducting airways (at 40x 
magnification) of a healthy control mouse. The right pictures demonstrate typical inflammed lung 
tissue (at 10x magnification) and bronchioli with mucus hypersecretion and hyperplasia of goblet 
cells (at 40x magnification). The scale bars in the lower right corner of all images equal 100 μm. 
 
The healthy lung parenchyma has a ―spongy‖ structure and includes, without limitations, 
thin-walled alveoli that are specialized for gas exchange, blood vessels and conducting 
airways. On the histological sections only small numbers of lymphocytes can be seen in the 
lung parenchyma.  
 
The lung tissue of mice with an asthma-like reaction shows strong infiltration by different 
lymphocytes and alveolar collapse. The parenchymal structure differs in free airspace 
because of cell influx into the lungs and mucus hypersecretion by the airway epithelium.  
In the mouse model used in this work, lung remodelling did not occur because of the short 
time of the allergic reaction, but on the histological section one can see first signs of airway 
deformation based on goblet cell hyperplasia, thicker muscle layer around the bronchi and 
increased numbers of blood vessels (Figure 12). The bronchioles in the lung section of AAI 
mice are constricted with a cellular infiltrate in the airways that is absolutely absent in the 
lungs of healthy mice. 
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3.1.2. Establishment of the gating strategy for flow cytometric analysis of the BAL 
The cell composition of the BAL fluid was analysed by FACS. Because the cell populations 
in BAL differ in size, granularity and the expression of different cell type-specific surface 
markers these characteristics can be used to determine the cell composition. 
 
Figure 13: Gating strategy for flow cytometric analysis. (A) To analyse the cell composition of the 
BAL from control and Ova-sensitized mice with or without GC-treatment, the analysed cells were 
first gated for singlets (FSC-H vs. FSC-A) and then for live lymphocytes (SSC-A vs. FSC-A, colored 
in light blue). The resulting live cells-gate was further analyzed for the expression of cell population-
specific markers. The eosinophil gate was defined as SiglecF high, F4/80 low population (colored in 
red); the macrophages as F4/80 high, SiglecF positive cells (colored in deep green); the monocytes 
as SiglecF low, F4/80 high cells (colored in light green); the neutrophils as GR1 high, SiglecF 
negative cells (colored in violet); T helper cells as CD4 high, CD3 high cell population (colored in 
blue). (B) Representative lymphocyte plots for one AAI mouse (SSC-A vs. FSC-A plot and SiglecF 
vs. F4/80 plot) and for a healthy control mouse (SiglecF vs. F4/80 plot, right picture) 
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First of all, it is important to separate the cells from „doublets―. Cell-„doublets― show the 
same FSC-Height but a bigger FSC-Area (more than from one cell). These ―false‖ cells can 
be excluded via gating only on the cells that are located in diagonal position. 
 
Because the BAL contains different population with diverse cell size and granularity, 
eosinophils, macrophages and T cells can be identified on these FSC/SSC plot (Figure 14). 
However, due to the overlapping of these populations it is impossible to reliably analyse the 
BAL cell composition without using fluorochrome-labelled antibodies. Therefore the 
isolated BAL was prepared for FACS analysis as described before. The cells were stained 
with Fc block to avoid unspecific bounding of antibodies. After this ―blocking‖ step the cells 
were stained with an antibody-cocktail consisting of SiglecF-PE, F4/80-FITC, GR1-APC-
Cy7, CD11b-PE-Cy7, CD3-PerCP and CD4-APC.  
 
The eosinophils were defined as small cells with considerable sideward light scattering 
properties, indicative of complex granules. Eosinophils have been described to express high 
levels of SiglecF. This marker is a sialic acid-binding Ig superfamily receptor (Zhang et al 
2007) and shall be deemed to be largely eosin-specific, but some reports suggest that 
alveolar macrophages during inflammatory process in the lungs can also express this 
marker. To separate eosinophils from macrophages, the cells were gated on SiglecF vs. 
F4/80, because F4/80 is described as a very specific marker for macrophages (Austyn et al., 
1981). Large cells with high granularity that express F4/80 at a high level can be identified 
as macrophages (or monocytes); cells with high SiglecF expression were defined as 
eosinophils. Monocytes were identified as F4/80 expressing cells, which are also GR1 and 
CD11b positive and smaller as macrophages with a lower SSC. Neutrophils have almost 
identical size as eosinophils but are less granular and express only GR1 and no SinglecF on 
their surface. T helper cells are small and show low granularity; these cells can be identified 
by gating on CD4 vs. CD3, two markers of CD4 positive T cells. 
 
3.1.3. Establishment of GC-therapy of AAI and mouse strain characteristics 
The histological observation concerning the increased influx of inflammatory cells into the 
lungs was confirmed by analysing cell numbers in the BAL from the wild type BALB/c and 
C57BL/6 mice. The healthy mice in both cases had only about 100 000 cells while in the 
lavage of asthmatic mice there were about 1.5 x 10
6
 inflammatory cells after the induction of 
the allergic response (Figure 14). The peak of inflammation was observed about 40 hours 
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after the last challenge with antigen. Based on this observation the analysis of BAL cell 
numbers and cell composition were always done at this time point.  
 
Although there are several reports, that the C57BL/6 mouse strain develops a less strong 
TH2 response compared to BALB/c mice, the analysis of inflammation in our mouse model 
of asthma showed no significant difference between these two genotypes (Figure 14).  
In order to investigate the mechanism of GC-action in the treatment of AAI, first 
experiments were done using wild type animals. The goal of this study was to analyse the 
normal response to the therapy with Dexamethasone and to establish the treatment protocol. 
Treatment with 10 mg per 1 kg body weight was proven to be successful and strong enough 
to significantly reduce inflammation in AAI-animals. The treatment of mice of both genetic 
backgrounds led to a strong reduction of the cell number in the BAL. While the BAL fluid 
of AAI-animals contained more than 1.5 x 10
6
 infiltrating cells, the BAL of GC-treated 



























Figure 14: BAL cell number of BALB/c and C57BL/6 mice. AAI was induced by repeated Ova-
immunisation and challenge. To analyse the effect of GC-therapy one part of the AAI mice was 
treated with Dex (10mg/kg). To compare infiltration into the lungs of healthy, AAI and Dex-treated 
AAI mice on a BALB/c or C57BL/6 background, the BAL was isolated 40 hrs after the last Ova-
challenge and the absolute cell number of BAL samples was determined using a Neubauer counting 
chamber. The diagram represents the mean absolute cell numbers +/- SEM (BALB/c: control n=15; 
AAI n=17; AAI+Dex n=16; C57BL/6: control n=17; AAI n=18; AAI+Dex n=21). 
 
The cell type composition was analysed by FACS as described above. The data 
demonstrated that the increased number of BAL cells in AAI mice directly correlated with a 
strong eosinophilia in the lungs. The largest fraction of BAL cells (more than 70 %) 
belonged to the eosinophil population after induction of asthma-like reaction while the 
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population of macrophages, neutrophils and T cells together make up less than 30 % of all 


























Figure 15: Analysis of the percentages of different BAL subpopulations in healthy (control), 
AAI and Dex-treated AAI wild type (BALB/c) mice. AAI was induced as described in Figure 10. 
The isolated BAL was analyzed by FACS to investigate the relative percentages of T helper cells, 
eosinophils, macrophages and neutrophils. The data represent the mean of the relative percentages 
with +/- SEM for 11 healthy, AAI and Dex-treated AAI mice. 
 
The treatment of wild type mice with Dexamethasone reduced the fraction of eosinophils to 
less than 40 %. The largest cell population in the BAL of healthy mice were macrophages, 
which make up about 70 % of all cells. The fraction of macrophages in Dexamethasone-
treated AAI mice increases in comparison to AAI mice and constitutes about one third of the 
BAL cells. Dex-treatment of AAI mice does not reduce the percent of neutrophils in the 
BAL: compared to the lung infiltrate of AAI mice the neutrophils in the Dexamethasone-
treated mice make up about one third of the BAL cells. 
 
To further analyse the cellular infiltration and GC-effects on the BAL cell composition, the 
absolute cell numbers of different BAL subpopulations were determined in BALB/c and 
C57BL/6 mice. The results demonstrated that AAI could be successfully induced in both 
mice strains with a very similar BAL cell composition and cell numbers. The largest cell 
population in the BAL of AAI mice consisted of eosinophils (with more than 1 x 10
6 
cells) 
while the BAL of normal healthy animal contains only a few hundred eosinophils.  
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Figure 16: BAL cell composition in BALB/c and C57BL/6 mice. Based on the percentage of the 
subpopulations, the absolute cell number of each subpopulation could be calculated. The BAL 
samples were collected from healthy (Control), AAI and Dex-treated AAI mice of BALB/c and 
C57BL/6 genotype as described before in Figure 14. The diagrams represent the mean of absolute 
cell number +/- SEM (BALBc: Control n=15, AAI n=15, AAI+Dex n=14; C57BL/6: Control n=13, 
AAI n=15, AAI+Dex n=16) 
 
The remaining of the BAL cell fraction from AAI mice of both strains consisted of 
macrophages and neutrophils. The Dexamethasone treatment successfully reduced the cell 
number of the eosinophils in both mouse strains (Figure 16). The cell number of 
macrophages and neutrophiles remained mostly unchanged after Dexamethasone treatment. 
This analysis and the observed effects of Dexamethasone on the number of inflammatory 
cells in the infiltrate demonstrated that both wild type mouse strains were treatable with 
Dexamethasone doses and showed a very similar response to the therapy. 
 
Another important marker of the allergic response is an increased antigen-specific 
immunoglobulin production with class switch to IgE and IgG isotypes. Although there are 
asthmatic patients without increased immunoglobulin levels, these mediators play a crucial 
role in developing an inflammatory reaction. In a healthy non-atopic organism the level of 
IgE and IgG are very low and nearly undetectable, while in the serum of an allergic person 
the level of these immunoglobin isotypes is hundred times increased. This observation was 
confirmed in our mouse model of an asthma-like reaction. The animals immunised and 
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sensitised to Ova showed a strong increase in the level of Ova-specific IgE, IgG2a and IgG1 















Figure 17: Antigen-specific immunoglobulin production in BALB/c and C57BL6 wild type 
mice. Serum was collected from each animal and the Ig level was measured using an Ova-specific 
Ig-ELISA. For Ig detection different dilutions of the serum samples were used:  
BALB/c: IgE 1:1000, IgG2a 1:10 000; IgG1 1:100 000; C57BL/6: IgE 1:100; IgG2a 1:1000; IgG1 
1:100 000. The data represent the mean OD +/- SEM (BALB/c: Control n=17, AAI n=18, AAI+Dex 
n=19; C57BL/6: Control n=16, AAI n=18, AAI+Dex n=21) 
 
High levels of IgE, IgG2a and IgG1 were detected in the serum of AAI mice of BALB/c and 
C57BL/6 mice. Both mouse strains produced a very high level of Ovalbumin-specific IgG1 
while the production of IgE and IgG2a was much less. While the serum of BALB/c mice 
could be diluted 1:1000 for the IgE detection the samples of C57BL/6 mice had to be diluted 
1:100. Also the preparation of samples for detection of IgG2a was made with different 
dilution grade because the serum of BALB/c mice could be diluted 10-fold more than that of 
C57BL/6 mice. The IgG1 level was comparable between both mouse strains. Treatment of 
AAI mice with Dexamethasone did not lead to reduced production of immunoglobulins. 
 
3.1.4. Establishment of NIR imaging of Asthma in the mouse model of AAI 
3.1.4.1. NIR Imaging with ProSense680 
To investigate the inflammation in the lungs, NIR Imaging was used as a non-invasive 
method. First of all, wild type mice under different conditions (control, AAI and 
Dexamethasone-treated AAI mice) were injected with the NIR imaging agent ProSense680. 
ProSense680 allows detecting activated eosinophils, macrophages, neutrophils and other 
inflammated cells in the lungs due to its fluorescence only in the activated stage after 
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Corresponding to the basal state of ProSense680 the fluorescent signal from the lung region 
of control healthy mice was very low. In contrast, the fluorescent signal from the lung region 




Figure 18: NIR in vivo imaging with ProSense680 as an imaging agent. AAI was induced by 
repeated sensitisation and challenge with Ova (with or without Dexamethasone treatment) as 
described before in Figure 10. The fluorescence level was measured 24 hrs after the last challenge 
with Ova (and 20 hrs after ProSense680 dye injection). The acquired images were analysed with 
OptiView software and demonstrate the fluorescence level in the lung region of healthy (control), 
AAI and Dexamethasone-treated AAI mice measured in vivo (control n=1; AAI n=2, AAI+Dex 
n=2). 
 
It could also be demonstrated that while the fluorescence level in AAI mice strongly 
increased compared to healthy mice there was no significant reduction of the fluorescence 
signal after Dex-treatment. This analysis was repeated every 12 hours for two days, but the 
correlation between the treatment and fluorescence signal from the lung region remained 
unchanged (data not shown).  
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The observation, that there was no significant difference between the fluorescence intensity 
from AAI and GC-treated lungs could was confirmed by quantification of the signal (Figure 
19). The calculation was done automatically using OptiView-2 02-00 software (ART). 
Thereby the counts of the fluorescent pixels were normalized to the laser power and the 
























Figure 19: Quantification of total fluorescence counts of activated ProSense680 from the lung 
region of control (n=1), AAI (n=2) and Dex-treated AAI (n=2) wt BALB/c mice. The fluorescence 
level was measured 24 hrs after the last challenge of the mice with Ova (20 hrs after ProSense680 
dye injection). AAI was induced as described before in Figure 10. The data represent the mean of 
total counts (normalized to the basal fluorescence from the lung region and the used laser power). 
 
 
3.1.4.2. NIR Imaging and Immunohistochemistry with Anti-SiglecF 
Lung infiltration by eosinophils and the effects of GC-treatment were also analysed using 
NIR Imaging with the eosinophil-specific marker SiglecF labelled with Alexa-Fluor750 as 
well as immunohistochemistry with an anti-SiglecF antibody. 
 
With the help of anti-SiglecF staining of lung sections it could be shown that SiglecF binds 
very specifically to the eosinophils in AAI mouse lungs. While the infiltrating eosinophils 
were located around the conducting small and large airways in the mice with an allergic 
reaction, the macrophages in the lungs of control mice remained unstained. 





Figure 20: anti-SiglecF staining of lung sections from healthy (control) and AAI wt BALB/c 
mice. For the histological analysis of eosinophils 10 µm cryo-sections of lung tissue were cut and 
stained with an anti-SiglecF antibody. The left pictures represent the lung parenchyma and the 
conducting airways (at 10x magnification) of healthy control mice. The right pictures show typical 
inflammatory lung tissues (at 10x magnification) and bronchioles surrounded by eosinophils of mice 
with AAI. The scale bars in the lower right corner of all images equal 100 μm. 
 
To analyse the eosinophilia in the lungs after the development of an asthma-like reaction 
different time points were used for the imaging with the anti-SiglecF-AlexaFluor750 
antibody. The peak of the fluorescence signal from the lung region was detected 24 hours 
after the last challenge (20 hours after the anti-SiglecF injection). 
 
Compared to the data obtained with ProSense680, where Dexamethasone had no effect on 
the fluorescence intensity of the lungs, the imaging data with the anti-SiglecF agent revealed 
a reduction of the fluorescence in vivo. Because of possible unspecific fluorescence signals 









Figure 21: NIRF imaging with anti-SiglecF-AlexaFluor750 in vivo and ex vivo (A). Acquisition 
data from in vivo and ex vivo anti-SiglecF imaging. (B) Quantative analysis of total fluorescence count 
from the lung region in vivo or isolated lungs ex vivo. (C) FACS analysis of eosinophilia in the BAL of 
the scanned animals. The fluorescence level was measured 24 hrs after the last challenge with Ova (20 
hrs after anti-SiglecF dye injection). For the ex vivo data acquisition, the lungs were dissected from the 
mice immediately after the in vivo scan followed by BAL for FACS analysis.  
 
The fluorescence of the lung region was reduced after Dexamethasone therapy of the 
asthma-like reaction in wild type mice. This respond to GC-treatment could be confirmed by 
subsequent FACS analysis of the BAL (Figure 21). The cell number of the eosinophils was 
significantly reduced from nearly 2.5 x 10
6
 cells in asthmatic mice to less than five hundred 
thousand eosinophils in the BAL of GC-treated ones (Figure 21 C). In this experimental 
setup the analysis of the fluorescence ex vivo provided a more specific picture of the 
eosinophilia than the in vivo data. 
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3.2. Identification of target cell populations of GCs by analyzing therapy 
efficiency in different GR-mutant mouse stains 
To identify essential target cells of GCs in this work were used cell-type specific GR-
deficient mice which lack the GR in myeloid cells (GR
lysM
, Tuckermann JP, et al. (2007), T 
cells (GR
lck
, Baumann S, et al. (2005)), DCs (GR
CD11c
, Caton ML, Smith-Raska MR, Reizis 
B (2007)) or B cells (GR
CD19
, Rickert RC, Roes J, Rajewsky K (1997). These mice were 
generated by crossing GR
flox 
mice (used in these experiments as wild type control mice) with 
lysMCre, lckCre, CD11CCre or CD19Cre mice respectively and back-crossed to either the 
C57BL/6 or BALB/c background.  
 
3.2.1. Analysis of GRlysM mice on BALB/c and C57BL/6 background 
The myeloid cell lineage plays an important role in the pathogenesis of many inflammatory 
and autoimmune diseases. These cells are located in the lung tissue (alveolar macrophages) 
but are also part of the host defense mechanisms and the largest leukocyte population in the 
healthy lungs. On the other hand macrophages play an important role for the improvement 
of lung functions and can be seen as important targets for GC-therapy.To investigate GC 
effects on myeloid cells during therapy of an asthmatic reaction mice were used which lack 
the GR in cells of the myeloid lineage. To compare the effects of the treatment and its 
efficiency wild type and GR
lysM
 mice on both BALB/c and C57BL/6 backgrounds were 
employed. 
 
3.2.1.1. Analysis of GR-expression in eosinophils in the BAL of GRlysM mice 
GR
lysM
 mice were reported to lack the GR in myeloid cells, such as monocytes, 
macrophages, neutrophils, and osteoclasts (Tuckermann et al., 2007). In order to investigate 
GR-expression in eosinophils, they were isolated from the BAL of AAI mice by FACS 
sorting. The mRNA expression level of the GR was determined by RT-qPCR. 
 
The data from this experiment demonstrated that in comparison to wild type mice on a 
BALB/c or C57BL/6 background GR-expression in GR
lysM
-eosinophils was partially 
reduced. Additionally, differences could be observed in eosinophils from GR
lysM
 mice on a 
BALB/c or C57BL/6 background. While GR
lysM
/BALB/c-eosinophils showed only about 
20 % of normal GR-expression, the GR
lysM
/C57BL/6-eosinophiles had more than 70 % of 
GR-expression.  



































 mice on a BALB/c and 
C57BL/6 background. Eosinophils were isolated from the BAL of GR
lysM
 mice (on a BALB/c and 
C57BL/6 background) and GR
flox
 mice by FACS sorting. The mRNA expression of the GR was 
measured by RT-qPCR and normalized to HPRT expression. The GR mRNA expression of GR
flox
 











Based on this observation, GR
lysM
 mice are useful for the evaluation of the role of 
macrophages and monocyte in asthma but only partially for the analysis of the role of 
eosinophils in this process. 
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3.2.2. Analysis of AAI and treatability of GRlysM mice on a BALB/c background 
with GCs 
3.2.2.1. BAL analysis 




 mice suggested a similar reaction 




























































Figure 23: BAL cell numbers (A) and BAL cell composition (B) in GR
lysM
 mice on a BALB/c 
background. (A) The BAL of healthy (control, C), AAI (A) and Dex-treated (AAI+Dex; A+D) mice 
was quantified concerning the absolute cell number with the help of Neubauer cell count chamber.  
(B) To investigate BAL cell subpopulations the isolated BAL samples were analyzed by FACS. The 
relative percentages and absolute cell numbers of the BAL were used for the calculation of the 
absolute cell numbers of the subpopulation. The data represent the mean absolute cell number +/-
 SEM (GR
flox
: control n=2. AAI n=5; AAI+Dex n=3; GR
lysM 
control n=3; AAI n=4; AAI+Dex n=4) 
 
The BAL cell composition revealed a strong eosinophilia in the lungs of wild type and 
GR
lysM
 mice that could be significantly reduced by GC-therapy. In the BAL of GC-treated 
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3.2.2.2. Proliferation and priming in GRflox and GRlysM mice 
GR-depletion in myeloid cells could cause altered proliferation and priming of antigen-
specific T and B cells. To test this possibility it was interesting to analyze the proliferation 
of splenocytes from these mutant mice.  







































 mice after 
antigen-specific restimulation ex vivo. Proliferation of splenocytes from healthy control (C), AAI 
(A) and Dex-treated AAI (A+D) mice was determined after 72 hrs incubation of 300 000 splenocytes 
with antigen-specific restimulation (Ova), compared to the basal proliferation (unstimulated cells). 
50µl of supernatant were collected and the IL-2 release was determined via ELISA. The cells were 
incubated for another 16 hrs in medium containing 
3
H-thymidine and were analysed for proliferation 
activity using a 
3
H-thymidine incorporation assay. The results show the mean proliferation (cpm) or 
IL-2 concentration [pg/ml] +/- SEM of triplicate measurements (GR
flox
: control n=1; AAI n=4, 
AAI+Dex n=2; GR
lysM 
: control n=2; AAI n=3; AAI+Dex n=2) 
 




 mice was increased 





mice showed nearly the same response to GC-therapy and their proliferation activity was 
suppressed. The same effects of GC-therapy could be seen on IL-2 secretion. Compared to 
the IL-2 concentration in supernatants of splenocytes from asthmatic mice the concentration 
of this cytokine in samples of GC-treated animals was several fold decreased.  
 
Because the IL-4 and IFNɣ concentration in the supernatants of the examined mice was very 
low it was difficult to determine the correlation between the treatment and IL-4 or IFNɣ 




 splenocytes ex vivo led to an 
increased secretion of IL-4 and IFNɣ in samples of asthmatic mice’s on a BALB/c 
background. The therapy with Dexamethasone led to stronger production of IL-4 and a 
reduction of IFNɣ production in both genotypes (data not shown). 
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3.2.2.3. Immunoglobulin secretion and isotype class switching 
Secretion of Ova-specific immunoglobulins in GR
lysM
 mice was not impaired by the 
GR-knockout in myeloid cells. As the Ig-analysis data could demonstrate the Ig class switch 
























 mice on a 
BALB/c background. The Ig secretion and isotype switch were analyzed using an Ova-specific Ig-
ELISA of serum from healthy (control), AAI and Dexamethasone-treated (AAI+Dex) mice. The 
dilution of the serum was dependent on the Ig isotype and the genetic background. GR
lysM
/BALB/c: 
IgE 1:100, IgG1 1:100000. The data show the mean OD +/- SEM (GR
flox
: control n=1; AAI n=4; 
AAI+Dex n=2; GR
lysM
: control n=1; AAI n=3; AAI+Dex n=2) 
 
The serum samples used for the detection of Ig isotypes were diluted to different degrees. 
For the IgE measurement the samples of GR
lysM
/BALB/c were diluted 1:100. The IgG1 
isotype was present in serum of Ova-sensitized mice at the highest concentration and could 





3.2.3. Analysis of AAI induction and the efficiency of GC-therapy inGRlck, GRlysMlck 
and GR
lysM







 mice on a C57BL/6 background were analyzed. GR
lck
 mice 
lack the GR on all T cell populations and can be used for the investigation of direct GC-
effects on T cells during GC-therapy of asthmatic reactions. The GR
lysM
 mice (described 
before) lack GR expression in myeloid cells. The GR
lysMlck
 mice are double knockout mice 
in which the GR is depleted not only on T cells but also in the myeloid lineage. This double 
knockout provides the possibility to investigate not only the role of T cells and myeloid cells 
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3.2.3.1. BAL analysis 






 mice was 
determined. The mutant strains developed a strong inflammatory reaction in the lungs with 







mice and reached more than 1.5 x 10
6
 cells.  





































 mice on a C57BL/6 background. (A) The BAL of healthy (control, C), AAI (A) and Dex-
treated (AAI+Dex, A+D) mice was quantified for absolute cell numbers with the help of a Neubauer 
cell count chamber. (B) To investigate the BAL cell subpopulations the isolated BAL samples were 
analyzed by FACS. The relative percentages and absolute cell numbers of the BAL were used for the 
calculation of the absolute cell numbers of the subpopulations. The data represent the mean absolute 
cell number +/- SEM (GR
flox
 control n=9; AAI n=8; AAI+Dex n=9; GR
lysM
 control n=5; AAI n=6; 
AAI+Dex n=8; GR
lck
: control n=6; AAI n=6; AAI+Dex n=7; GR
lysMlck
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As it could be shown by FACS analysis of the BAL (Figure 26 B), the cellular infiltration 
was dominated by eosinophils and could be strongly reduced by GC-therapy in all mutant 
mouse strains. The response to the therapy in mutant mice was similar and did not reveal 





3.2.3.2. Proliferation test of of GRflox, GRlysM, GRlck and GRlysMlck splenocytes ex vivo 
To analyze GC-effects on proliferation splenocytes were restimulated with Ova ex vivo.  





























 mice after 
antigen-specific restimulation ex vivo. Proliferation activity of splenocytes from healthy control 
(C), AAI (A) and GC-treated (A+D) mice was determined after 72 hrs incubation with antigen 
specific restimulation (Ova), compared to the basal proliferation (unstimulated cells). The cells were 
analysed for proliferation activity with 
3
H-thymidine incorporation assay. The results show the mean 
proliferation (cpm) +/- SEM of triplicate measurements (GR
flox
 control n=9; AAI n=8; AAI+Dex 
n=9; GR
lysM
 control n=5; AAI n=6; AAI+Dex n=8; GR
lck
: control n=6; AAI n=6; AAI+Dex n=7; 
GR
lysMlck
: control n=2; AAI n=2; AAI+Dex n=3). 
 
Restimulation with Ova ex vivo led to an increased proliferation of splenocytes. Ova-specific 









 splenocyte showed similar proliferation in GC-treated mice. 
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3.2.3.3. Immunoglobulin production of GRlysM, GRlck and GRlysMlck  







 mice revealed successful induction of Ig production after immunization with Ova 





















































 mice. The secretion of Ig isotypes was analyzed by Ova-specific Ig-ELISA. Serum samples 
for IgE measurement could be diluted 1:100 while the same serum samples for IgG1 detection were 
diluted 1:1000. The data were calculated as mean of OD +/- SEM (GR
flox
 control n=9; AAI n=8; 
AAI+Dex n=9; GR
lysM
 control n=5; AAI n=6; AAI+Dex n=8; GR
lck
: control n=6; AAI n=6; 
AAI+Dex n=7; GR
lysMlck
: control n=2; AAI n=2; AAI+Dex n=3) 
 
Immunoglobulin class switching occurred similarly after Ova-immunization in wild type 
GR
flox
 and all GR
 
knockout mouse strains. GC-therapy had no effects on Ig production in 
any of the strains. 
 
3.2.4. Analysis of AAI Induction and Treatability of GRCD19 mice with GCs 
B cells are involved in asthmatic reactions and play an important role through the release of 
allergen-specific IgE which can activate mast cells, basophils and other inflammatory cells 
like macrophages and eosinophils (Sokol et al., 2009). The immunoglobulin class switching 
to the isotype IgE can be induced by the IL-4 and IL-13 produced by TH2 cells.  
 
To investigate the role of B cell suppression by GC-therapy in asthmatic reactions GR
CD19
 
mice that lack GR expression on B cells were used. 
 
3.2.4.1. BAL analysis 
The analysis of the BAL from GR
CD19
 mutants demonstrated successfully induction of the 
inflammatory response by Ova-immunization. 














































 mice on a 
C57BL/6 background. The BAL of control (C), AAI (A) and Dex-treated (AAI+Dex) mice was 
quantified for absolute cell numbers with the help of a Neubauer cell count chamber. (B) To 
investigate BAL cell subpopulations the BAL samples were analyzed by FACS. The relative 
percentages and absolute cell numbers of the BAL were used for the calculation of the absolute cell 
numbers of the subpopulations. The data represent the mean absolute cell number +/- SEM deviation 
(GR
flox
: control n=2; AAI n=2; AAI+Dex n=4; GR
CD19
: control n=2; AAI n=3; AAI+Dex n=3) 
 





Both mouse strains responded similarly to GC-therapy. 
 
3.2.4.2. Proliferation test of GRCD19 and GRflox splenocytes ex vivo 
Proliferation activity was tested by 
3
H-thymidin incorporation assay. Proliferation was 





behaved qualitatively similar. 
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 mice after antigen-specific 
restimulation ex vivo. Proliferation activity of splenocytes from healthy control (C), AAI (A) and 
GC-treated (A+D) mice was determined after 72 hrs incubation with antigen specific restimulation 
(Ova), compared to the basal proliferation (unstimulated cells). The cells were analysed for 
proliferation activity by 
3
H-thymidine incorporation assay. Results show the mean proliferation 
activity (cpm) +/- SEM of triplicate measurements. (GR
flox
: control n=2; AAI n=2; AAI+Dex n=4; 
GR
CD19
: control n=2; AAI n=3; AAI+Dex n=3) 
 
3.2.4.3. Immunoglobulin production in GRCD19 mice 
In order to test immunoglobulin class switching after Ova-immunization an Ova-specific Ig-




























 mice. The Ig 
secretion and isotype switch were analyzed by Ova-specific Ig-ELISA with isolated serum from 
healthy (control), AAI and Dexamethasone-treated (AAI+Dex) mice. The serum samples for IgG1 
detection was diluted 1:1000. The data were calculated as the mean of the OD +/- SEM (GR
flox
: 
control n=2; AAI n=2; AAI+Dex n=4; GR
CD19
: control n=2; AAI n=3; AAI+Dex n=3) 
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3.2.5. Analysis of AAI induction and treatability of GRCD11c and GRflox with GCs 
DCs play an important role in generating T cell responses (Belz et al., 2004) and initiating 
and perpetuating T cell hyperresponsiveness associated with asthmatic reactions (van Rijt et 
al., 2005; Hammad et al., 2010). DCs as professional antigen presenting cells in the lungs 
transport the majority of antigens to the draining LNs and can direct T cell differentiation 
towards a TH2 response during an asthmatic reaction in the lungs. To understand the 
importance of DC suppression by GC-therapy during treatment of the asthma-like reaction 
GR
CD11c
 mice were used where GR-expression is almost completely ablated in DCs and 
partially in macrophages and T cells.  
 
3.2.5.1. BAL analysis 




 mice led to a strong inflammatory response 
characterized by high numbers of infiltrating cells and strongly increased eosinophil number 











































 mice on a 
C57BL/6 background. (A) The BAL of healthy (C), AAI and Dexamethasone-treated (AAI+Dex) 
mice was quantified for the absolute cell number with help of a Neubauer cell count chamber.  
(B) To investigate the BAL cell subpopulations the isolated BAL samples were analyzed by FACS. 
The relative percentages and absolute cell numbers of the BAL were used for the calculation of the 
absolute cell numbers of the subpopulation. The data represent the mean absolute cell number +/-
SEM (GR
flox
: C n=2; AAI n=4; AAI+Dex n=5; GR
CD11c
: C n=2, AAI n=2; AAI+Dex n=2) 
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Leukocyte infiltration in the lungs of GR
CD11c
 mice was comparable to GRflox control mice. 
The only dissimilarity was the evaluated number of neutrophils in the BAL. While the 
infiltration in asthmatic wild type animals was clearly dominated by eosinophils, the BAL of 
asthmatic GR
CD11c
 mice contained more than 25 % of neutrophils. However, the GC-effect 




 animals.  
 
3.2.5.2. Proliferation and cytokine release by GRCD11c splenocytes 
To examine the influence of GC on the proliferation activity of splenocytes and the 
dependence of this reaction on DCs, the data obtained from restimulated GR
flox
 splenocytes 
from GC-treated asthmatic mice were compared to results from GR
CD11c 
samples.  
Restimulation of wild type and GR
CD11c
 splenocytes from asthmatic mice led to an increased 
proliferation and elevated production of IL-2. The splenocytes of both tested genotypes 
could be successfully suppressed in their proliferation activity and IL-2 production by GC-
therapy.  












































 mice after 
antigen-specific restimulation ex vivo. The proliferation activity of splenocytes from healthy 
control, AAI and GC-treated (AAI+Dex) mice was determined after 72 hrs incubation with antigen 
specific restimulation (Ova), compared to the basal proliferation (unstimulated cells). The cells were 
analysed for proliferation activity with 
3
H-thymidine incorporation assay. IL-2 production was 
measured by ELISA using cell culture supernatants. The results show the mean proliferation activity 
(cpm) and the IL-2 concentration (pg/ml) +/- SEM of triplicate measurements. (GR
flox 
: C n=2; AAI 
n=4; AAI+Dex n=5; GR
CD11c




H-thymidine incorporation assay and the IL-2 secretion analysis showed that the 
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3.2.5.3. Immunoglobulin production and class switching in GRCD11c and GRwt mice 
In order to analyze the Ova-specifici immunoglobulins in GR
CD11c
 mice serum samples were 
used for IgE, IgG2a and IgG1 detection.  















































 mice on a 
C57BL/6 background. The Ig secretion and isotype switch were analyzed by Ova-specific Ig-
ELISA with the serum from healthy (control), AAI and Dexamethasone-treated (AAI+Dex) mice. 
The dilution of the serum was dependent on the Ig isotype: IgE 1:50, IgG2a 1:1000, IgG1 1:100000. 
The data show the mean OD +/- SEM (GR
flox
: Control n=2; AAI n=4; AAI+Dex n=5; GR
CD11c
: C 
n=2, AAI n=2; AAI+Dex n=2) 
 
Ova-specific immunoglobulins of all these isotypes were strongly increased after Ova-
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3.2.6. Analysis of the AAI induction and treatability of KitW-sh/W-sh mice with GCs 
Mast cells are one of the most important player in inflammatory reactions during asthma. 
These cells make up only a very small part of the BAL cells but within the airway tissue 
they encompass more than 20 % of all inflammatory cells. Mast cells are located on the 
surface and within the airways and can directly respond to provocative stimuli.  
To investigate the importance of mast cells suppression by GCs during the therapy of 
allergic response in the lungs the mast cell deficient mutant mice Kit
W-sh/W-sh 
mice (in 
following text designated as cKit) were analysed. 
 
3.2.6.1. BAL analysis 
cKit mice developed a strong inflammation after immunisation and challenge with Ova. The 
inflammatory response in the employed asthma-model was not impaired by the absence of 




































Figure 35: BAL cell numbers (A) and BAL cell composition (B) of cKit and wild type control 
mice (con) on a C57BL/6 background. (A) The BAL cells of healthy (Control), AAI and Dex-
treated (AAI+Dex) mice were quantified for the absolute cell numbers with the help of a Neubauer 
cell count chamber. (B) To investigate the BAL cell subpopulations the isolated BAL samples were 
analyzed by FACS. The relative percentages and the absolute cell numbers of the BAL were used for 
the calculation of the absolute cell number of the subpopulation. The data represent the mean 
absolute cell number +/- SEM (Con: control n=3; AAI n=4; AAI+Dex n=6; cKit: control n=3; AAI 
n=5; AAI+Dex n=6) 
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Infiltration based on absolute cell numbers and the composition of the BAL cells was similar 
in wild type controls and cKit mice. Both mouse strains response to the asthma-induction 
with a cellular influx into the lungs dominated by eosinophils. The absolute number of BAL 
cells was also comparable between both genotypes.  
 
GC-therapy successfully suppressed cellular infiltration and reduced the absolute cell 
number of the infiltrate from more than 1.5 x 10
6
 to less than 200 000 cells and eosinophilia 
(from more than 800 000 eosinophils in the asthmatic BAL to 10 000 cells in GC-treated 
animals). 
 
3.2.6.2. Proliferation and IL-2 secretion by splenocytes from cKit  mice 
To analyze the effects of GCs on proliferation and priming, splenocytes from healthy, 
asthmatic and GC-treated mice were isolated and used for a 
3
H-thymidine incorporation 
assay and the analysis of IL-2 by ELISA.  




































Figure 36: Proliferation and priming in wild type controls (con) and cKit mice after antigen-
specific restimulation ex vivo. Proliferation of splenocytes from healthy (C), AAI and GC-treated 
(AAI+Dex) mice was determined after 72 hrs incubation with antigen-specific restimulation (Ova), 
compared to the basal proliferation (unstimulated cells). The cells were analysed for proliferation 
activity with 
3
H-thymidine incorporation assay. The IL-2 release was determined by ELISA. The 
results show the mean proliferation (cpm) or IL-2 concentration +/- SEM of triplicate measurements. 




H-thymidine assay and the results from the IL-2 ELISA showed enhanced proliferation 
and increased IL-2 secretion in samples of AAI mice. This could be prevented by GC-
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3.3. The role of DNA-binding-dependent transactivation function of the GR for 
GC-therapy of AAI 
It is well documented that most GC effects are mediated by the GC receptor (GR) via 
transactivation or transrepression. To determine the relevance of these two GR functions for 
GC intervention in asthma, GR
dim
 mice (on a BALB/c background) were tested for the 
treatment efficiency of Dexamethasone. Because of a point mutation GR
dim
 mice express a 
modified form of the GR that is no longer able to dimerise and therefore lacks DNA-binding 
dependent gene regulation.  
 
3.3.1. BAL analysis of GRdim mice 





mice were used for induction and treatment of a mouse model of Asthma.  




































 mice. The AAI was induced by repeated Ova-immunisation and 
challenges, the AAI+Dex animals were treated with Dexamethasone. The BAL was isolated 40 hrs 
after the last Ova-challenge. The absolute cell number in the BAL samples was determined using a 
Neubauer cell count chamber. The data represent the mean of cell number +/- SEM (GR
wt
: Control 
n=13; AAI n=13; AAI+Dex n=14; GR
dim
: Control n=13; AAI n=12; AAI+Dex n=17). 
 





was strongly increased and the BAL in Ova-sensitised mice contained more than 1.5 x 10
6
 
cells while the control healthy mice had only around 100 000 cells in the BAL. Treatment of 
the inflammatory reaction with Dexamethasone reduced the absolute cell number in the 
BAL of GR
wt
 mice while GC-therapy of GR
dim 
mice had no influence on the number of 
lung-infiltrating cells (Figure 37). 
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The observation that the number of infiltrating cells in the lungs was increased could be 
corroborated by FACS analysis of the cell composition. While healthy mice in both cases 
have a large population of macrophages in the lungs and nearly no eosinophils, the asthmatic 
mice developed a strong eosinophilia with about 70 % of eosinophils in the BAL. Because 
of this strong eosinophilia the relative percentage of other cell type were strongly reduced in 
comparison to the BAL from healthy mice. This replacement in cell population arrangement 
was seen in the both genotypes. 

































Figure 38: Analysis of the absolute cell number and the relative percentage of different 




 mice. The relative percentage of T helper 
cells, eosinophils, macrophages and monocytes were determined by FACS analysis. Based on the 
relative percentage of the subpopulations and the absolute cell numbers of the BAL cells, the 
absolute cell number of each subpopulation could be calculated. The diagrams represent the mean of 
absolute cell numbers +/- SEM (GR
wt
: Control n=9; AAI n=11; AAI+Dex n=11; GR
dim
: Control 
n=13; AAI n=10; AAI+Dex n=14). 
 
The GC-treatment could suppress the infiltration of the lungs with eosinophils only in GR
wt
 
mice. While the cell number of eosinophils in AAI was significantly reduced from more 
than 1 x 10
6
 cells in GR
wt
 mice to about 100 000 eosinophils in Dex-treated mice, the 
treatment of GR
dim
 led to minimal changes. After GC-therapy the BAL of GR
dim
 mice still 
consist of more than 60 % of eosinophils and the changes in eosinophil numbers after GC-
therapy were not significant. The numbers of neutrophils was not reduced after 
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Dexamethasone-treatment in both genotypes. The relative percentage of this population was 
increased after therapy with GCs.  
 
3.3.2. Proliferation and cytokine release by GRdim splenocytes ex vivo 
To examine the effects of GC-treatment on the proliferation and priming of splenocytes 
antigen-specific restimulation was used ex vivo. This restimulation of splenocytes with 
Ovalbumin led to an increased proliferation of Ova-specific cells of both genotypes. This 
was demonstrated by 
3
H-thymidine incorporation assay and the analysis of IL-2 production 
by ELISA. The 
3
H-thymidine incorporation assay showed no differences in the proliferation 
between AAI and Dexamethasone-treated animals. However, the analysis of IL-2 in the 
supernatant of cells from AAI in GR
wt
 mice showed not only strongly increased secretion of 
this cytokine but also a significantly reduction of its production in Dexamethasone-treated 
animals. This effect of Dexamethasone was not observed for GR
dim
 splenocytes. 























































 mice ex vivo. Proliferation and cytokine release was determined for splenocytes 
(from healthy=C, AAI=A and GC-treated A+D mice) after 72 hrs with antigen specific restimulation 
with Ova, compared to the basal proliferation and cytokine secretion (unstimulated cells). The cells 
were analysed for proliferation activity using a 
3
H-thymidine incorporation assay (data shown as 
cpm–mean +/- SEM). The cell culture supernatants were analyzed for IL-2, IL-4 and IFNγ by 
ELISA. Results shown are the mean concentration +/- SEM of triplicate measurements (GR
wt
: 
Control n=9; AAI n=11; AAI+Dex n=11; GR
dim
: Control n=13; AAI n=10; AAI+Dex n=14). 
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 mice showed an increased 
secretion of IL-4 and IFNγ. While the splenocytes from GC-treated animals of both 
genotypes showed no significantly increase in IL-4 secretion, the IFNγ production showed a 
different regulation. The splenocytes from asthmatic GR
wt 
mice secreted less IFNγ after 
Dexamethasone-therapy while the GR
dim
 splenocytes from GC-treated mice produced more 
IFNγ compared to the production of splenocytes from AAI mice. 
 
3.3.3. Antigen-specific immunoglobulin production 

































































 mice. For detection and measurement of Ig serum was collected from each animal 40 hrs 
after the last challenge with Ova with or without treatment with Dex. The Ova-specific 
immunoglobulin ELISA was used as technique for the analysis. For Ig detection different sample 
dilutions were used dependent on the Ig isotype: IgE 1:100, IgG2a 1:10 000; IgG1 1:100 000. The 
data represent the mean OD +/- SEM deviation. (GR
wt
: Control n=9; AAI n=11; AAI+Dex n=11; 
GR
dim
: Control n=13; AAI n=10; AAI+Dex n=14). 
 
As it can be seen in this analysis there are no differences in Ig production between allergic 












 mice a HE-staining of 
lung sections was used in addition to the FACS analysis shown before. 
 





 (B) mice. For the histological analysis of structural and cellular changes of lung tissue 




 mice the lungs were collected 40 hrs after the last 
challenge with Ova. After fixation with PFA the tissue samples were cut in 4 µm sections and stained 
with HE. (A) The pictures show the alveolar tissue and the conducting airways (at 20x magnification) 
of healthy control, AAI and Dex-treated AAI GR
wt
 mice. (B) The pictures show lung sections from 
healthy control and inflammatory lung tissue (at 20x magnification) of AAI and Dex-treated GR
dim
 




 mice developed a strong inflammation after induction of an asthma-like reaction in the 
lungs accompanied by massive cell infiltration. The cell influx into the alveolar tissue and the 
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 mice. The airway epithelium showed first remodelling 
stages with hyperplasia of goblet cells and mucus hypersecretion.  
The anti-inflammatory effect of GCs on lung infiltration can only be seen in GR
wt
 mice 
whereas the number of infiltrating cells in the lungs of treated GR
dim
 mice was not reduced 
through GC-therapy (Figure 41). The treatment of GR
wt
 animals led to an observable effect on 
the lung sections: the exoneration of bronchioles from mucus and enlargement of free space 
for gas exchange with normal alveolar tissue reformation. These anti-inflammatory effects 




3.3.5. ProSense680 imaging of GRwt and GRdim mice 
To investigate inflammation in the lungs of GR
dim
 mice after induction of asthma-like reaction 
the non-invasive method NIR Imaging with the ProSense680 probe was additionally used. In 
this experimental setup were used the same parameters (time point and concentration) for 
imaging as previously established with BALB/c wild type mice.  
 




 mice with ProSense680. The fluorescence level of the 
activated ProSense680 probe was measured 24 hrs after the last challenge of the mice with Ova (20 
hrs after ProSense680 dye injection with 5 nmol ProSense680 i.v.). The AAI was induced like 
described before in Figure 10. The pictures were analysed with OptiView software and show the 
fluorescence level in the lung region of healthy (control) and AAI mice measured in vivo  
 
Fluorescence scanning of the thoracic region showed a strong induction of the allergic 




 mice. Both mouse strains demonstrated very similar 
ProSense680 activation suggesting a comparable inflammation level.  
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3.3.6. Detection of IL-5 secretion in serum samples of GRdim mice 
Because the maturation and release of eosinophils from the bone marrow is dependent on IL-5 
secretion of this cytokine plays an important role in the asthmatic reaction. IL-5 can be 
produced by TH2 cells but also by mast cells and eosinophils themselves. This autocrine 
mechanism of IL-5 secretion may contribute to the chronic course of allergic inflammation in 
the lungs with strong eosinophilia.  
 
Because IL-5 is thought to play an important role in asthmatic bronchomucosal inflammation 
and could be a potential therapeutic target in asthma therapy it was interesting to analyse its 
























 mice. The isolated 
serum samples (from control, AAI and Dex-treated (AAI+Dex) mice) were analyzed by IL-5 ELISA. 
The data represent the mean concentration +/- SEM (GR
wt
: control n=12, AAI n=14; AAI+Dex n=19; 
GR
dim
: control n=11; AAI n=12; AAI+Dex n=11) 
 
This experiment demonstrated an increase of IL-5 secretion into the serum of AAI mice of 
both genotypes. The slightly reduction of IL-5 concentration after Dexamethasone-treatment 
could be seen in the serum of GR
dim
 mice while the level of IL-5 production in GR
wt
 mice 
remained nearly unchanged.  
 
3.3.7. Effects of GCs on the barrier function of the lung endothelium in GRdim mice 
with AAI  
Because the altered microvascular permeability is related to the injury process during an 
inflammatory reaction this parameter is an important sign of disease progression. To 
investigate the influence of GC-therapy on the barrier function of the asthmatic lung 
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 mice were analyzed using a modified Evans blue 
extravasation technique.  
Figure 44: Microvascular 





 mice. The barrier function 
of the lung endothelium was tested 
via the Evans blue extravasation 
technique. Evans blue solution (25 
mg/kg) was injected i.v. and 
circulated for 30 min through the 
blood in healthy, AAI and Dex-
treated AAI mice. Afterwards the 
Evans blue was extracted from the 
pulmonary tissues during 24 hrs of 
incubation at 60 °C in Formamide. The concentration of Evans blue was determined by 
spectrophotometric analysis. The data represent the mean of Evans blue concentration +/- SEM (GR
wt
: 
Control n=2; AAI n=2; AAI+Dex n=2; GR
dim
: Control n=2; AAI n=2; AAI+Dex n=3) 
 
To analyze the microvascular permeability, Evans blue was injected i.v. and after a circulating 
phase the lungs were dissected and the Evans blue could be extracted from the lung tissue. 
This analysis showed that the permeability of the endothelium was significantly increased 
after induction of an asthma-like reaction. While this pathogenic process could be 
successfully suppressed by GC-therapy in the lungs of GR
wt
 mice the barrier function of 
GR
dim
 mice could be not improved by Dexamethasone treatment. 
 
3.3.8. Gene expression analysis of the BAL and Lung in GRdim mice 
The GR is known to modulate gene transcription via DNA-binding-dependent 
(transactivation) and DNA-binding independent (transrepression) mechanisms.  
To better understand the effects of GC-therapy on the gene expression the samples were 
analyzed via RT-qPCR. The relative gene expression of each group was normalized to the 
mean gene expression of asthmatic mice of each genotype. As a consequnce of the allergic 
response in the lungs after induction of an asthma-like reaction the gene expression of a 
variety of cytokines and chemokines is altered. The expression of most of them is strongly 
increased in AAI animals. In order to analyze the differences in the regulation of gene 




 mice RT-qPCR analysis was 
used. To investigate the effects of GCs on the infiltrating cells and the lung parenchyma 
































The inflammatory response in the lungs led to an increased expression of several 
inflammatory mediators in BAL and lung tissue on mRNA level.  
 
The first group of analyzed genes served as markers for the cell type specific infiltration and 
cell migration into the lungs: IL-5, Eotaxin-2, MCP-1, MIP-1a, CXCR3 and CXCR4. Gene 
expression analysis of these cytokines and chemokines demonstrates an induction of mRNA 
expression after the development of an asthma-like reaction in the lungs.  
 
IL-5 and Eotaxin-2 play an important role in the development of eosinophilia in the lungs. 





 mice. IL-5 was also downregulated in GR
wt
 lungs while the GR
dim
 























 mice. BAL samples and lung tissue were isolated from healthy (control), 




 mice. The AAI induction and Dex-treatment was done as 
described before in Figure 29. The data represent the mean mRNA expression normalized to samples 
of AAI mice +/- SEM (GR
wt
: control n=2; AAI n=2; AAI+Dex n=2; GR
dim














































































































CXCR3 is preferentially expressed on activated TH1, NK and some epithelial and endothelial 
cells. Its expression is important for lymphocyte migration into the lungs and its ligands can 
block the migration of TH2 cells and effector T cells in response to CCR3. CXCR3 expression 
was only lightly upregulated after induction of an asthma-like reaction in the infiltrating cells. 







CXCR4 mobilizes hematopoietic stem cells into the bloodstream during an inflammatory 
response. The data from BAL cell samples show CXCR4 expression was not significantly 
increased or suppressed in any experimental group. While all BAL samples showed 
comparable CXCR4 expression, the induction of an asthma-like reaction led to an increased 
expression of this gene in lung tissue samples of GR
wt 
mice. GC-therapy did not change 




























































Figure 46: The RT-qPCR analysis of CXCR3 and CXCR4 mRNA expression in lung tissue and 




 mice. BAL samples and lung tissue were isolated from healthy 




 mice. The AAI induction and Dex-treatment was 
done as described before in Figure 29. The data represent the mean mRNA expression normalized on 
samples of AAI mice +/- SEM (GR
wt
: control n=2; AAI n=2; AAI+Dex n=2; GR
dim
: control n=2; AAI 
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To investigate inflammatory mediators which play a role in macrophage and monocyte 






























































Figure 47: The RT-qPCR analysis of MCP-1 and MIP-1α mRNA expression in lung tissue and 




 mice. On the analysis day the BAL samples and lung tissue were 




 mice. The AAI induction 
and Dex-treatment was done as described before in Figure 29. The data represent the mean mRNA 
expression normalized on samples of AAI mice +/- SEM (GR
wt
: control n=2; AAI n=2; AAI+Dex 
n=2; GR
dim
: control n=2; AAI n=3; AAI+Dex n=3) 
 
It was reported that alveolar macrophages produced increased amount of these two cytokines 





 mice with an allergic reaction and nearly unchanged expression 
of MIP-1a. After GC-therapy MCP-1 and MIP-1α expression were slightly induced in BAL 
samples. The expression of these cytokines was strongly induced in the lungs of asthmatic 
animals. Treatment with Dexamethasone led to a further increase of MCP-1 and MIP-1α in 
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Other analyzed genes belong to a group of genes that impact inflammation: IL-4, IL-13, 



























































Figure 48: RT-qPCR analysis of IL-4, IL-13 and RANTES mRNA expression in lung tissue and 




 mice. BAL samples and lung tissue were isolated from healthy 




 mice. The AAI induction and Dex-treatment was 
done as described before in Figure 29. The data represent the mean mRNA expression normalized on 
samples of AAI mice +/- SEM (GR
wt
: control n=2; AAI n=2; AAI+Dex n=2; GR
dim
: control n=2; AAI 
n=3; AAI+Dex n=3) 
 
The TH2 cytokines IL-4 and IL-13 play a key role in disease progression by activating and 
recruiting a variety of inflammatory cells such as eosinophils, mast cells and B cells into the 
lungs. These cytokines were strongly induced in the BAL and lung samples of asthmatic 
animals of both genotypes. The GC-therapy led to different effects on IL-4 and IL-13 
expression: While IL-4 mRNA expression in BAL samples of GR
wt 
mice was downregulated 
the expression of this cytokine in the lung was elevated. The opposite effect was observed in 
samples of GR
dim
 mice: IL-4 expression was elevated in BAL samples of GC-treated mice 
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RANTES leads to increased eosinophilia independent on the presence of the allergen. The 
mRNA expression data demonstrate a strong suppression of RANTES expression after GC-
therapy in samples of AAI GR
wt
 mice. In contrast, GC-therapy of GR
dim
 mice did not affect 

































































 mice. BAL samples and lung tissue were isolated from healthy (control), 




 mice. The AAI induction and Dex-treatment was done as 
described before in Figure 29. The data represent the mean mRNA expression normalized on samples 
of AAI mice +/- SEM (GR
wt 
: control n=2; AAI n=2; AAI+Dex n=2; GR
dim
: control n=2; AAI n=3; 
AAI+Dex n=3) 
 
The inflammatory enzyme iNOS is a characteristic marker of the inflamed epithelium and 
activated macrophages. The results of the iNOS gene expression analysis demonstrated that 
the allergic response in the lungs led to only a minor increase in iNOS expression in the 
infiltrating cells but the induction of an asthma-like reaction caused a significant upregulation 
of iNOS expression in lung tissue of both genotypes. The therapy with Dexamethasone 
suppressed iNOS expression in the lung cells of GR
wt 
mice while the expression of this 
inflammatory enzyme was up-regulated in GC-treated asthmatic GR
dim
 mice.  
 
IL-10 was shown to play a conflicting role in disease development and progression. While 
this cytokine is an important anti-inflammatory cytokine, the over-expression of this mediator 
can lead to the development of fibrosis in asthmatic lungs. IL-10 expression was unchanged 
in the BAL samples of GR
wt
 mice while the samples of asthmatic GR
dim
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slightly induction of IL-10 expression after the GC-treatment. In contrast, the expression of 




 mice. This elevated 
expression of IL-10 after induction of an asthma-like reaction could be strongly suppressed in 
GR
wt
 mice by Dexamethasone treatment while the IL-10 mRNA expression in the lungs of 
GC-treated GR
dim
 mice was unchanged. 
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3.4. The role of non-hematopoietic cell types in the therapy of asthma with GCs 
3.4.1. Bone marrow chimeras 
To investigate the role of non-immune cells in the treatment of asthmatic reactions bone 









 bone marrow. This resulted in four experimental groups in total. 
 
Figure 50: Reconstitution schema of hematopoietic system. GRwt and GRdim recipient mice at 
the age of 8-10 weeks were lethally irradiated with 8.5 Gy at a rate of 1 Gy per minute to delete their 





donor mice. After 6 weeks the reconstitution efficiency of hematopoietic system (HS) was 

















 HS. After complete reconstitution of the haematopoietic system the 
AAI was induced as described before. 
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3.4.1.1. BAL analysis 














































 recipient mice were 




donor mice. After complete reconstitution of the 
haematopoietic system the AAI was induced and the BAL was isolated 40 hrs after the last Ova-
challenge. The absolute cell number in the BAL was determined with a Neubauer cell count chamber. 
The data represent the mean cell number +/- SEM from four separate experiments (GR
wt
 recipient with 
GR
wt 
BM: Control n=6; AAI n=7; AAI+Dex n=8; GR
wt
 recipient with GR
dim 
BM: Control n=5; AAI 
n=8; AAI+Dex n=8; GR
dim
 recipient: with GR
wt 





BM: Control n=3; AAI n=3; AAI+Dex n=3) 
 





 bone marrow chimeras. Without immunization and sensitization with Ova 
the mice did not develop an inflammatory response and showed normal cell numbers in the 
BAL.  
 




 bone marrow chimeras all 
showed very similar lung infiltration with about 2 x 10
6
 cells in the asthmatic BAL. The 
reduction of the cell number after the GC-therapy was only dependent on the genotype of the 
recipient mice and did not show any correlation with the genotype of the donor cells.  
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GRwt recipient GR
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 bone marrow chimeras. The relative percentages of T helper cells, eosinophils, 
macrophages and monocytes were determined by FACS analysis. Based on this relative percentage of 
the subpopulations and the absolute cell number of the BAL, the absolute cell number of each 
subpopulation could be calculated. The data represent the mean of the cell numbers +/- SEM from four 
separate experiments (GR
wt
 recipient with GR
wt 





BM: Control n=5; AAI n=8; AAI+Dex n=8; GR
dim
 recipient: with GR
wt 
BM: 
Control n=7; AAI n=8; AAI+Dex n=11; GR
dim
 recipient with GR
dim 
BM: Control n=3; AAI n=3; 
AAI+Dex n=3) 
 
The cellular infiltration of the lungs with eosinophils could be successfully suppressed by 
GC-therapy of bone marrow chimeras with GR
wt
 mice as recipient. This GC-effect was 
independent of the genotype of the hematopoietic system. The subpopulations of the BAL of 
GR
wt




 immune system were largely similar. While GR
wt
 bone 
marrow chimeras were fully treatable with Dexamethasone, GR
dim
 bone marrow chimeras 
showed unaltered infiltration of the lungs and no influence of GC-therapy independent of the 
genotype of the immune cells. 
 
3.4.1.2. Proliferation and priming of splenocytes from GRwt and GRdim chimeras 
after antigen-specific restimulation ex vivo 
To investigate the effects of GC-treatment on the proliferation of antigen-specific T and B 
cells restimulation of splenocytes with Ova ex vivo was done. The isolated cells were cultured 
for 72 hours with and without Ova. IL-2 was analysed by ELISA, proliferation by 
3
H-
thymidine incorporation assay.  
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Figure 53: Proliferation and 





 chimeras after antigen-
specific restimulation ex vivo. 
Proliferation of splenocytes from 
healthy control (C), AAI and GC-
treated (AAI+Dex) mice was 
determined after 72 hrs incubation 
with antigen specific restimulation 
(Ova), compared to the basal 
proliferation (unstimulated cells). The 
cells were analysed for their 
proliferation activity with an 
3
H-
thymidine incorporation assay. The 
IL-2 release was determined by 
ELISA. The results show the mean 
proliferation activity (cpm) or the 
cytokine concentration +/- SEM of 
triplicate measurements of 4 separate 
experiments. (GR
wt
 recipient with 
GR
wt 
BM: Control n=6; AAI n=7; 
AAI+Dex n=8; GR
wt
 recipient with 
GR
dim 
BM: Control n=5; AAI n=8; 
AAI+Dex n=8; GR
dim
 recipient: with 
GR
wt 
BM: Control n=7; AAI n=8; 
AAI+Dex n=11; GR
dim
 recipient with 
GR
dim 
BM: Control n=3; AAI n=3; 
AAI+Dex n=3) 
 
The proliferation test demonstrated that the restimulation of splenocytes with Ova led to an 
increased proliferation of all types of chimeras. GR
wt 
chimeras showed a stronger proliferation 
as GR
dim
 restimulated splenocytes in AAI mice. The treatment of animals with GCs 
influenced proliferation activity only in GR
wt
 chimeras. While the proliferation of splenocytes 
from GR
wt
 chimera with GR
wt
 immune system could be significantly suppressed via GC-
therapy, the proliferation of GR
wt
 chimera with GR
dim
 immune system was not downregulated 
in GC-treated animals. The GR
dim
 chimeras demonstrated a slightly increased proliferation in 
GC-treated animals with both type of GR-expression of immune cells. Thus, proliferation is 
only suppressed if both the immune system and the recipient are GR
wt
. The IL-2 secretion 
confirmed the observation from the 
3
H-thymidine incorporation assay. The produced level on 
IL-2 was strongly increased in supernatants of splenocytes from asthmatic mice, but the 
concentration of this cytokine was only reduced in the samples of GR
wt
 chimeras reconstituted 
with bone marrow from GR
wt 
mice. No reliable results were obtained for IL-4 and IFN-ɣ 
secretion. 






GRwt BM GRdim BM
GRwt recipient GRdim recipient














GRwt BM GRdim BM
GRwt recipient














3.   RESULTS 
 
104 
3.4.1.3. Immunoglobulin production in GRwt and GRdim bone marrow chimeras 




 chimeras the Ig level were 
significantly increased. The treatment of the asthmatic mice with Dexamethasone did not 
suppress this elevated immunoglobulin concentration in serum in any type of chimeras.  







































































bone marrow chimera. The 




 chimera was analyzed via Ova-specific Ig-ELISA. The samples 
were diluted dependent on Ig isotype: IgE 1:100, IgG2a 1:1000, IgG1 1:100 000. The data represent 
the mean OD +/- SEM from 4 separate experiments (GR
wt
 recipient with GR
wt 
BM: Control n=6; AAI 
n=7; AAI+Dex n=8; GR
wt
 recipient with GR
dim 





BM: Control n=7; AAI n=8; AAI+Dex n=11; GR
dim
 recipient with GR
dim 
BM: 
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3.4.1.4. Gene expression analysis in lung tissue of bone marrow chimeras  
The hitherto made experiments with the chimeric mice suggested a crucial role of the lung 
tissue rather than the BAL cells for GC-therapy of asthma. Therefore gene expression was 
studied by RT-qPCR in lung tissue.  
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Figure 55: RT-qPCR analysis of β-Tryptase, IL-9, TSLP, Eotaxin2, IL-25 and IL-33 mRNA 




 chimeras. The AAI induction and Dex-
treatment was done as described before in Figure 38. The data represent the mean mRNA expression 
normalized to HPRT expression. The resulting mean of the AAI sample expression was set equal to 1. 
The data represent the results from 4 separate experiments +/- SEM (GR
wt
 recipient with GR
wt 
BM: 
Control n=6; AAI n=7; AAI+Dex n=8; GR
wt
 recipient with GR
dim 
BM: Control n=5; AAI n=8; 
AAI+Dex n=8; GR
dim
 recipient: with GR
wt 





BM: Control n=3; AAI n=3; AAI+Dex n=3) 
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To investigate the effects of GC-therapy on mast cells and their activation the expression of  
β-Tryptase was analysed. The results of this analysis demonstrated that β-Tryptase 
suppression by GCs depended on the genotype of the immune system. Only chimeras with a 
GR
wt 
hematopoietic system showed down-regulation of this gene after Dexamethasone-
therapy.  
 
In contrast, the expression of the TH2 cytokine IL-9 was only dependent on the genotype of 
the recipient mice. The lung tissue samples of GR
wt
 mice showed a reduced expression of this 
cytokine in GC-treated animals. The reconstituted GR
dim
 recipients showed no down-
regulation of IL-9 mRNA expression. IL-9 plays an important role in mast cell development 
and activation as well as in asthma pathogenesis. IL-9 also plays a role in airway remodeling 
and immune-cell recruitment into the lungs by promoting inflammatory mediator release such 
as Eotaxin. Eotaxin, as described before, plays a key role in eosinophilia development in the 
asthmatic lungs. The upregulation of Eotaxin2-expression during AAI could be slightly 
downregulated in lung samples of chimeras reconstituted with GR
wt





TSLP belongs to the key mediators of asthmatic reaction. This epithelial derived cytokine not 
only promotes the development and migration of basophils but is also associated with 
increased IL-4 and IL-13 production. Its expression could be only downregulated in lung 
tissue of chimeras with GR
wt
 as recipient independent on the genotype of the reconstituted 
immune system. Also the expression of IL-25 was only dependent on the genotype of the lung 
tissue and independent of the immune system genotype. The IL-25 mRNA expression could 
be downregulated in lung tissue of GR
wt
 chimeras while GR
dim
 chimeras demonstrated a 
similar expression level with or without Dexamethasone treatment.  
 
IL-33 plays an important role in release of the inflammatory mediators by T cells, eosinophils, 
mast cells and basophils. It was reported that IL-33 can be produced by epithelia and 
myeloide cells as an alarmin for the rapid induction of IL-13–driven immunity (Prefontaine et 
al., 2010). The secretion of IL-33 could be not suppressed by GC-treatment independent of 
the genotype. Only GR
dim
 chimera with a GR
wt
 hematopoietic system showed a slight 
reduction of IL-33 mRNA expression. Opposite to this effect of Dexamethasone-treatment the 
expression of IL-33 in the lung tissue of GR
wt
 chimeras was somewhat elevated upon therapy. 
































Figure 56: RT-qPCR analysis of RANTES, CXCR3, IL-4, IL-5 and IL-13 mRNA expression in 




 chimeras. AAI induction and Dex-treatment was done as 
described before in Figure 38. The data represent the mean mRNA expression normalized to HPRT 
expression. The resulting mean of AAI sample expression was set equal to 1. The data represent 
results from 4 separate experiments +/- SEM (GR
wt
 recipient with GR
wt 
BM: Control n=6; AAI n=7; 
AAI+Dex n=8; GR
wt
 recipient with GR
dim 





BM: Control n=7; AAI n=8; AAI+Dex n=11; GR
dim
 recipient with GR
dim 
BM: Control n=3; 
AAI n=3; AAI+Dex n=3) 
 
RANTES plays a critical role in recruiting of T cells, eosinophils and basophils to the site of 
inflammation. Although this chemokine is described to be overexpressed in asthmatic lung 
tissue the data from this analysis did not demonstrate a significantly induction in samples 
from AAI mice. The suppression of RANTES mRNA expression could be observed only in 
samples of the chimeras with a GR
wt
 hematopoietic system. 
RANTES
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To investigate the regulation of CXCR3 mRNA expression RT-qPCR was performed. No 
clear effect of Dexamethasone treatment was observed due large variations. The expression of 
IL-4 mRNA was strongly induced in asthmatic lung tissue samples and further elevated in 
GC-treated animals. While the level of IL-4 mRNA expression in samples of GC-treated 
animals was elevated in all samples this increase of expression was stronger in chimeras with 
a GR
wt
 hematopoietic system. The mRNA expression of IL-13 could be suppressed only in 
chimeras with a GR
wt 
hematopoietic system independent on the genotype of the recipient.  
 
The correlation between the IL-5 expression and the chimera type is difficult because of the 
strong variation of the expression data. However, it appears IL-5 mRNA expression is 
downregulated upon GC-therapy in all chimera types independent on the genotype of the lung 
cells or the reconstituted hematopoietic system. The expression of iNOS was induced in 
asthmatic lung tissue. The treatment of the chimeras with GCs led to a suppression of iNOS 
mRNA expression in all chimeras independent of their genotype. 
 
Occludin is a protein located in the tight junctions. According to the current literature this 
protein plays an important role for the maintenance of epithelial barriers functions (Xiao et 
al., 2013). Because of the loss of proper barrier function during an asthmatic reaction, the 
expression of Occludin in GC-treated animals was investigated. The data from the RT-qPCR 
analysis of lung tissue samples demonstrated a slightly decrease in mRNA expression in all 
GC-treated chimeras except for GR
wt
 chimeras with a GR
dim
 immune system.  
 
The expression of MCP-1 was elevated in all chimeras after the GC-therapy except for GR
dim
 
chimera reconstituted with GR
dim
 bone marrow. IL-10 expression was induced after the 
development of an asthmatic reaction in lung tissue. This overexpression of IL-10 could be 
suppressed in GR
wt
 chimera by GC-treatment independent of the immune system genotype. 
IL-10 mRNA expression in the samples of GC-treated GR
dim
 chimeras was not suppressed. 
 
CXCL12 (or SDF-1) is an inflammatory cytokine that is chemotactic for inflammatory cells 
such macrophages. This cytokine exerts its function through CXCR4. CXCR4 (or SDF-1 
receptor) expression is upregulated during AAI while its expression in healthy lungs is nearly 
absent. The data show no strongly upregulation of CXCL12 mRNA expression after induction 
of an asthmatic reaction except for GR
wt
 chimeras with a GR
wt 
immune system while the 
expression of CXCR4 was elevated in all asthmatic chimeras. GC-therapy led to a strong 
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suppression of CXCR4 expression in all Dexamethasone-treated chimeras independent of the 
genotype while the expression of CXCL12 was only slightly decreased. The expression of 
CXCL12 in lung samples of GR
wt
 chimera with a GR
dim
 hematopoietic system remained 


























































Figure 57: RT-qPCR analysis of iNOS, Occludin, MCP-1, IL-10, CXCL12 and CXCR4 mRNA 




 chimeras. AAI induction and Dex-treatment 
was done as described before in Figure 38. The data represent the mean mRNA expression normalized 
to HPRT expression. The resulting mean of AAI sample expression was set equal to 1. The data 
represent results from 4 separate experiments +/- SEM (GR
wt
 recipient with GR
wt 
BM: Control n=6; 
AAI n=7; AAI+Dex n=8; GR
wt
 recipient with GR
dim 
BM: Control n=5; AAI n=8; AAI+Dex n=8; 
GR
dim
 recipient with GR
wt 
BM: Control n=7; AAI n=8; AAI+Dex n=11; GR
dim
 recipient with GR
dim 
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3.4.2. Analysis of GRSPCcreERT2 mice 
In recent years it turned out that non-immune cells of the lungs play an important role during 
the development of allergic reactions. While it is clear that these cells are involved in asthma 
pathogeneses their relevance for the treatment of asthma is yet unclear. 
 
To analyze the role of epithelial cells of the lungs for GC-therapy of AAI inducible AT2-
spezific GR-knockout mice (GR
SPCcreERT2
) were used. To induce the ablation of the GR in 
AT2 epithelial cells of the lungs, the GR
SPCcreERT2 
mice were treated with tamoxifen for one 
week. To investigate the efficiency of the tamoxifen-inducible GR-knockout system the AT2 
cells were isolated from lung tissue of wild type and GR
SPCcreERT2 
mice by FACS sorting. 
After isolation of RNA from separated AT2 cells GR gene expression was analyzed by RT-
qPCR. The relative GR mRNA expression data show that the tamoxifen treatment of 
GR
SPCcreERT2
 mice successfully reduced GR expression in AT2 cells. The remaining 
expression of the GR in GR
SPCcreERT2
 cells was less than 35 % of GR-expression in GR
flox
 



























 mice. To 
induce the GR knockout in AT2 cells GR
SPCcreERT2
 mice were treated with tamoxifen for one week. 2 
days after the last tamoxifen administration the mice were used for induction of AAI as described 




 mice were used for gene 
expression analysis by RT-qPCR. The RT-qPCR was repeated twice. The data show the mean relative 
GR mRNA expression +/- SEM. The expression data was normalized to HPRT expression and the 
mean expression of GR
flox






GR mRNA expression in AT2 epithelial cells of GR
SPCcreERT2
 mice is significantly 
(p< 0.0001) reduced. Hence, this mutant strain is a suitable tool to understand AT2 cell 
function in lung disease treatment with GCs. 
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3.4.2.1. BAL analysis 
The induction of an asthma like reaction in GR
SPCcreERT2 
mice led to a significantly increased 
number of infiltrating cells in the BAL. The ablation of the GR in AT2 cells did not impair 
this inflammatory response (Figure 59). GC-therapy of these mutant mice did not suppress 
this cellular lung infiltration in the same way as in wild type mice. While the BAL of GC-
treated wild type animals contained less than 150 000 cells the BAL of GR
SPCcreERT2
 mice 
have more than 700 000 infiltrating cells. This means about 90 % reduction of infiltrating 












































 mice. The BAL of healthy (control), AAI and Dexamethasone-treated (AAI+Dex) mice 
was quantified for absolute cell number with the help of a Neubauer cell count chamber. To 
investigate the BAL cell subpopulations the isolated BAL samples were analyzed by FACS. The 
relative percentages and absolute cell number of the BAL were used for the calculation of the absolute 
cell numbers of the subpopulations. The data represent the mean absolute cell number and the relative 




control n=1; AAI n=2; AAI+Dex n=2; GR
SPCcreERT2
: control n=1; AAI 
n=3; AAI+Dex n=3) 
 
The cell composition of the BAL from control and asthmatic mice showed no differences 
between wild type and GR
SPCcreERT2
. The cellular influx in allergic lungs was dominated by 
eosinophilic granulocytes and their relative percentage was about 80 % of all BAL cells in 
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both mouse strains. The BAL of control mice consisted of macrophages and monocytes and 
showed no sign of inflammation or infection (hardly any neutrophils). However, the response 
to GC-therapy revealed significant differences dependent on GR expression in AT2 cells. 
While the asthmatic mice with normal GR expression level showed strongly reduced relative 
percentage and cell number of eosinophils (Figure 59) GC-therapy of GR
SPCcreERT2
 mice did 
not affect the eosinophilia in the lungs at all.  
 
3.4.2.2. Ova-specific immunoglobulin production in GRSPCcreERT2 mice 
In order to investigate the Ig class switching after induction of an asthma-like reaction in 
GR
SPCcreERT2
 mice after tamoxifen treatment the serum samples were analyzed for Ova-
specific IgE, IgG2a and IgG1. Immunization with Ova induced significantly increased 
production of Igs. The induction did not show any differences between wild type and 
GR
SPCcreERT2



















 mice. The 
induction of an asthma-like reaction led to a significantly increased production of Ova-specific IgE, 




 mice. The data show the mean OD +/- SEM (GR
flox 
: 
control n=1; AAI n=2; AAI+Dex n=2; GR
SPCcreERT2
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3.4.2.3. Gene expression analysis in AT2 cells from GRSPCcreERT2 mice 
It is currently believed that the airway epithelium is a major source of cytokines, chemokines 
and other inflammatory mediators during asthmatic reactions in the lungs. Therefore, in 
addition to its respiratory and barrier function, it plays an important role for the immune 
response, the modulation of inflammatory diseases and providing local host defense. The 
airway epithelium contains of several cell types which have different functions.  
 
From an immunological point of view AT2 cells are most interesting. They play the role of 
professional APCs and can present antigens on MHCII molecules. Additionally, AT2 cells 
can produce a large spectrum of inflammatory mediators that modulate inflammation and 
affect the adoptive and innate immune response in the lungs. 
 
Since the lung epithelium is a major source of diverse chemokines, cytokines and other 
inflammatory mediators it was interesting to investigate the modulation of gene expression by 
GC-therapy. To this end the AT2 cells were isolated by FACS sorting and the modulation was 
analyzed by RT-qPCR.  
 
The results of RT-qPCR approach demonstrate that the induction of an asthma-like reaction in 




 mice leads to an increased expression of a large spectrum 
of inflammatory mediators. The mRNA expression of important cytokines and chemokines 
such IL-1β, IL-33, IL-6, IL-4, IL-13, IL-25 and Eotaxin-2 was strongly increased in the 
samples of animals with an asthma-like reaction. The treatment with GCs led to a strong 
suppression of IL-1β mRNA expression in GR
flox
 mice while the expression in GR
SPCcreERT2
 
AT2 cells was slightly increased. The same response to the treatment could be observed in the 
analysis of IL-33, IL-6, Eotaxin-2, RANTES, iNOS and TNF-α. The expression of these 
genes could be downregulated by Dexamethasone only in samples of GR
flox












































































































































Figure 61: Gene expression analysis of inflammatory mediators IL-1β, IL-33, IL-6, iNOS, 




 mice. AT2 cells were 
isolated from the lungs of healthy, AAI and Dex-treated AAI mice. The asthma-like reaction was 
induced like described before in Figure 10.The data represent the normalized (on the AAI-samples) 
mean of the relative mRNA expression +/- SEM (GR
flox 
: control n=1; AAI n=2; AAI+Dex n=2; 
GR
SPCcreERT2
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At the same time, the expression of TSLP, ZO-1 and Occludin were increased after GC-
therapy in AT2 cells of both genotypes but to a different extent. Interestingly the enhancement 
of TSLP expression after Dex-therapy was stronger in AT2 samples from GR
SPCcreERT2
. While 
the ZO-1 expression in Dex-treated AT2 cells from wild type animals was about three-fold 




































































 mice. AT2 cells were isolated from lung samples of healthy, AAI and 
Dex-treated AAI mice. The asthma-like reaction was induced like described before in Figure 10.The 
analysis data represent the normalized (on the AAI-samples) mean of the relative mRNA expression 
+/- SEM (GR
flox 
: control n=1; AAI n=2; AAI+Dex n=2; GR
SPCcreERT2
: control n=1; AAI n=3; 
AAI+Dex n=3) 
 





 AT2 cells, the IP-10 expression demonstrated large differences concerning the 
GC-effects. GC-therapy led to an increased IP-10 expression in GR
flox 
AT2 cells while IP-10 
was reduced in samples of GR
SPCcreERT2























































4.1. Asthma and the experimental mouse model of allergic airway inflammation 
Allergic asthma is an inflammatory disease with constantly rising incidence in the 
industrialized countries. According to the World Health Organization, more than 235 million 
people currently suffer from this respiratory disorder. Because the cause and risk factors for 
asthma development are only poorly understood, a plethora of studies have been performed 
investigating this topic. Beside genome-wide linkage screens of asthmatic and healthy people, 
experimental mouse models offer the opportunity to study the pathogenesis and development 
of asthma. Although mouse models can not completely reproduce the pathophysiology of 
human asthma mice develop a strong allergic airway inflammation, after sensitization and 
challenge with antigens, with a bright spectrum of characteristic clinical symptoms including 
eosinophilia, airway hyperresponsiveness, mucus hypersecretion and increased IgE level. The 
asthma-like reaction that was used in this work is achieved by immunizing and challenging 
the mice with Ovalbumin as the antigen in combination with Alum as a potent adjuvant. The 
repeated immunizations and challenges induce a robust, allergic pulmonary inflammation in 
laboratory rodents (Kumar et al., 2008).  
 
The AAI model that was used in this work included a strong cellular infiltration of the lungs 
with immune cells. This effect was seen by analyzing BAL samples by FACS and lung 
sections by histology, respectively. The wild type and the diverse mutant mice developed 
comparable lung infiltration after induction of AAI independent of the background. Opposite 
to several other studies, C57BL/6 mice developed nearly the same level of inflammation after 
induction of AAI. While the cell number in the BAL of healthy mice was dominated by 
macrophages and consisted of less than 1 x 10
5
 cells, induction of AAI increased lung 
infiltration to up to 2 x 10
6
 cells dominated by eosinophils (60-80 %). The absolute cell 
numbers of lymphocytes, macrophages and neutrophiles were also increased in the BAL of 
mice with AAI. The relative percentage of the different cell populations in the BAL revealed 
that although the absolute cell numbers were increased after AAI induction the percentages of 
macrophages and neutrophiles were lower in diseased mice compared to healthy animals. The 
data from the FACS analysis of the BAL correlated with the histological studies. While the 
healthy lung showed a ―spongy‖ structure with thin-walled alveoli and free airflow 
conducting airways the lung sections of mice with AAI demonstrated a dramatic lung 
inflammation with cellular and mucosal infiltration. The inflammation was largely located in 
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the peribronchial and perivascular areas but could also be seen in the lung parenchyma. The 
characteristic airway remodeling seen in severe asthma in humans occurs only in a mild form 
in the used mouse model because of the short inflammation phase. Nonetheless, first signs of 
airway deformation could already be observed: mucus hypersecretion led to a hyperplasia of 
the goblet cells and the asthmatic airways were characterized by a ―waved‖ airway wall with 
reduced free space for gas exchange.  
 
Beside infiltration and mucus hypersecretion, the mice with AAI demonstrated strongly 
elevated levels of antigen-specific immunoglobulin production. The sensitization to 
Ovalbumin successfully led to an isotype switch to IgE, IgG1 and IgG2a in both mouse 
strains. Opposite to several publications the C57BL/6 mice with AAI produced only slightly 
reduced amount of immunoglobulins compared to the BALB/c mouse strain. Based on these 
observations the AAI induction protocol could be successfully used for eliciting an asthma-
like reaction in the subsequent experiments with different mouse strains on a BALB/c or a 
C57BL/6 background without changes in the protocol.  
 
4.1.1. Establishment of the GC therapy  
The aim of this work was to investigate the mechanisms of GCs in the treatment of asthmatic 
reactions. After the establishment of the AAI model, the treatability of wild type mice was 
analyzed. The data from several experiments with BALB/c and C57BL/6 mice demonstrated, 
that potent effects of GCs on airway inflammation could be achieved already after two 
intraperitoneal injections with Dexamethasone (10 mg per 1 kg body weight). GC therapy led 
to a strong reduction of the number of BAL cells in both mouse strains. This effect was 
mainly based on the significant suppression of lung eosinophilia. The BAL isolated from the 
animals with AAI contained more than 1 x 10
6
 eosinophils (about 70 % of all BAL cells) 
while the eosinophils in GC-treated mice made up less than 40 % of the whole BAL. In 
contrast, GC therapy did not show any effects on IgE, IgG2a and IgG1 production 
independent of the genetic background. Although the production of these immunoglobulin 
isotypes plays an important role in the pathogenesis of asthma the reduction of their 
concentration in serum does not seems to be critical for the therapeutic efficiency of GCs. 
Possible explanations for the absent reduction of immunoglobulin level after GC therapy 
could be the mechanism published by Jabara and Zieg. They reported that high dose therapy 
with GCs may maintain high immunoglobulin levels via upregulation of CD40 ligand 
expression and induction of CD40L-dependent immunoglobulin isotype switching (Jabara et 
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al., 2001; Zieg et al., 1994). Another possible reason for the high levels of IgE, IgG2a and 
IgG1 in the serum irrespective of GC treatment could be the short duration of the therapeutic 
phase. 
 
4.2. Role of GR DNA-binding and dimerization for GC-therapy of AAI as a 
model of Asthma 
GCs were introduced into the clinics as a powerful therapy for many inflammatory diseases 
more than half a century ago (Lühder and Reichardt, 2009). Although these drugs are amongst 
the most widely prescribed anti-allergic compounds worldwide the precise mechanism of GC 
action is not fully understood. The current knowledge assumes that the efficiency of GC 
therapy dependents on a variety of mechanisms addicted to different disease type (Baschant et 
al., 2012). Based on these findings it seems to be impossible to define a single mode of GC 
action or target cell type for all inflammatory diseases. As described before, the majority of 
GC effects are mediated by the GR via transcriptional activation or repression of target genes. 
The first mode of action requires dimerization of the GR, its binding to regulatory DNA 
elements and subsequent activation of target genes. Alternatively, the GR may control 
transcription via transrepression in a DNA binding-independent manner, which is mediated by 
tethering interactions with other transcription factors. The potent immunosuppressive effects 
of GC therapy were reported to be largely dependent on the inhibition of pro-inflammatory 
gene expression via transrepression while the transactivation was rather thought to account for 
many side effects.  
 
To determine the requirement of GR DNA-binding for asthma, the efficiency of GCs in the 
treatment of AAI was compared between wild type and GR
dim
 mice. The goal of this study 
was to evaluate the relevance of the two major modes of GC action. Based on the 
observations from the histological sections, NIR Imaging and the FACS data both mouse 
strains developed a comparably strong inflammation in the lungs after AAI induction. The 
infiltration see in histological sections was mostly located close to the wall of the conducting 
airways and blood vessels but was also present in the alveolar tissue. Additionally, the airway 
epithelium showed the first remodelling stages with hyperplasia of goblet cells and mucus 
hypersecretion. The cellular infiltration in both strains consisted of about 70 % eosinophils 
after AAI induction. In contrast, the main population in the airways of healthy mice was 
identified as macrophages. This replacement in cell populations was seen in both genotypes 
and is characteristic for asthmatic reactions. Importantly, the anti-inflammatory effect of GC 
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therapy on lung infiltration could only be seen in treated wild type mice whereas the 
inflammation in the GR
dim
 mice remained almost unchanged. While the cell number of 
eosinophils in wild type mice was significantly reduced from more than 1 x 10
6
 cells in AAI 
to about 1 x 10
5
 eosinophils in Dex-treated mice, the treatment of GR
dim
 led only to a minimal 
reduction. After GC-therapy the BAL of GR
dim
 mice still consisted of more than 60 % of 
eosinophils and the change in eosinophil numbers after GC-therapy was not significant. The 
same effects of GC therapy could be seen in lungs sections. While the GC treatment of wild 
type mice led to a strongly reduced mucus secretion and cellular infiltration accompanied by 
an enlargement of the free space for gas exchange, these anti-inflammatory effects were 
absent in Dex-treated GR
dim
 mice. The treatment of wild type animals with GCs did not only 
lead to the reduction of cellular infliltration and eosinophilia but also to the replenishment of 
macrophages in the lungs. Because macrophages play an important role for the treatment of 
allergic reactions and are necessary for the healing process after the inflammation of tissues 
this recurrence can be seen as sign of successfully therapy. The population of neutrophiles 
was not reduced by GC therapy in both mouse strains. Opposite to the effect on eosinophils, 
the relative percentage of neutrophils was even increased after Dex-therapy. This ambivalent 
effect of GCs on different granulocyte populations was already observed previously in several 
other studies. A current report suggests that the persistent airway neutrophilia observed in 
patients with asthma might be caused by the failure of GCs to suppress IL-8 mRNA 
expression (Fukakusa et al., 2005). The neutrophilia was also reported to correlate with 
asthma severity (Wenzel et al., 1997). On the one hand these granulocytes play a role in the 
initiation and resolution of an asthma attack but on the other hand these cells are also 
important for the digestion of airway mucus plugs, which block the airways during acute 
asthma (Innes et al., 2008). Because of this controversial role it is difficult to speculate on the 
role of GC effects on neutrophils. 
 
To further investigate the role of the DNA-binding dependent mode of the GR, proliferation 
and priming of antigen-specific T and B cells were analysed ex vivo. Ova-restimulated 
splenocytes from AAI mice showed increased proliferation and an elevated production of 
IL-2, IL-4 and IFNɣ. The data from the 
3
H-thymidine incorporation assay revealed no 
differences in proliferation between AAI and GC-treated mice of both genotypes. However, 
the analysis of the IL-2 concentration in the supernatants of these splenocytes demonstrated 
not only a strong increase in the IL-2 secretion in AAI samples but also a significantly 
reduction of its production in samples from GC treated wild type mice. This suppression of 
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IL-2 production by GC therapy was absent in GR
dim
 samples. One possibility to explain this 
observation could be different effects of GCs on B and T cells. It is possible that although 
proliferation and activation of T cells can be successfully reduced by GC therapy, B cell 
proliferation remained unaltered. The data on IL-4 and IFNɣ secretion support this 
hypothesis. IFNɣ production was strongly increased in samples from wild type and GR
dim
 
mice with AAI in comparison to control splenocytes from healthy mice. Nonetheless, GC-
therapy led to a reduced IFNɣ secretion only in samples from wild type mice. Opposite to this 
effect, the increased production of IL-4 in samples from wild type and GR
dim
 mice with AAI 
could not be suppressed by GC-treatment in any strain. This effect on IL-4 could be explained 
by the influence of GCs on the TH1/TH2 balance. According to several reports GCs may cause 
a selective suppression of TH1 immunity and a shift toward TH2-mediated humoral immunity. 
GCs may inhibit the production of TH1 cytokines including IFNɣ by APCs and TH1 cells, but 
upregulate the production of TH2 cytokines, like IL-4, by TH2 cells (Elenkov., 2004). Another 
explanation comes from the fact that IL-4 unlike IFNɣ can be produced not only by T cells 
but also by B cells. Because of this, the observed dissimilarity of cytokine regulation by GCs 
could depend on the different effects of GCs on B and T cells. While the suppression of T cell 
activation and proliferation seems to be dependent on DNA-binding mode of GR action the 
effects on B cells did not show any observable correlation with the absence or presence of this 
mode of GR action. 
 
To investigate the requirement of GR DNA-binding on the secretion of other pro-
inflammatory cytokines the IL-5 concentration was analysed in serum samples from wild type 
and GR
dim 
mice. Because IL-5 plays a critical role in the maturation and release of eosinophils 
from the bone marrow the increased secretion of this cytokine plays an important role in the 
pathogenesis of asthma. This cytokine can be produced by TH2 cells but also by mast cells 
and eosinophils and act in an autocrine manner. An increased IL-5 concentration could be 
seen in serum samples of AAI mice of both genotypes but GC-therapy did not lead to a major 
change in both genotypes.  
 
Additionally, the serum of wild type and GR
dim
 animals was analyzed for antigen-specific 
immunoglobulin levels. The induction of AAI led to a strong increase of IgE, IgG2a and IgG1 
production in mice of both genotypes. The serum samples of GC-treated animals showed no 
differences in immunoglobulin secretion irrespective of the genotype. 
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4.2.1. Effects of GCs on the barrier function of the lung endothelium 
The altered microvascular permeability was proposed to be one of the critical factors of 
asthma pathogenesis. The increased permeability and the loss of proper barrier function, 
which occur in asthmatic lungs, lead to different pathogenic effects including the generation 
of airway submucosal and mucosal oedema consisting of plasma exudates (Persson., 1986) 
and an increased change for a contact of APCs with antigen and the infiltration of the lungs 
with immune cells. It is currently believed that this increased permeability can cause an 
increased responsiveness of the airways in asthma. In this work the barrier function of the 
lung endothelium was analysed using the Evans blue extravasation technique. The data from 
this experiment demonstrated a strong correlation between Evans blue dye leakage and airway 
inflammation. The concentration of Evans blue in the lung tissue of AAI mice was 
significantly increased compared to samples from healthy animals. While the increased 
permeability could be successfully suppressed by GC-therapy in the lungs of wild type mice 
the barrier function of GR
dim
 mice could be not improved by Dexamethasone treatment. 
Based on this observation, it is possible that the DNA-binding dependent GR action is 
necessary for the recovery of the endothelial barrier function during therapy. This therapeutic 
effect could be based on many factors including the effects on the cytoskeleton and tight 
junction proteins. Several publications reported that in this context the tight junction 
transmembrane proteins occludin and ZO-1 play a crucial role for microvascular permeability 
(Hirase et al., 1997; Xiao et al., 2013). This hypothesis was tested later using GR
dim
 bone 
marrow chimeras and GR
SPCcreERT2
 mice (see below). 
 
4.2.2. Effects of GCs on gene expression in BAL and lung parenchymal cells 
The effects of GC therapy on inflammation are thought to strongly depend on the regulation 
of gene expression. The GR is known to modulate the expression of many genes either by 
transactivation or transrepression. In order to investigate differences in gene regulation in the 
absence of the DNA-binding dependent mode of GR action, samples from wild type and 
GR
dim
 mice were analyzed via RT-qPCR. Since a variety of cytokines, chemokines and other 
inflammatory mediators are involved in asthmatic reactions but may be differently regulated 
dependent on the cell type, the analysis was done with BAL samples and lung samples 
separately. These independent analyses of gene expression provided the opportunity to 
investigate the influence of GCs on the infiltrating cells as well as inflamed tissue. The 
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allergic response in the lungs led to an increased expression of many pro-inflammatory genes 
in BAL and lung tissue samples.  
 
The only genes with nearly unaltered gene expression in the BAL were MIP-1α and CXCR4 
while in the lung samples these genes also showed increased expression. Interestingly, 
expression of the important mediators of monocytes and macrophages migration MCP-1 and 
MIP-1α was strongly increased in lung samples from AAI mice and GC therapy led to further 
elevation. The expression of CXCR4 remained unchanged without any observable effect of 
AAI induction and GC therapy. This result was surprisingly because of the reported role for 
this chemokine receptor in the mobilization of hematopoietic stem cells into the bloodstream 
during an inflammatory response and its expression on TH2 cell subset. iNOS and IL-10 
expression in BAL samples was nearly the same independent of the treatment. However, 
because the iNOS is a characteristic marker of the inflamed epithelium and activated 
macrophages it was interestingly to analyze its expression in the lung tissue. Based on the 
obtained data, the regulation of these two genes in the inflamed tissue was more critical for 
therapeutic efficiency of AAI as their regulation in the cellular infiltrate. The results of the 
iNOS gene expression analysis in lung tissue samples revealed a successful suppression of 
iNOS expression in samples of wild type mice while the expression of this inflammatory 
enzyme was even upregulated in GC-treated asthmatic GR
dim
 mice. IL-10 showed a very 
similar regulation as iNOS. In contrast to the expression of this cytokine in the BAL samples, 
the IL-10 expression in the lung samples was strongly increased after AAI induction. This 
overexpression of IL-10 in the inflamed lungs could be strongly suppressed in wild type mice 
by Dexamethasone treatment while the IL-10 mRNA levels in the lung samples of GC-treated 
GR
dim
 mice was slightly upregulated. These data demonstrate that these two inflammatory 
mediators are more important in the inflamed tissue than in the infiltrating cells. Additionally, 
the expression of these two genes was strongly dependent on the DNA-binding dependent 
mode of GR action in the lungs.  




Figure 63: Effects of GC therapy on gene expression of inflammatory mediators in BAL and lung 
samples of wild type and GR
dim
 mice. The data represent an overview of all results obtained by RT-
qPCR analysis. 
 
The induction of AAI led to an elevated expression of IL-5 and Eotaxin-2, the prominent 
markers of eosinophilia. This upregulation could be strongly suppressed by GC therapy in 
BAL cells from wild type and GR
dim
 mice. Although GCs could reduce the expression of 
these genes in infiltrating cells in GR
dim 
mice, the expression of IL-5 and Eotaxin-2 in lung 
parenchymal cells was not altered by Dexamethasone treatment. On the one hand, these 
results show that the observed lung infiltration with eosinophils (see FACS data) is more 
dependent on the cytokine and chemokine expression in lung cells. On the other hand these 
data demonstrate the differences in gene regulation by GCs between individual cell types. 
This ambivalent effect of GC therapy was also seen in the regulation of CXCR3 expression. 
While its expression in the BAL samples was nearly unaltered after GC therapy in both 
genotypes, the expression in lung tissue samples was reduced in wild type and GR
dim
 mice. 
CXCR3 was preferentially reported to be expressed on activated TH1 cells, NK cells but also 
on epithelial and endothelial cells of the lungs. It was also reported, that the expression of this 
chemokine receptor can influence the migration of TH2 cells into the lungs and the activation 
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of effector T cells. However, based on this result, the reduction of CXCR3 in the inflamed 




The expression of a number of key mediators of asthmatic reactions was influenced by GC 
therapy in a DNA-binding dependent mode of action. The elevated expression of IL-4 and 
IL-13 was proposed to play a crucial role in the pathogenesis of asthma by activating and 
recruiting a variety of inflammatory cells involved in inflammation. Increased IL-4 and IL-13 
levels were observed in BAL and lung samples of AAI mice of both genotypes. The 
expression of IL-13 was suppressed in a DNA-binding dependent mode of action in BAL and 
lung samples. The expression of IL-4 in the lungs but not the BAL of wild type mice was 
increased because of GC therapy and suppressed in the BAL but not lung samples. These 
confusing effects could be based on a variety of factors including differences in the cell 
composition between BAL and lung tissue and possible dissimilarity in TH2/TH1 balance 
regulation. The inflammatory mediator RANTES was strongly increased after AAI induction. 
RANTES was reported to be able to induce eosinophilia in the lungs independent of the 
presence of the allergen thereby increasing asthma severity in patients. The expression data 
demonstrated a strong suppression of RANTES after GC-therapy in samples of wild type 
mice with AAI. While the expression in allergic wild type mice was significantly 
downregulated, GC-therapy of GR
dim
 mice did neither affect RANTES mRNA expression in 
BAL nor lung tissue samples. This observation showed a strong dependency of RANTES 
regulation on the DNA-binding dependent mode of GR action. 
 
4.2.3. Conclusion 
The results of this part of the work demonstrate that the therapeutic efficiency in the treatment 
of asthma with GCs is fully dependent on DNA-binding and dimerisation of the GR. In the 
absence of transactivation GC treatment could neither reduce the lung infiltration with 
eosinophils nor prevent airway remodeling and suppress gene expression of key mediators of 
asthmatic reaction. Furthermore, GC effects are neither critically dependent on the 
suppression of proliferation of splenocytes nor of IL-2, IL-4 or IFNɣ production. Also the 
unaltered antigen-specific immunoglobulin levels were irrelevant for therapeutic efficiency in 
wild type mice. Based on gene expression analysis of BAL and lung samples the following 
mediators appear to be important for the treatability of AAI with GCs: IL-4 and IL-13, IL-5 
and Eotaxin-2 as well as iNOS and RANTES.  
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4.3 Identification of target cells of GCs therapy of asthma in the mouse model of 
AAI 
Because the GR is present in almost every vertebrate cell, it is important to determine the 
crucial target cells, which are important for the anti-inflammatory effects of GCs during 
asthma therapy. To identify the essential target cells of GC therapy of an asthmatic reaction in 







) or B cells (GR
CD19
) were used.  
 
The analysis of lung infiltration in wild type and mutant mice revealed very similar 
efficiencies of GC therapy in all mutant mouse strains. Dexamethasone treatment successfully 
reduced the cellular influx into the lungs of wild type and mutant mice independent on GR-
expression in T cells, myeloid cells (including eosinophils), DCs or B cells. GC therapy did 
not only reduce the cell number in the BAL from mutant mice with AAI but also the 
alterations in the composition of the BAL were similar. Additional analysis of proliferation, 
cytokine production and immunoglobulin also secretion showed mostly the same regulation 









mice are treatable with Dexamethasone indicates that suppression of eosinophils, 
macrophages and neutrophils, DCs, T and B cells is probably not essential for therapeutic 
efficiency. This indicated that the therapy efficiency was more dependent on the non-
hematopoietic cells of the lungs than on the immune cells themseves.  
 
The role of non-immune cells during the pathogenesis of asthma and its therapy is only 
partially understood. However, recent publications suggest that the structural cells of the 
lungs play an important function in disease initiation and progression. The non-immune cells 
like epithelial cells, fibroblasts, endothelial cells and smooth muscle cells not only build the 
lung structure and provide the gas exchange function but also produce a large amount of 
inflammatory and regulatory mediators. To investigate structural cells of the lungs are for 
GC-therapy, bone marrow chimeras with GC-refractory GR
dim
 mice were generated. Since 
GR
dim
 mice are almost untreatable because of the absent DNA-binding mode of GR action, 
bone marrow chimeras with wild type or GR
dim
 mice as recipient and wild type mice or GR
dim
 
mice as donors of bone marrow cells for the reconstitution of the immune system could be 
used to dissect the role of immune cells as opened to structural cells of the lungs for GC-
therapy of asthma. The analyses of the therapeutic efficiency of GC therapy of the bone 
marrow chimeras showed that the effect of GC-treatment is dependent on the responsiveness 
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of the non-immune cells. In spite of a wild type hematopoietic system bone marrow chimeras 
with GR
dim
 mice as recipients were not treatable with Dexamethasone. This effect was 
observed by FACS analysis of the BAL concerning cell composition and absolute cell 
numbers. The AAI in the lungs of bone marrow chimeras with wild type mice as recipient 
could be successfully suppressed independent of the genotype of the hematopoietic system. 
The eosinophilia in the lungs of bone marrow chimeras with GR
dim
 mice as recipient with 
both sorts of the reconstituted hematopoietic system was unaltered by GC therapy. The only 
observable difference in the reaction to GCs was observed in the regulation of proliferation 
and cytokine secretion of splenocytes ex vivo. Proliferation and IL-2 secretion were only 
reduced by GCs in samples of bone marrow chimera with wild type immune system and 
recipient mice. The chimeras with a GR
dim
 immune system showed a slight increase in 
proliferation and IL-2 secretion in mice treated with Dexamethasone. The chimeras with wild 
type mice as recipients and GR
dim
 mice as bone marrow donors showed only a small reduction 
of IL-2 production and unaltered proliferation despite the therapy. However, this small 
difference in the control of the splenocytes did not result in an observable effect on 
therapeutic efficiency. 
 
Beside the structural cells of the lungs mast cells could be a key regulator of the inflammatory 
reaction. In contrast to other immune cells, which can be easily replaced via reconstitution of 
the hematopoietic system, most mast cells which reside in the tissue have a life span of 
several weeks or months and cannot be completely substituted from the donor bone marrow in 
irradiated recipient mice. Because mast cells are supposed to be a target cell of GCs, it was 
important to investigate the dependency of GC-therapy on the suppression of mast cells. 
Interestingly, the development and pathogenesis of an asthmatic reaction in cKit mice was 
similar to wild type mice. Furthermore, mast cell-deficient mice were fully treatable by GCs. 
Taken together, lung parenchymal cells but not mast cells appear to be the major target of 
GC-therapy of asthma in AAI mouse model. 
 
4.3.1. Effects of GC therapy on the regulation of gene expression in the lungs 
In order to further investigate the mechanisms of GC-therapy in GR
dim
 bone marrow chimeras 
the expression of various important inflammatory mediators was analyzed by RT-qPCR. The 
analysis of gene expression in the lungs of GC treated bone marrow chimeras allowed to 
dissect the effects of GCs on immune cells and structural cells in the lungs.  
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The expression of different genes that play important role in the pathogenesis of asthma was 
analyzed in order to find the critical ones for GC-therapy of an asthmatic reaction. The result 
of this analysis showed that the respective genes can be classified into three groups.  
 
The first group of genes showed strong a dependency on the treatability of the immune 
system (Figure 64). The effects of GCs in this group correlated with the genotype of the bone 
marrow but not with genotype of the recipient mice. These genes included β-Tryptase, 
Eotaxin-2, RANTES, IL-13, IL-5 and Occludin. Wild type mice reconstituted with GR
dim 
bone marrow did not show suppression of these genes while GR
dim
 chimeras with wild type 
bone marrow showed nearly the same gene regulation as wild type chimeras. Although the 
genes in this group are known as activation markers and important regulators of eosinophilia, 
induction of a TH2 response and barrier function of the lungs, they do not seem to be critical 
for the suppression of inflammation by GCs during asthma treatment. Although these genes in 
GR
dim
 chimeras with a wild type immune system were regulated in the same manner as in 
wild type chimeras with a wild type immune system was not accompanied by similar GC 
effects on lung infiltration. 
 
Figure 64: Immune system dependent GC-effects on gene expression in lung tissue of wild type 
and GR
dim
 bone marrow chimeras reconstituted with wild type or GR
dim
 bone marrow. The data 
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The second group of genes showed a strong dependency on the treatability of the lung 
structural cells. These genes could be suppressed by GC therapy only in chimeras with wild 
type mice as recipients independent of the genotype of the reconstituted immune system. 
These genes include IL-9, TSLP, IL-25, IL-33 and IL-10. 
 
The genes, the expression of which showed dependency on the responsiveness of structural 
cells of the lungs, are known as important regulators of the inflammatory response. GC 
therapy of wild type chimeras led to a reduction of IL-9, TSLP, IL-25 and IL-10 expression 
irrespective of the genotype of the bone marrow while the expression of IL-33 was 
upregulated. In contrast, these genes were not altered by GC-therapy in all bone marrow 
chimeras with GR
dim
 mice as recipients.  
 
The suppression of IL-9 could play an important role in the treatment of asthmatic reaction 
because this cytokine influences mast cell development and activation and also drives mucus 
production by a direct influence on airway epithelia and also by interacting with IL-13. 
Additionally IL-9 plays a role in airway remodeling and immune-cell recruitment into the 
lungs by promoting inflammatory mediators release such as Eotaxin-2.  
 
The expression of TSLP was reported to be a critical link between the initial epithelial 
response and the development of airway inflammation (Holgate, 2007). This cytokine is 
produced by epithelial cells and capable to direct DCs towards TH2 response. Additionally 
TSLP can directly influence mast cell activation and a TH2 cytokine production. Secretion of 
TSLP is increased in the epithelium of asthmatic patients and correlates with disease severity. 
The data from the analysis of TSLP expression in the lung of bone marrow chimera 
demonstrated that therapeutic effectiveness and TSLP regulation correlated.  
 
IL-25 is also a cytokine that promotes TH2 immune responses in asthmatic reactions at 
mucosal epithelial surfaces. This cytokine was reported to be able to initiate an asthmatic 
reaction with goblet cell hyperplasia, eosinophilia and IL-9 production independent of IL-4. 
The suppression of IL-25 expression could only be seen in animals with wild type mice as a 
recipient. Thus, downregulation of IL-25 by GCs and treatability correlate, suggesting a 
causal relationship of gene regulation and asthma therapy. 




Figure 65: Lung cells dependent GC-effects on gene expression in lung tissue of wild type and 
GR
dim
 bone marrow chimeras reconstituted with wild type or GR
dim
 bone marrow. The data 
represent an overview of the results obtained by RT-qPCR analysis. 
 
The function of IL-10 in asthma pathogenesis is not completely understood. This cytokine 
was reported to have an anti-inflammatory function because of the inhibition of TH2 cytokine 
production via IL-10 secreting T reg cells (Robinson et al., 2004; Xystrakis et al., 2006). 
Beside T reg cells also alveolar macrophages and mast cells can produce this cytokine in the 
lungs. The reduction of mRNA expression therefore could be a sign of the downregulation of 
mast cell activity by GCs.  
 
The regulation of the last cytokine in this group- IL-33- is complex. It is known, that it plays a 
crucial role in the initiation of an asthmatic reaction. This cytokine is one of the earliest-
released signaling molecules following epithelial damage in the lungs. Its enhanced 
expression leads to the activation of TH2 cells, DCs, mast cells and eosinophils and the 
secretion of a variety of inflammatory mediators. The expression of IL-33 was upregulated in 
the samples of GC treated chimeras when wild type mice were used as recipients. This effect 
of GC therapy was surprising but is in line with data from asthmatic patients as reported by 
Prefontaine and colleagues. They demonstrated that the expression of IL-33 originates from 
structural cells of the airways and that it does not respond to classical anti-inflammatory drugs 
used to treat asthma (Prefontaine et al., 2010). 
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The third group of genes included those with a complex regulation pattern. The expression of 
iNOS and CXCR4 was reduced by GC treatment in all types of bone marrow chimeras while 
the expression of IL-4 was upregulated. CXCL12 expression could be suppressed in all 
chimeras excluding wild type chimeras with a GR
dim
 immune system. CXCR3 demonstrated 
was upregulated after Dexamethasone treatment in all chimeras excluding wild type chimera 
with a wild type immune system. This data shows another facet of complexity and divergence 
of the factors that influence the therapeutic efficiency of GCs. 
 
Based on the results of the gene expression analysis of lung samples from GR
dim
 bone marrow 
chimeras GC therapy seems to be largely dependent on the suppression of characteristical 
genes expressed by inflamed lung cells. The suppression of IL-9, IL-10, TSLP and IL-25 by 
GCs and treatability strongly correlate, suggesting a key role of these mediators in the asthma 
pathogenesis. These mediators such as TSLP and IL-25 are good candidates for important 
targets of GC-therapy in the treatment of asthma. The regulation of other genes that were 
reported to be markers for mast cell activation (β-Tryptase), myeloid cell migration and 
activation (MCP-1, Mip-1α, iNOS), eosinophilia (IL-5, Eotaxin-2) and T cell priming (IL-4, 
IL-13, RANTES) did not directly correlate with therapeutic efficiency, suggesting a 
secondary role of these cytokines and chemokines in regulation of inflammatory response by 
GCs.  
 




The possibility to treat mice lacking the GR in T and B, DCs and myeloid cells, the 
experiments with mast cell deficient mice and bone marrow chimeras suggested that non-
immune cells (like epithelial cells of the lung) play an important role in the suppression of 
inflammatory reactions by GCs during asthma therapy.  
 
To investigate the role of the epithelial cells as targets of GC-therapy inducible GR
SPCcreERT2
 
mice were used in this work. Because of the efficiently diminished expression of the GR in 
AT2 epithelial cells and the normal lung physiology of these mutant mice they could be used 
to investigate this issue without limitations. While the pathogenesis of the asthmatic reaction 
was similar compared to wild type animals, the analysis of the therapeutic efficiency showed 
that the treatability of the mutant mice was impaired. The cellular infiltration of the mutant 
lungs was only partially reduced after GC therapy. The analysis of the BAL cell composition 
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demonstrated almost the same level of eosinophilia in samples of GR
SPCcreERT2 
with or without 
treatment. Based on these data, the AT2 cells play a crucial role during asthma therapy with 
GCs.  
 
Gene expression analysis of sorted AT2 cells was done to identify regulatory mechanisms of 
GCs in the treatment of asthma. 
 
Figure 66: Effects of GC therapy on gene expression in AT2 cells isolated from Dexamethasone 
treated AAI mice of wild type and GR
SPCcreERT2
 genotype. The data represent an overview of the 
results obtained by RT-qPCR analysis. 
 
Current publications reported an important role of pulmonary epithelial cells during lung 
infection and a critical role of epithelial cells in the initiation of an asthmatic reaction. An 
important role in this process was assigned to the TLR-mediated pathway. After contact with 
microbes or microbial products, TLR-mediated signals result in the production of TNF-α, 
IL-1β, TSLP and IL-33 by epithelial cells. These cytokines stimulate the expression of 
adhesions molecules on vascular endothelial cells, activate DCs and promote a TH2 response, 
initiating an asthmatic reaction. Several publications point towards TLR as a possible target 
for a more specific asthma therapy. The data from the initial analysis of GR
SPCcreERT2
 mice 
revealed a strong upregulation of mediators that are correlated with TLR-signals and 
diminished effects of GC-therapy on their downregulation compared to the wild type samples. 
Although these results represent only a first data set a correlation between the treatability of 
the mice and the expression pattern of AT2 cells could be seen. The regulation of all analysed 
genes by GC treatment was different in mutant mice compared to wild type samples. While 
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GCs in wild type animals successfully downregulated the mRNA expression of critical 
inflammatory mediators like IL-1β, IL-33 and iNOS these genes showed increased expression 
in samples of GR
SPCcreERT2
 mice. The expression of TSLP was increased in AT2 samples of 
GC-treated GR
SPCcreERT2
 mice while the expression of other important mediator like 
RANTES, Eotaxin-2 and TNF-α reminded unaltered independent on GC therapy. The barrier 
function of epithelial cells was impaired in both genotypes after induction of AAI but only in 
wild type mice the GC treatment led to an increased expression of ZO-1. The upregulation of 
ZO-1 expression is reported to be a sign of an improvement of the epithelial barrier function 
during the therapy and is important to closer contact of DCs with the environment.  
 
Based on the initial observations, the following genes could be key players for the therapeutic 
efficiency of GCs: ZO-1 (important for the barrier function); TNFα, IL-1β and IL-33 (initiator 
and mediators of inflammatory response), Eotaxin-2 and RANTES (mediators of cellular 
infiltration) and TSLP (activation of DCs and initiation of asthmatic reaction). A possible 
explanation of the observed effects could be the regulation of TLR signalling by GCs, which 
could lead to a strong inhibition of DCs maturation in the lungs. The fact that the recruitment, 
activation and intraepithelial migration of DCs in response to microbial components as 
inhaled endotoxin requires only triggering of epithelial TLR-4 (Hammad H. et al., 2009) 
demonstrates how important the interaction between the immune system and epithelial cells 
and effect of GC treatment on the epithelial cells activation is. Finally, mast cell activation 
and subsequent secretion of proinflammatory mediators is directly induced by TLR ligands as 
well and can be regulated by GCs via effects on TLR expression.  
 
4.3.3. Conclusion 
The experimental data obtained with cell type specific GR knockout mutant mice and GR
dim
 
bone marrow chimeras suggest a crucial role of non-immune cells of the lungs during the 
therapy of asthmatic reactions with GCs. The loss of GR expression in T cells, myeloid cells, 
DCs and B cells did not result in an impaired therapeutic efficiency of GCs. Also when the 
immune system did not respond to GCs, inflammation could still be suppressed by GCs in 
bone marrow chimera with wild type mice as recipients. The data on GR
SPCcreERT2
 mice 
further support the hypothesis that AT2 epithelial cells are important targets of GCs during 
asthma treatment. Based on the gene expression analysis and current publications in field, 
AT2 cells seems to play a key role in the development of asthma and its pathogenesis and 
might be critical for the therapeutic efficiency of GCs.   
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